WO2013012975A1 - Procédés pour augmenter des rendements en produits - Google Patents

Procédés pour augmenter des rendements en produits Download PDF

Info

Publication number
WO2013012975A1
WO2013012975A1 PCT/US2012/047278 US2012047278W WO2013012975A1 WO 2013012975 A1 WO2013012975 A1 WO 2013012975A1 US 2012047278 W US2012047278 W US 2012047278W WO 2013012975 A1 WO2013012975 A1 WO 2013012975A1
Authority
WO
WIPO (PCT)
Prior art keywords
coa
reductase
pathway
microbial organism
dehydrogenase
Prior art date
Application number
PCT/US2012/047278
Other languages
English (en)
Inventor
Anthony P. Burgard
Robin E. Osterhout
Jun Sun
Priti Pharkya
Original Assignee
Genomatica, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomatica, Inc. filed Critical Genomatica, Inc.
Priority to BR112014001174A priority Critical patent/BR112014001174A2/pt
Priority to EP12815606.4A priority patent/EP2734627A4/fr
Publication of WO2013012975A1 publication Critical patent/WO2013012975A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids

Definitions

  • This invention relates generally to biosynthetic processes and, more specifically to organisms having enhanced carbon fixation capabilities.
  • 1,3-butanediol (1,3-BDO) is a four carbon diol traditionally produced from acetylene via its hydration. The resulting acetaldehyde is then converted to 3-hydroxybutyraldehdye which is subsequently reduced to form 1,3-BDO. More recently, acetylene has been replaced by the less expensive ethylene as a source of acetaldehyde.
  • 1 ,3-BDO is commonly used as an organic solvent for food flavoring agents. It is also used as a co-monomer for polyurethane and polyester resins and is widely employed as a hypoglycemic agent.
  • Optically active 1,3-BDO is a useful starting material for the synthesis of biological!' active compounds and liquid cry stals.
  • Another use of 1,3-butanediol is that its dehydration affords 1,3 -butadiene (Iehikawa et al. Journal of Molecular Catalysis A-Chemical 256: 106-112 (2006); lchikawa et al. Journal of Molecular Catalysis A-Chemical 231 : 181-189 (2005), which is useful in the manufacture synthetic rubbers (e.g., tires), latex, and resins.
  • the reliance on petroleum based feedstocks for either acetylene or ethylene warrants the development of a renewable feedstock based route to 1,3-butanediol and to butadiene.
  • Isopropanol is a colorless, flammable liquid that mixes completely with most solvents, including water.
  • the largest use for IPA is as a solvent, including its well known yet small use as "rubbing alcohol,” which is a mixture of IPA and water.
  • rubbing alcohol is a mixture of IPA and water.
  • IPA is found in many everyday products such as paints, lacquers, thinners, inks, adhesives, general-purpose cleaners, disinfectants, cosmetics, toiletries, de-icers, and pharmaceuticals.
  • Low-grade IPA is also used in motor oils.
  • IPA is also used as a chemical intermediate for the production of isopropylamines (Ag products), isopropylethers, and isopropyl esters.
  • Isopropanol is manufactured by two petrochemical routes. The predominant process entails the hydration of propylene either with or without sulfuric acid catalysis. Secondarily, IPA is produced via hydrogenation of acetone, which is a by-product formed in the production of phenol and propylene oxide.
  • 4-hydroxybutanoic acid (4-hydroxybutanoate, 4-hydroxybutyrate, 4-HB) is a 4- carbon earboxylic acid that is used as a building block for various commodity and specialty chemicals. In particular, 4-HB can serve as an entry point into the 1,4-butanediol family of chemicals, which includes solvents, resins, polymer precursors, and specialty chemicals.
  • 1,4-butanediol is a valuable chemical for the production of high performance polymers, solvents, and fine chemicals. It is the basis for producing other high value chemicals such as tetrahydrofuran (THF) and gamma-butyro lactone (GBL).
  • the value chain is comprised of three main segments including; (1) polymers, (2) THF derivatives, and (3) GBL derivatives.
  • BDO is a comonomer for polybutylene terephthalate (PBT) production.
  • PBT is a medium performance engineering thermoplastic used in automotive, electrical, water systems, and small appliance applications. Conversion to THF, and subsequently to
  • polytetramethylene ether glycol provides an intermediate used to manufacture spandex products such as LYCRA* ' fibers.
  • PTMEG is also combined with BDO in the production of specialty polyester ethers (COPE).
  • COPEs are high modulus elastomers with excellent mechanical properties and oil/environmental resistance, allowing them to operate at high and low temperature extremes.
  • PTMEG and BDO also make thermoplastic polyurethanes processed on standard thermoplastic extrusion, calendaring, and molding equipment, and are characterized by their outstanding toughness and abrasion resistance.
  • the GBL produced from BDO provides the feedstock for making pyrrolidones, as well as serving the agrochemical market.
  • the pyrrolidones are used as high performance solvents for extraction processes of increasing use, including for example, in the electronics industry and in pharmaceutical production.
  • BDO is produced by two main petrochemical routes with a few additional routes also in commercial operation.
  • One route involves reacting acetylene with formaldehyde, followed by hydrogenation.
  • More recently BDO processes involving butane or butadiene oxidation to maleic anhydride, followed by hydrogenation have been introduced.
  • BDO is used almost exclusively as an intermediate to synthesize other chemicals and polymers.
  • Additional product molecules that can be produced by the teachings of this invention include but are not limited to ethano!, butanol, isobutanol, isopropanol, succinic acid, fumaric acid, malic acid, 3-hydroxypropionic acid, lactic acid, adipic acid, 6-amiiiocaproic acid, hexamethylenediamine, caprolactam, 3-hydoxyisobutyric acid, 2-hydroxyisobutyric acid, methacrylic acid, acrylic acid, 1,3-propanediol, glycerol, and long chain hydrocarbons, alcohols, acids, and esters.
  • embodiments disclosed herein relate to a non-naturally occurring microbial organism that includes a microbial organism having a reductive TCA pathway which includes at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA.
  • the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an aipha-ketoglutarate:ferredoxin oxidoreduciase.
  • embodiments disclosed herein relate to a method for enhancing carbon flux through acetyl-CoA that includes culturing this non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block.
  • embodiments disclosed herein relate to a non-naturally occurring microbial organism that includes a microbial organism having a Wood-Ljungdahl pathway which includes at least one exogenous nucleic acid encoding a Wood-Ljungdahl pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA.
  • the at least one exogenous nucleic acid is selected from a) Formate dehydrogenase, b)
  • Mefhyltetrahydrofolate orrinoid protein methyltransferase (AcsE), g) Corrinoid iron-sulfur protein (AcsD), h) Nickel-protein assembly protein (AcsF & CooC), i) Ferredoxin (Qrf7), j) Acetyl-CoA synthase (AcsB & AcsC), k) Carbon monoxide dehydrogenase (AcsA),and 1) Pyruvate ferredoxin oxidoreduciase or pyruvate dehydrogenase, and m) pyruvate formate lyase.
  • AcsE Mefhyltetrahydrofolate orrinoid protein methyltransferase
  • AcsD Corrinoid iron-sulfur protein
  • AcsF & CooC Nickel-protein assembly protein
  • Qrf7 Ferredoxin
  • embodiments disclosed herein relate to a method for enhancing carbon flux through acetyl-CoA that includes culturing this non-naturaily occurring microbial organism under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block,
  • embodiments disclosed herein relate to a non-naturaily occurring microbial organism that includes a microbial organism having a methanol Wood-Ljungdahl pathway which includes at least one exogenous nucleic acid encoding a methanol Wood- Ljungdahl pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA.
  • the at least one exogenous nucleic acid is selected from a) Methanol
  • embodiments disclosed herein relate to a method for enhancing carbon flux through acetyl-CoA, comprising culturing this non-naturaily occurring microbial organism under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block.
  • embodiments disclosed herein relate to a non-naturaily occurring microbial organism that includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equi valents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock.
  • the at least one exogenous nucleic acid is selected from a carbon monoxide dehydrogenase, a hydrogenase, an NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin.
  • embodiments disclosed herein relate to a method for enhancing the availability of reducing equivalents in the presence of carbon monoxide or hydrogen thereby increasing the yield of redox-limited products via carbohydrate- based carbon feedstock, the method includes culturing this non-naturaily occurring microbial organism under conditions and for a sufficient period of time to produce a product.
  • embodiments disclosed herein relate to a non-naturally occurring microbial organism that includes a microbial organism having a reductive TCA.
  • the pathway which includes at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme, the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fimiarate reductase, and an alpha-ketoglutarate:ferredoxin oxidoreductase; and at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a
  • embodiments disclosed herein relate to a method that includes culturing a non-naturally occurring microbial organism that includes a microbial organism having a reductive TCA pathway comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme.
  • the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fimiarate reductase, and an alpha-ketoglutarate: ferredoxin oxidoreductase; and at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) CO 2 and I3 ⁇ 4, 3) CO and C0 2 , 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, CO?, and H 2 to produce a product.
  • exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H:ferredoxin oxidoreductase, and a ferredox
  • Figure la shows the pathways for the biosynthesis of 1,3-butanedioI from acetyl- Co A; the enzymatic transformations shown are carried out by the following enzymes: 1 ) Acetoacetyl-CoA thiolase (AtoB), 2) Acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), 3) 3-oxobutyraldehyde reductase (aldehyde reducing), 4) 4 ⁇ hydroxy,2-butanone reductase, 5) Acetoacetyl-CoA reductase (CoA-dependent, aldehyde forming), 6) 3- oxobutyraldehyde reductase (ketone reducing), 7) 3-hydroxybufyraklehyde reductase, 8) Acetoacetyl-CoA reductase (ketone reducing), 9) 3-hydroxybutyryl-CoA reductase (aldeh
  • Figure lb shows the pathways for the biosynthesis of isopropanol from acetyl-CoA; the enzymatic transformations shown are carried out by the followmg enzymes: 1) Acetoacetyl- CoA thiolase (AtoB), 2) Acetoacetyl-CoA transferase, acetoacetyl-CoA hydrolase, acetoacetyl- CoA synthetase, or phosphotransacetoacetylase/acetoacetate kinase, 3) Acetoacetate decarboxylase (Adc), and 4) Isopropanol dehydrogenase (Adh)
  • Figure lc shows the pathways for the biosynthesis of 4-hydroxybutyrate (4-HB); the enzymatic transformations shown are carried out by the following enzymes: 1) Acetoacetyl- CoA thiolase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-Hydroxybutyryl-CoA transferase, hydrolase or synthetase, 6) Phosphotrans-4-hydroxybutyrylase, and 7) -Hydroxy butyrate kinase.
  • AtoB Acetoacetyl- CoA thiolase
  • Hbd 3-Hydroxybutyryl-CoA dehydrogenase
  • Crt Crotonase
  • Crotonyl-CoA hydratase (4-Budh)
  • Figure Id shows the pathways for the biosynthesis of 1 ,4-butanediol; the enzymatic transformations shown are carried out by the following enzymes: 1) Acetoacetyl-CoA thiolase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-hydroxybutyryl-CoA reductase (alcohol forming), 6) 4- hydroxybutyryl-Co A reductase (aldehyde forming), 7) 1 ,4-butanediol dehydrogenase, 8) 4- Hydroxybutyryi-CoA transferase, 4-Hydroxybutyryl-CoA synthetase, 4-Hydroxybutyryl-CoA hydrolase, or Phosphotrans-4-hydroxybutyrylase/4
  • Figure 2a shows the reverse TCA cycle for fixation of CO?, on carbohydrates as substrates.
  • the enzymatic transformations are carried out by the enzymes as shown.
  • Figure 2b shows the flux distribution showing an enhanced maximum theoretical yield of isopropanol on glucose when carbon is routed via the reductive TCA cycle
  • Figure 3 a shows a flow diagram depicting the Wood-Ljungdahl pathway and formation routes for acetate and ethanol; the transformations that are carried out in organisms capable of growth on synthesis gas are 1) CO dehydrogenase, 2) hydrogenase, 3) energy- conserving hydrogenase (ECH), and 4) bi-functional CO dehydrogenase/acetyl -Co A synthase.
  • FIG. 3b shows a pathway for the utilization of methanol for the formation of acetyl- CoA; the enzymatic transformations shown are carried out by the following enzymes: 1 ) Methanol methyltransferase (MtaB), 2) Corrinoid protein (MtaC), 3)
  • Methyltetrahydrofolate orrinoid protein metbyitransferase (MtaA), 4)
  • Methyltetrahydrofolatexorrinoid protein methyltransferase (AcsE), 5) Corrinoid iron-sulfur protein (AcsD), 6) Nickel-protein assembly protein (AcsF & CooC), 7) Ferredoxm (Qrf7), 8) Acetyl-CoA synthase (AcsB & AcsC), and 9) Carbon monoxide dehydrogenase (AcsA).
  • Figure 4a shows a pathway for enabling carbon fixation from syngas into acetyl Co A.
  • the reducing equivalents are derived from carbohydrates such as glucose.
  • the enzymatic transformations are carried out by the following enzymes: 1 ) Formate dehydrogenase, 2) Formyitetrahydrofolate synthetase, 3) Methenyltetrahydrofoiate cycloiiydrolase, 4)
  • Memyltetrahydro folate corrinoid protem methyltransferase (AcsE), 7) Corrinoid iron-sulfur protein (AcsD), 8) Nickel-protein assembly protein (AcsF & CooC), 9) Ferredoxin (Qrf7), 10) Acetyl-CoA synthase (AcsB & AcsC), 1 1) Carbon monoxide dehydrogenase (AcsA), 12) Pyruvate formate lyase (Pfl), 13) Pyruvate ferredoxin oxidoreductase (For) or pyruvate dehydrogenase (PDH).
  • AcsE corrinoid protem methyltransferase
  • AcsD Corrinoid iron-sulfur protein
  • AcsF & CooC Nickel-protein assembly protein
  • Ferredoxin Qrf7
  • Acetyl-CoA synthase
  • Figure 4b shows a pathway for enabling carbon fixation from methanol into acetyl CoA
  • the reducing equivalents are derived from carbohydrates such as glucose
  • "n” depicts the number of moles of methanol that are provided .
  • the enzymatic transformations are carried out by the following enzymes: 1) Methanol methyltransferase (MtaB), 2) Corrinoid protein (MtaC), 3) Methyltetrahydrofolate:corrinoid protem methyltransferase (MtaA), 4)
  • Figure 5b shows the flux distribution with an enhanced maximum theoretical yield of
  • Methyltetrahydro folate corrinoid protein methyltransferase (MtaA), 4)
  • Methyltetrahydro-foiate corrinoid protein methyltransferase (AcsE), 5) Corrinoid iron-sulfur protein (AcsD), 6) Carbon monoxide dehydrogenase (AcsA), 7) Nickel-protein assembly protein (AcsF & CooC), 8) Ferredoxin (Qrf7), 9) Acetyl-CoA. synthase (AcsB & AcsC), 10)
  • Pyruvate ferredoxin oxidoreductase (For), 1 1) Pyruvate dehydrogenase (PDH), 12) Pyruvate formate lyase (PIT), 13) Formate dehydrogenase, 14) Acetoacetyl-CoA thiolase (AtoB), 15)
  • Acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), 16) 3-Oxobutyraldehyde reductase (aldehyde reducing), 17) 4-Hydroxy-2-butanone reductase, 18) Acetoacetyl-CoA reductase (CoA-dependent, aldehyde forming), 19) 3-Oxobutyraldehyde reductase (ketone reducing), 20) 3-Hydroxybutyraldehyde reductase, 21) Acetoacetyl-CoA reductase (ketone reducing), 22) 3-Hydroxybutyryl-CoA reductase (aldehyde forming), 23) 3-Hydroxybutyryl- CoA reductase (alcohol forming); when glucose and methanol are fed in 1.0:0.4 ratio, it affords an increase from 1 mol 1,3-butanedio
  • Figure 6a shows the flux distribution with an enhanced maximum theoretical yield of isopropanoi from glucose when carbon fixation via the Wood-Ljungdahl pathway is employed in the absence of methanol; the enzymatic transformations shown are carried out by the following enzymes: 1) Formate dehydrogenase, 2) Formyltetrahydro folate synthetase, 3) Methenyltetra-hydrofolate cyclohydrolase, 4) Methylenetetrahydrofolate dehydrogenase, 5) Methylenetetrahydro folate reductase, 6) Methyitetrahydrofolatexomnoid protein
  • AcsE Corrinoid iron-sulfur protein
  • AcsD Corrinoid iron-sulfur protein
  • AcsF & CooC Nickel-protein assembly protein
  • Ferredoxm Orf7, 10) Acetyl-CoA synthase (AcsB & AcsC), 11) Carbon monoxide dehydrogenase (AcsA), 12) Pyruvate formate lyase (Ffl ), 13) Pyruvate ferredoxm oxidoreductase (Por) or pyruvate dehydrogenase (PDH), 14) Acetoacetyl-CoA thiolase (AtoB), 15) AcetoacetyI-CoA:acetate:CoA transferase (AtoAD), 16) Acetoacetate decarboxylase (Adc), and 17) Isopropanoi dehydrogenase (Adh).
  • Figure 6b shows the flux distribution with an enhanced maximum theoretical yield of isopropanoi from glucose when carbon fixation via the methanol Wood-Ljungdahl pathway is employed using both syngas and methanol; the enzymatic transformations shown are carried out by the following enzymes: 1) Methanol methyltransferase (MtaB), 2) Corrinoid protein (MtaC), 3) Methyltetrahydrofolatexorrinoid protein methyltransferase ( taA), 4)
  • Methyltetrahydro folate corrinoid protein methyltransferase (AcsE), 5) Corrinoid iron-sulfur protein (AcsD), 6) Carbon monoxide dehydrogenase (AcsA), 7) Nickel-protein assembly protein (AcsF & CooC), 8) Ferredoxin (Orf7), 9) Acetyl-CoA synthase (AcsB & AcsC), 10) Pyruvate ferredoxin oxidoreductase (Por), 11) Pyruvate dehydrogenase (PDH), 12) Pyruvate formate lyase (Pfl), 13) Formate dehydrogenase, 14) Acetoacetyl-CoA thiolase (AtoB), 15) Acetoacetyl-CoA:acetate:CoA transferase (AtoAD), 16) Acetoacetate decarboxylase (Adc), and
  • Figure 7a shows flux distribution for improvement in 1,4-BDO yields from carbohydrates when reducing equivalents from syngas components are available; the enzymatic transformations shown are carried out by the following enzymes: 1) Hydrogenase, 2) Carbon monoxide dehydrogenase, 3) Suecinyl-CoA transferase, Succinyl-CoA hydrolase, or Succinyl- CoA synthetase (or succinyf-CoA ligase), 4) Succinyl-CoA reductase (aldehyde forming), 5) 4- Hydroxybutyrate dehydrogenase, 6) 4-Hydroxybutyrate kinase, 7) Pb.osphotrans-4- hydroxybutyrylase, 8) 4-Hydroxybutyryi-CoA reductase (aldehyde forming), 9) l,4-butanedio3.
  • Figure 7b shows flux distribution for improvement in 1,3-BDO yields from carbohydrates when reducing equivalents from syngas components are available; the enzymatic transformations shown are carried out by the following enzymes: 1) Hydrogenase, 2) Carbon monoxide dehydrogenase, 3) Succinyl-CoA transferase, or Succinyl-CoA.
  • Figure 7c shows flux distribution for improvement in butanol yields on carbohydrates when reducing equivalents from syngas components are available; the enzymatic
  • Figure 7d shows flux distribution for improvement in yields of 6-aminocaproic acid and hexamethvlene diamine on carbohydrates when reducing equivalents from syngas components are available; the enzymatic transformations shown are carried out by the following enzymes: 1) Hydrogenase, 2) Carbon monoxide dehydrogenase, 3) 3-Oxoadipyi-CoA thiolase , 4) 3-Oxoadipyl-CoA reductase, 5) 3-Hydroxyadipyl-CoA dehydratase, 6) 5-Carboxy-2- pentenoyl-CoA reductase, 7) Adipyl-CoA reductase (aldehyde forming), 8) 6-Aminocaproate transaminase, or 6-Aminocaproate dehydrogenase, 9) 6-Aminocaproyl-CoA/acyl-CoA transferase, or 6-Aminocaproyl-CoA synth
  • transaminase or HMD A dehydrogenase.
  • Figure 7e shows flux distribution for improvement in yields of glycerol and 1,3- propanediol on carbohydrates when reducing equivalents from syngas components are available; the enzymatic transformations shown are carried out by the following enzymes: 1) Hydrogenase, 2) Carbon monoxide dehydrogenase , 3) Dihydroxyacetone kinase , 4) Glycerol dehydrogenase, 5) Glycerol dehydratase, 6) 1,3 -Propanediol dehydrogenase.
  • Figure 8 shows the pathway for the reverse TCA cycle coupled with carbon monoxide dehydrogenase and hydrogenase for the conversion of syngas to acetyl-CoA.
  • Figure 9 shows Western blots of 10 micrograms ACS90 (lane 1), ACS91 (lane2), Mta98/99 (lanes 3 and 4) cell extracts with size standards (lane 5) and controls of M.
  • thermoacetica CODH (Moth_1202/1203) or Mtr (Moth_l 197) proteins (50, 150, 250, 350, 450, 500, 750, 900, and 1000 ng).
  • Figure 10 shows CO oxidation assay results.
  • Cells M. thermoacetica or E. coli with the CODH/ACS operon; ACS90 or ACS91 or empty vector: pZA33S
  • Assays were performed at 55oC at various times on the day the extracts were prepared. Reduction of rnethylviologen was followed at 578 nm over a 120 sec time course.
  • This invention is directed, in part to engineered biosynthetic pathways to improve carbon flux through the central metabolism intermediate, acetyl-CoA, en route to product molecules.
  • Exemplary product molecules include, without limitation, 1,3-butanediol, isopropanoi, 4-hydroxybutyrate, and 1 ,4-butanediol, although given the teachings and guidance provided herein, it will be recognized by one skilled in the art that any product molecule that has acetyl-CoA as a building block can exhibit enhanced production through increased carbon flux through acetyl-CoA.
  • the present invention provides non-naturally occurring microbial organisms having one or more exogenous genes encoding enzymes that can catalyze various enzymatic transformations en route to acetyi-CoA.
  • these enzymatic transformations are part of the reductive tricarboxylic acid (RTCA) cycle and are used to improve product yields from carbohydrate-based carbon feedstock,
  • This invention is also directed, in part, to improving product yields based on enzymatic transformations of the Wood-Ljungdahl pathway.
  • syngas components such as CO and 3 ⁇ 4
  • Such reducing equivalents can improve product yields from carbohydrate-based carbon feedstock as described herein below.
  • the microorganisms of the invention can be, for example, microorganisms engineered to contain a reductive TCA and/or Wood-Ljungdahl pathway starting from any of a variety of host microorganisms, as disclosed herein.
  • the present invention increases the yields of products by (i) enhancing carbon fixation via the Wood- Ljungdahl pathway and/or the reductive TCA cycle, and (ii) accessing additional reducing equivalents from gaseous syngas components such as CO, CO 2 , and/or H 2 .
  • Products that can be produced by non-naturally occurring organisms and methods described herein include, without limitation, ethanol, butanol, isobutanol, 1,3-butanediol, isopropanoi, 4-hydroxybutyrate, 1,4- butanediol, succinic acid, ramaric acid, malic acid, 3-hydroxypropionic acid, lactic acid, adipic acid, 6-am.inocaproic acid, hexameihylenediamine, caprolactam, 3-hydoxyisobutyric acid, 2- hydroxyisobutyric acid, metbacrylic acid, acrylic acid, 1 ,3-propanediol, glycerol, and long chain hydrocarbons, alcohols, acids, and esters,
  • the CQ?-fixing reductive tricarboxylic acid (RTCA) cycle is an eiiderge ic anabolic pathway of C0 2 assimilation which uses NAD(P)H and ATP ( Figure 2a).
  • One turn of the RTCA cycle assimilates two moles of CO? into one mole of aeetyl-CoA, or four moles of CO? into one mole of oxaloacetate.
  • This additional availability of acetyl-CoA improves the maximum theoretical yield of product molecules derived from carbohydrate-based carbon feedstock.
  • Exemplary carbohydrates include but are not limited to glucose, sucrose, xylose, arabinose and glycerol.
  • Figure 2b provides an exemplary flux distribution showing how r the maximum theoretical isopropanoi yield increases from 1 mole/mole glucose to 1.33 moles per mole glucose.
  • the reductive TCA. cycle was first reported in the green sulfur photosynthetic bacterium Chlorobium limicola (Evans et ai., Proc. Natl. Acad. Sci. U.S.A. 55:928-934 (1966)). Similar pathways have been characterized in some prokaryotes (proteobacteria, green sulfur bacteria and thermophilic Knallgas bacteria) and sulfur-dependent archaea (Hugler et al. J. Bacterial. 187:3020-3027 (2005); Hugler et al. Environ.
  • the reverse reaction cleavage of citrate to oxaloacetate and acetyl-CoA, is ATP-dependent and catalyzed by ATP citrate lyase or citryl- CoA synthetase and citryi-CoA lyase.
  • the conversion of succinate to fumarate is catalyzed by succinate dehydrogenase while the reverse reaction is catalyzed by fumarate reductase.
  • succinyi-CoA is formed from the NAD(P) ; dependent decarboxylation of 2-oxoglutarate by the AKGDH complex.
  • the reverse reaction is catalyzed by alpha- ketogrutarate:ferredoxin oxidoreductase.
  • the invention provides oii- naturally occurring organisms that enhance carbon flux through acetyl-CoA by engineering one or more enzymes that are part of the reverse TCA cycle.
  • the invention provides enhanced product yields via carbohydrate-based carbon feedstock by fixing carbon dioxide and/or methanol via the Wood- Ljungdahl pathway or components thereof.
  • Synthesis gas is a mixture of H 2 and CO that can be obtained via gasification of any organic feedstock, such as coal, coal oil, natural gas, biomass, or waste organic matter. Numerous gasification processes have been developed, and most designs are based on partial oxidation, where limiting oxygen avoids full combustion, of organic materials at high temperatures (500-15G0°C) to provide syngas as a 0.5: 1 -3: 1 H 2 /CO mixture.
  • biomass of many types has been used for syngas production and this source represents an inexpensive and flexible feedstock for the biological production of renewable chemicals and fuels.
  • acetogens such as Moorella thermoacetica, C. Ijungdahlii and C. carboxidivorans, can grow on a number of carbon sources ranging from hexose sugars to
  • Hexoses such as glucose
  • EMP Embden-Meyerhof- Parnas
  • Acetyl-CoA can be used to build biomass precursors or can be converted to acetate which produces energy via acetate kinase and phosphotransacetylase. The overall conversion of glucose to acetate, energy, and reducing equivalents is
  • Acetogens extract even more energy out of the glucose to acetate conversion while also maintaining redox balance by further converting the released C0 2 to acetate via the Wood- Ljungdahl pathway:
  • Methanol is a relatively inexpensive organic feedstock that can be derived from synthesis gas components, CO and 3 ⁇ 4, via catalysis.
  • a non-naturally occurring microbial organism of the invention capable of utilizing methanol can also utilize gases including, for example, CO, C0 2 , and/or H 2 for conversion to acetyl-CoA, cell mass, and products.
  • acetogens such as Moorella thernioacetica (formerly, Clostridium,
  • thermoaceticum use syngas via the Wood-Ljungdahl pathway.
  • This pathway includes two branches: the Eastern (or methyl) branch converts C0 2 to methyltetrahydrofolate (Me-THF) and the Western (or carbonyl) branch that converts methyl-THF, CO, and Coenzyme-A into acetyl- CoA (Figure 3B).
  • Any non-naturally occurring microorganism of the invention expressing genes encoding enzymes that catalyze the carbonyl-branch of the Wood-Ljungdahl pathway in conjunction with a MtaABC-type methyltransferase system is capable of 'fixing' carbon from exogenous CO and/or C0 2 and methanol to synthesize aeetyl-CoA, cell mass, and products.
  • ATP consumption can be circumvented by ensuring that the methyl group on the methyl branch product, methyl-THF, is obtained from methanol rather than CO?.
  • acetate formation has a positive ATP yield that can help support cell growth and maintenance.
  • anapleurosis e.g., E. coif
  • This electron acceptor is used to accept electrons from the reduced quinone formed via succinate dehydrogenase
  • a further use of adding an external electron acceptor is that additional energy for cell growth, maintenance, and product formation can be generated from respiration of acetyl -CoA.
  • engineering a pyruvate ferredoxin oxidoreductase (PFOR) enzyme into a non-naturally occurring microbial organism allows the synthesis of biomass precursors in the absence of an external electron acceptor.
  • Carbon from syngas and/or methanol can be fixed via the Wood-Lj imgdahl pathway and portions thereof when using carbohydrate-based carbon feedstock for the formation of molecules such as 1 ,3-butanediol, isopropanol, 4-hydroxybutyrate, and 1 ,4-butanediol, or other desired product, using the pathways described herein.
  • the combination of certain syngas-utilization pathway components with the aeetyl-CoA to 1 ,3-butanediol, isopropanol, 4- hydroxybutyrate, or 1 ,4-butanediol, or other desired products pathways results in high yields of these products from carbohydrates by providing an efficient mechanism for fixing the carbon present in carbon dioxide, fed exogenously or produced endogenous! ⁇ ', into acetyi-CoA as shown below.
  • E em lar ' carbohydrates include but are not limited to glucose, sucrose, xylose, arabinose and glycerol.
  • the enzymatic transformations for carbon fixation are shown in Figure 4A and 4B respectively.
  • non-naturally occurring microbial organisms and conversion routes described herein provide an efficient means of converting carbohydrates to products such as isopropanoi, 4-hydroxybutyrate, or 1,4-butanedioi, or other desired product.
  • Additional product molecules that can be produced by the teachings of this invention include but are not limited to ethanol, butanol, isobutanol, isopropanoi, 1 ,4-butanediol, succinic acid, fumaric acid, malic acid, 4-hydroxybutyric acid, 3-hydroxypropionic acid, lactic acid, adipic acid, 6-aminocaproic acid, hexamethylenediamine, caprolactam, 3-hydoxyisobutyric acid, 2-hydroxyisobutyric acid, metbacrylic acid, acrylic acid, glycerol, 1 ,3-propanediol, and long chain hydrocarbons, alcohols, acids, and esters.
  • non-naturally occurring when used in reference to a microbial organism or microorganism of the invention is intended to mean th at the microbial organism has at least one genetic alteration not normally found in a naturally occurring strain of the referenced species, including wild-type strains of the referenced species.
  • Genetic alterations include, for example, modifications introducing expressible nucleic acids encoding metabolic polypeptides, other nucleic acid additions, nucleic acid deletions and/or other functional disruption of the microbial organism's genetic material. Such modifications include, for example, coding regions and functional fragments thereof, for heterologous, homologous or both heterologous and homologous polypeptides for the referenced species.
  • Additional modifications include, for example, non-coding regulatory regions in which the modifications alter expression of a gene or operon.
  • Exemplary metabolic polypeptides include enzymes or proteins within a 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, isopropanoi, 6- aminocaproic acid, hexamethylene diamine, caprolactam, glycerol, or 1 ,3-propanediol, or other desired product hiosynthetic pathway.
  • a metabolic modification refers to a biochemical reaction that is altered from its naturally occurring state. Therefore, non-naturally occurring microorganisms can have genetic modifications to nucleic acids encoding metabolic polypeptides, or functional fragments thereof. Exemplary metabolic modifications are disclosed herein.
  • the term "isolated" when used in reference to a microbial organism is intended to mean an organi sm that is substantially free of at least one component as the referenced microbial organism is found in nature.
  • the term includes a microbial organism that is removed from some or all components as it is found in its natural environment.
  • the term also includes a microbial organism that is removed from some or all components as the microbial organism is found in non-naturally occurring environments. Therefore, an isolated microbial organism is partly or completely separated from other substances as it is found in nature or as it is grown, stored or subsisted in non-naturally occurring environments.
  • Specific examples of isolated microbial organisms include partially pure microbes, substantially pure microbes and microbes cultured in a medium that is non-naturally occurring.
  • microbial As used herein, the terms "microbial,” “microbial organism” or “microorganism” are intended to mean any organism that exists as a microscopic cell that is included within the domains of archaea, bacteria or eukarya. Therefore, the term is intended to encompass prokaryotic or eukaryotic cells or organisms having a microscopic size and includes bacteria, archaea and eubacteria of ail species as well as eukaryotic microorganisms such as yeast and fungi. The term also includes cell cultures of any species that can be cultured for the production of a biochemical.
  • CoA or "coenzyme A” is intended to mean an organic cofactor or prosthetic group (nonprotein portion of an enzyme) whose presence is required for the activity of many enzymes (the apoenzyme) to form an active enzyme system.
  • Coenzyme A functions in certain condensing enzymes, acts in acetyl or other acyl group transfer and in fatty acid synthesis and oxidation, pyruvate oxidation and in other acetylation.
  • substantially anaerobic when used in reference to a culture or growth condition is intended to mean that the amount of oxygen is less than about 10% of saturation for dissolved oxygen in liquid media.
  • the term also is intended to include sealed chambers of liquid or solid medium maintained with an atmosphere of less than about 1 % oxygen,
  • Exogenous as it is used herein is intended to mean that the referenced molecule or the referenced activity is introduced into the host microbial organism.
  • the molecule can be introduced, for example, by introduction of an encoding nucleic acid into the host genetic material such as by integration into a host chromosome or as non-chromosomal genetic material such as a plasmid. Therefore, the term as it is used in reference to expression of an encoding nucleic acid refers to introduction of the encoding nucleic acid in an expressible form into the microbial organism. When used in reference to a biosynthetie activity, the term refers to an activity that is introduced into the host reference organism.
  • the source can be, for example, a homologous or heterologous encoding nucleic acid that expresses the referenced activity following introduction into the host microbial organism. Therefore, the term “endogenous” refers to a referenced molecule or activity that is present in the host. Similarly, the term when used in reference to expression of an encoding nucleic acid refers to expression of an encoding nucleic acid contained within the microbial organism. The term “heterologous” refers to a molecule or activity derived from a source other than the referenced species whereas
  • homologous refers to a molecule or activity derived from the host microbial organism.
  • exogenous expression of an encoding nucleic acid of the invention can utilize either or both a heterologous or homologous encoding nucleic acid.
  • the more than one exogenous nucleic acids refers to the referenced encoding nucleic acid or biosynthetie activity, as discussed above. It is further understood, as disclosed herein, that such more than one exogenous nucleic acids can be introduced into the host microbial organism on separate nucleic acid molecules, on polycistronic nucleic acid molecules, or a combination thereof, and still be considered as more than one exogenous nucleic acid. For example, as disclosed herein a microbial organism can be engineered to express two or more exogenous nucleic acids encoding a desired pathway enzyme or protein.
  • two exogenous nucleic acids encoding a desired activity are introduced into a host microbial organism
  • the two exogenous nucleic acids can be introduced as a single nucleic acid, for example, on a single plasmid, on separate plasmids, can be integrated into the host chromosome at a single site or multiple sites, and still be considered as two exogenous nucleic acids.
  • exogenous nucleic acids can be introduced into a host organism in any desired combination, for example, on a single piasmid, on separate plasmids, can be integrated into the host chromosome at a single site or multiple sites, and still be considered as two or more exogenous nucleic acids, for example three exogenous nucleic acids.
  • the number of referenced exogenous nucleic acids or biosynthetic activities refers to the number of encoding nucleic acids or the number of biosynthetic activities, not the number of separate nucleic acids introduced into the host organism.
  • the non-naturally occurring microbial organisms of the in vention can contain stable genetic alterations, which refers to microorganisms that can be cultured for greater than five generations without loss of the alteration.
  • stable genetic alterations include modifications that persist greater than 10 generations, particularly stable modifications will persist more than about 25 generations, and more particularly, stable genetic modifications will be greater than 50 generations, including indefinitely.
  • E. coli metabolic modifications are described with reference to a suitable host organism such as E. coli and their corresponding metabolic reactions or a suitable source organism for desired genetic material such as genes for a desired metabolic pathway.
  • a suitable host organism such as E. coli and their corresponding metabolic reactions or a suitable source organism for desired genetic material such as genes for a desired metabolic pathway.
  • desired genetic material such as genes for a desired metabolic pathway.
  • the E. coli metabolic alterations exemplified herein can readily be appl ed to other species by incorporating the same or analogous encoding nucleic acid from species other than the referenced species.
  • S uch genetic alterations include, for example, genetic alterations of species homologs, in general, and in particular, orthologs, paralogs or nonorthologous gene displacements.
  • An ortholog is a gene or genes that are related by vertical descent and are responsible for substantially the same or identical functions in different organisms.
  • mouse epoxide hydrolase and human epoxide hydrolase can be considered orthologs for the biological function of hydrolysis of epoxides.
  • Genes are related by vertical descent when, for example, they share sequence similarity of sufficient amount to indicate they are homologous, or related by evolution from a common ancestor.
  • G enes can also be considered orthologs if they share three-dimensional structure but not necessarily sequence similarity, of a sufficient amount to indicate that they have evolved from a common ancestor to the extent that the primary sequence similarity is not identifiable.
  • Genes that are orthologous can encode proteins with sequence similarity of about 25% to 100% amino acid sequence identity. Genes encoding proteins sharing an amino acid similarity less that 25% can also be considered to have arisen by vertical descent if their three-dimensional structure also shows similarities. Members of the serine protease family of enzymes, including tissue plasminogen activator and elastase, are considered to have arisen by vertical descent from a common ancestor.
  • Orthologs include genes or their encoded gene products that through, for example, evolution, have diverged in structure or overall activity. For example, where one species encodes a gene product exhibiting two functions and where such functions have been separated into distmct genes in a second species, the three genes and their corresponding products are considered to be orthologs. For the production of a biochemical product, those skilled in the art will understand that the orthologous gene harboring the metabolic activity to be introduced or disrupted is to be chosen for construction of the non-naturally occurring microorganism. An example of orthologs exhibiting separable activities is where distinct activities have been separated into distinct gene products between two or more species or within a single species.
  • a specific example is the separation of elastase proteolysis and plasminogen proteolysis, two types of serine protease activity, into distinct molecules as plasminogen activator and elastase.
  • a second example is the separation of mycoplasma 5 '-3' exonuclease and Drosophila DNA polymerase III activity.
  • the DN A polymerase from the first species can be considered an ortholog to either or both of the exonuclease or the polymerase from the second species and vice versa.
  • paralogs are homologs related by, for example, duplication followed by evolutionary divergence and have similar or common, but not identical functions
  • Paralogs can originate or derive from, for example, the same species or from a different species.
  • microsomal epoxide hydrolase epoxide hydrolase I
  • soluble epoxide hydrolase epoxide hydrolase II
  • Paraiogs are proteins from the same species with significant sequence similarity to each other suggesting that they are homologous, or related through co-evolution from a common ancestor.
  • Groups of paralogous protein families include Hip A homo logs, luciferase genes, peptidases, and others.
  • a nonorthologous gene displacement is a nonorthologous gene from one species that can substitute for a referenced gene function in a different species. Substitution includes, for example, being able to perform substantially the same or a similar function in the species of origin compared to the referenced function in the differen species. Although generally, a nonorthologous gene displacement will be identifiable as structurally related to a known gene encoding the referenced function, less structurally related but functionally similar genes and their corresponding gene products nevertheless will still fall within the meaning of the term as it is used herein.
  • a nonorthologous gene includes, for example, a paralog or an unrelated gene.
  • Orthoiogs, paraiogs and nonorthologous gene displacements can be determined by methods well known to those skilled in the art. For exampl e, inspection of nucleic acid or amino acid sequences for two polypeptides will reveal sequence identity and similarities between the compared sequences. Based on such similarities, one skilled in the art. can determine if the similarity is sufficiently high to indicate the proteins are related through evolution from a common ancestor. Algorithms well known to those skilled in the art, such as Align, BLAST ' , Clustal W and others compare and determine a raw sequence similarity or identity, and also determine the presence or significance of gaps in the sequence which can be assigned a weight or score.
  • Such algorithms also are known in the art and are similarly applicable for determining nucleotide sequence similarity or identity. Parameters for sufficient similarity to determine relatedness are computed based on well known methods for calculating statistical similarity, or the chance of finding a similar match in a random polypeptide, and the significance of the match determined. A computer comparison of two or more sequences can, if desired, also be optimized visually by those skilled in the art. Related gene products or proteins can be expected to have a high similarity, for example, 25% to 100% sequence identity.
  • Proteins that are unrelated can have an identity which is essentially the same as would be expected to occur by chance, if a database of sufficient size is scanned (about 5%). Sequences between 5% and 24% may or may not represent sufficient homology to conclude that the compared sequences are related. Additional statistical analysis to determine the significance of such matches given the size of the data set can be carried out to determine the relevance of these sequences.
  • Exemplary parameters for determining relatedness of two or more sequences using the BLAST algorithm can be as set forth below. Briefly, amino acid sequence alignments can be performed using BLASTP version 2,0.8 (Jan-05-1999) and the following parameters: Matrix: 0 BLOSUM62; gap open: 11; gap extension: 1; x dropoff: 50; expect: 10.0; wordsize: 3; filter: on. Nucleic acid sequence alignments can be performed using BLASTP version 2,0.8 (Jan-05-1999) and the following parameters: Matrix: 0 BLOSUM62; gap open: 11; gap extension: 1; x dropoff: 50; expect: 10.0; wordsize: 3; filter: on. Nucleic acid sequence alignments can be performed using
  • This invention is directed, in part, to engineered hiosynthetic pathways to improve carbon flux through the central metabolism intermediate such as acetyl-CoA, succinyl-CoA, or other reductive TCA cycle intermediate, en route to production of a desired product.
  • the present invention provides non-naturaily occurring microbial organisms having one or more exogenous genes encoding enzymes that can catalyze various enzymatic transformations en route to acetyl-CoA, succmyl-CoA, or other reductive TCA intermediate.
  • these enzymatic transformations are part of the reductive tricarboxylic acid (RTCA) cycle and are used to improve product yields from carbohydrate-based carbon feedstock.
  • RTCA reductive tricarboxylic acid
  • the present invention increases the yields of desired product, as disclosed herein, by (i) enhancing carbon fixation via the reductive TCA cycle, and/or (ii) accessing additional reducing equivalents from gaseous syngas components such as CO, C0 2 , and/or H 2 .
  • the CQ 2 -fixmg reductive tricarboxylic acid (RTCA) cycle is an endergenic anabolic path way of CO?, assimilation which uses NAD(P)H and ATP ( Figure 2a).
  • One turn of the RTCA cycle assimilates two moles of CO? into one mole of acetyl-CoA, or four moles of CO? into one mole of oxaloacetate.
  • This additional availability of acetyl-CoA improves the maximum theoretical yield of product molecules derived from carbohydrate-based carbon feedstock.
  • Exemplary carbohydrates include but are not limited to glucose, sucrose, xylose, arabinose and glycerol.
  • the reductive TCA cycle coupled with carbon monoxide and hydrogenase enzymes, can be employed to allow syngas utilization by microorganisms.
  • Synthesis gas is a mixture of primarily H? and CO that can be obtained via gasification of any organic feedstock, such as coal, coal oil, natural gas, biornass, or waste organic matter.
  • organic feedstock such as coal, coal oil, natural gas, biornass, or waste organic matter.
  • Numerous gasification processes have been developed, and most designs are based on partial oxidation, where limiting oxygen avoids full combustion, of organic materials at high temperatures (500-1500°C) to provide syngas as a 0.5:1-3:1 3 ⁇ 4/CO mixture, in addition to coal, biomass of many types has been used for syngas production and represents an inexpensive and flexible feedstock for the biological production of renewable chemicals and fuels.
  • reductive and oxidative (Krebs) TCA cycles are present in the same organism (Hugler et al., supra (2007); Siebers et al., J. Bacterial. 186:2179-2194 (2004)).
  • Some methanogens and obligate anaerobes possess incomplete oxidative or reductive TCA cycles that may function to synthesize biosynthetic intermediates (Ekiel et al, J. Bacterial. 162:905-908 (1985); Wood et al., FEA S Microbial. Rev. 28:335-352 (2004)).
  • the components of synthesis gas can provide sufficient CO?., reducing equivalents, and ATP for the reductive TCA cycle to operate.
  • One turn of the RTCA cycle assimilates two moles of C0 2 into one mole of acetyl-CoA and requires 2 ATP and 4 reducing equivalents.
  • CO and 3 ⁇ 4 can provide reducing equivalents by means of carbon monoxide dehydrogenase and hydrogenase enzymes, respectively.
  • Reducing equivalents can come in the form ofNADH, NADPH, FADH, reduced quinones, reduced ferredoxins, and reduced flavodoxins.
  • the reducing equivalents can serve as cofactors for the RTCA cycle enzymes (e.g., malate dehydrogenase, fumarate reductase, alpha- ketogiutarate: ferredoxin oxidoreductase (alternatively known as 2 ⁇ oxoglutarate:ferredoxin oxidoreductase, alpha-ketoglutarate synthase, or 2-oxoglutarate synthase), and isocitrate dehydrogenase).
  • malate dehydrogenase e.g., malate dehydrogenase, fumarate reductase, alpha- ketogiutarate: ferredoxin oxidoreductase (alternatively known as 2 ⁇ oxoglutarate:ferredoxin oxidoreductase, alpha-ketoglutarate synthase, or 2-oxoglutarate synthase)
  • isocitrate dehydrogenase
  • the electrons from these reducing equivalents can altematively pass through an ion-gradient producing electron transport chain where they are passed to an acceptor such as oxygen, nitrate, oxidized metal ions, protons, or an electrode.
  • the ion-gradient can then be used for ATP generation via an ATP synthase or similar enzyme.
  • TCA cycle Many of the enzymes in the TCA cycle are reversible and can catalyze reactions in the reductive and oxidative directions. However, some TCA cycle reactions are irreversible in vivo and thus different enzymes are used to catalyze these reactions in the directions required for the reverse TCA cycle. These reactions are: 1. conversion of citrate to oxaloacetate and acetyl-CoA, 2. conversion of fumarate to succinate, and 3, conversion of succinyl-CoA to alpha-ketoglutarate. In the TCA cycle, citrate is formed from the condensation of oxaloacetate and acetyl-CoA.
  • citrate lyase can be coupled to acetyl-CoA synthetase, an acetyl-CoA transferase, or phosphotransacetylase and acetate kinase to form acetyl-CoA and oxaloacetate from citrate.
  • succinate dehydrogenase The conversion of succinate to fumarate is catalyzed by succinate dehydrogenase while the reverse reaction is catalyzed by fumarate reductase.
  • succinyl-CoA is formed from the NAD(P) ; dependent decarboxylation of oxaloacetate by the alpha- ketoglutarate dehydrogenase complex.
  • the reverse reaction is catalyzed by alpha- ketoglutarate:ferredoxin oxidoreductase.
  • An organism capable of utilizing the reverse tricarboxylic acid cycle to enable production of acetyl-CoA-derived products on 1) CO, 2) C0 2 and H 2 , 3) CO and C0 2 , 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, C0 2 , and H 2 can include any of the following enzyme activities: ATP-citrate lyase, citrate lyase, aconitase, isocitrate dehydrogenase, alpha-ketoglutarate:ferredoxm oxidoreductase, succinyl-CoA synthetase, succinyl-CoA transferase, fumarate reductase, fumarase, malate dehydrogenase, acetate kinase, phosphotransacetylase, acetyl-CoA synthetase, NAD(P)H:ferredoxin
  • Carbon from syngas can be fixed via the reverse TCA cycle and components thereof. Specifically, the combination of certain syngas-utilization pathway components with the pathways for formation of a desired product from acetyl-CoA. results in high yields of these products by providing an efficient mechanism for fixing the carbon present in carbon dioxide, fed exogenously or produced endogenous! ⁇ ' from CO, into acetyi-CoA.
  • a desired product pathway in a non-naturally occurring microbial organism of the invention can utilize any combination of CO, H 2 , or mixtures thereof to enhance the yields of biosynthetic steps involving reduction, including addition to driving the reductive TCA cycle.
  • a non-naturally occurring microbial organism having a desired product pathway includes at least one exogenous nucleic acid encoding a reductive TCA.
  • the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ketoglutarate: ferredoxm oxidoreductase; and at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H: ferredoxm oxidoreductase, and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) CO 2 and H 2 , 3) CO and C0 2 , 4) synthesis gas comprising CO and 3 ⁇ 4, and 5) synthesis gas comprising CO, C0 2 , and 3 ⁇ 4.
  • a method includes culturing a non-naturally occurring microbial organism having a desired product pathway also comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme.
  • the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha- ketoglutarate:ferredoxin oxidoreductase.
  • such an organism can also include at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) C0 2 and H 2 , 3) CO and CO?, 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, CO 2 , and H 2 to produce a product.
  • exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) C0 2 and H 2 , 3) CO and CO?, 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, CO 2 , and H 2 to produce a product
  • a non-naturally occurring microbial organism having a desired product pathway further includes at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA.
  • the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ketoglutarate: ferredoxm oxidoreductase.
  • a non-naturally occurring microbial organism having a desired pathway includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide and/or hydrogen, thereby increasing the yield of redox-liraited products via carbohydrate-based carbon feedstock.
  • the at least one exogenous nucleic acid is selected from a carbon monoxide dehydrogenase, a hydrogenase, an NAD(P)H: ferredoxin oxidoreductase, and a ferredoxin.
  • the present invention provides a method for enhancing the availability of reducing equivalents in the presence of carbon monoxide or hydrogen thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock, the method includes culturing this non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce a desired product.
  • the non-iiaturally occurring microbial organism having a desired product pathway includes two exogenous nucleic acids each encoding a reductive TCA pathway enzyme. In some embodiments, the non-naturally occurring microbial organism having a desired product pathway includes three exogenous nucleic acids each encoding a reductive TCA pathway enzyme, in some embodiments, the non-naturally occurring microbial organism includes three exogenous nucleic acids encoding an ATP-citrate lyase, a fumarate reductase, and an alpha ⁇ ketoglutarate:ferredoxin oxidoreductase.
  • the non-naturally occurring microbial organism includes three exogenous nucleic acids encoding a citrate lyase, a fumarate reductase, and an alpha-ketoglutarate:ferredoxin oxidoreductase.
  • the non-naturally occurring microbial organisms having a desired product pathway further include an exogenous nucleic acid encoding an enzyme selected from a pyru aterferredoxin oxidoreductase, an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a succinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a phospbotransacetylase, an acetyl-CoA synthetase, an NAD(P)H:ferredoxin oxidoreductase, and combinations thereof.
  • an enzyme selected from a pyru aterferredoxin oxidoreductase, an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a
  • the non-naturally occurring microbial organism having a desired product pathway further includes an exogenous nucleic acid encoding an enzyme selected from carbon monoxide dehydrogenase, acetyl-CoA. synthase, ferredoxin, NAD(P)H:ferredoxin oxidoreductase and combinations thereof.
  • the non-naturally occurring microbial organism having a desired product pathway utilizes a carbon feedstock selected from CO, C0 2 , C0 2 and H 2 , synthesis gas comprising CO and H 2 , and synthesis gas comprising CO, CO 3 ⁇ 4 and 3 ⁇ 4.
  • the non-naturally occurring microbial organism having a desired product pathway utilizes hydrogen for reducing equivalents.
  • the non-naturally occurring microbial organism having a desired product pathway utilizes CO for reducing equivalents
  • the non-naturally occurring microbial organism having a desired product pathway utilizes combinations of CO and hydrogen for reducing equivalents,
  • the non-naturally occurring microbial organism having a desired product pathway further includes one or more nucleic acids encoding an enzyme selected from a phosphoenolpyruvate carboxylase, a phosphoenolpyruvate carboxykinase, a pyruvate carboxylase, and a malic enzyme.
  • the non-naturaliy occurring microbial organism having a desired product pathway further includes one or more nucleic acids encoding an enzyme selected from a malate dehydrogenase, a fumarase, a fumarate reductase, a succinyl-CoA synthetase, and a suceinyl-CoA transferase.
  • the non-naturaliy occurring microbial organism having a desired product pathway further includes at least one exogenous nucleic acid encoding a citrate lyase, an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a succinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a phosphotransacetylase, an acetyl-CoA synthetase, and a ferredoxin.
  • the microbial organisms and methods of the invention can provide production efficiencies of at least 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% ⁇ , 90%, 91%, 92%, 93%, 94%, 95%, 96% ⁇ , 97%, 98%, 99% and/or approaching maximum theoretical yield for fixing C02.
  • the microbial organisms and methods of the invention can provide production efficiencies of at least 60% ⁇ , 65%, 70%), 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86% ⁇ , 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and/or approaching maximum theoretical yield for producing hydrogen or 2[H].
  • the microbial organisms and methods of the invention can provide production efficiencies of at least 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82% ⁇ , 83%, 84%, 85%, 86%, 87% ⁇ , 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and/or approaching maximum theoretical yield for producing reducing equivalents.
  • the microbial organisms and methods of the invention can provide production efficiencies of at least 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%), 98%, 99% and/or approaching maximum theoretical yield for producing
  • the microbial organisms of the invention can utilize carbon fixation efficiencies sufficient to grow ceils on a large scale chemotrophically while maintaining anaerobic or microanaerobic conditions (that is, chemotrophic carbon fixation).
  • chemotrophic carbon fixation can utilize a chemotrophic carbon fixation cycle via a phototrophic reductive TCA cycle pathway.
  • the microbial organisms of the invention can utilize, for example, photrotrophic, including photoautotrophic, carbon fixation in the absence of light harvesting (that is, does not require light or is not coupled to photosynthesis), in the absence of photophosphoiyiation, in the absence of oxygenic phosphorylation or photophosphorylation, and/or in the absence of anoxygenic phosphorylation or photophosphorylation.
  • the microbial organisms of the invention can utilize carbon fixation in the absence of (1) photobiologieai; (2) photoelectrochemical splitting of water and/or (3) thermosolar hydrogen production, as disclosed herein.
  • a host microorganism that is naturally devoid of a carbon fixation pathway, including, for example, a reductive TCA cycle or other carbon fixation cycle.
  • a host microorganism lacks an endogenous carbon fixation cycle and/or reductive TCA cycle, as disclosed herein.
  • the host microorganism can naturally contain one or more enzymes in a reductive TCA or carbon fixation cycle so long as the host microorganisms lacks at least one enzyme that confers a reductive TCA cycle or carbon fixation cycle to the host microorganism.
  • microorganism is understood herein to be a microorganism devoid of or lacking an endogenous reductive TCA cycle and/or carbon fixation cycle.
  • the chosen host microorganism can be chosen, for example, from microorganisms other than photosynthetic microorganisms (phototrophs, including, for example, photoheterotrophs and/or photoautotrophs), including plant microorganisms and/or other microorganisms normally having a carbon fixation cycle.
  • phototrophs including, for example, photoheterotrophs and/or photoautotrophs
  • the chosen host microorganism also can be chosen, for example, from microorganisms other than iithotrophs (including, for example, iithoheterotrophs and/or lithoautotrophs) and/or chosen, for example, from microorganisms other than organotropic (including chemoheterotrophs and/or chemoa totrophs).
  • the host can be chosen from a microorganism other than, for example, a green sulphur bacteria such as Chlorobiales or
  • C limicola
  • cyanobacterium cyanobacterium
  • proteobacteria Archaea and/or Crenarchaeota, including for
  • reduetiveTCA cycle is capable of increasing theroretical yield of biomass and/or biosynthetic products other than acetate.
  • reductive TC A cycle can operate at a sufficient rate to sustain and/or improve g owth and/or metabolic product production, including acetate and/or other natural or engineered metabolic products such as those exemplified herein.
  • the invention provides a non-naturally occurring microbial organism, comprising a microbial organism having pathway for a desired product, including those products disclosed herein, comprising at least one exogenous nucleic acid encoding a desired product pathway enzyme or protein expressed in a sufficient amount to produce a desired product, where the non- naturally occurring microbial organism further comprises (i) a reductive TCA pathway comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme, wherem the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ketoglutarate:ferredoxin oxidoreductase; (ii) a reductive TCA pathway comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme, wherein the at least one exogenous nucleic acid is selected from a pyr
  • the microbial organism comprising (i) can further comprise an exogenous nucleic acid encoding an enzyme selected from a pyruvate :ferredoxin oxidoreductase, an aconitase, an isoci irate dehydrogenase, a
  • succinyl-CoA synthetase a suecinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a phosphotransacetyfase, an acetyl-CoA synthetase, an NAD(P)H:ferredoxin oxidoreductase, ferredoxin, and combinations thereof.
  • the microbial organism comprising (ii) can further comprise an exogenous nucleic acid encoding an enzyme selected from an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a suecinyl- CoA transferase, a fumarase, a malate dehydrogenase, and combinations thereof.
  • the invention provides a non-naturally occurring microbial organism comprising a microbial organism having a reductive TCA pathway comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA, wherein the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ketoglutarate :ferredoxin oxidoreductase; and wherein the microbial organism optionally: produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway; produces a desired product at a concentration of at least 0.01 grams per liter of culture; produces a desired product with a yield of at least 0.005 grams per wet cell weight; produces a desired product at a rate of at least 0.01 grams per
  • the microbial organism produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway. In another embodiment, the microbial organism produces a desired product at a concentration of at least 0.01 grams per liter of culture. In other embodiments, the microbial organism produces a desired product with a yield of at least 0.005 grams per wet cell weight. In some embodiments, the microbial organism produces a desired product at a rate of at least 0.01 grams per liter per hour. In another embodiment, the microbial organism is present in a culture volume of at least one liter. In some embodiments, the microbial organism is resistant to toxicity of the desired product.
  • the microbial organism can comprise at least two or at least three exogenous nucleic acids each encoding a reductive TCA pathway enzyme, for example, three exogenous nucleic acids encode an ATP-citrate lyase, a fumarate reductase, and an alpha-ketoglutarateiferredoxin oxidoreductase; or encode a citrate lyase, a fumarate reductase, and an alpha-ketoglutarate: ferredoxin oxidoreductase.
  • a microbial organism can further comprise an exogenous nucleic acid encoding an enzyme selected from a pyruvate: ferredoxin oxidoreductase, an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a succinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a phospbotransacetylase, an acetyl-CoA synthetase, an NAD(P)H:ferredoxin oxidoreductase, ferredoxin, and combinations thereof.
  • an enzyme selected from a pyruvate: ferredoxin oxidoreductase, an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a succinyl
  • the microbial organism can further comprise an exogenous nucleic acid encoding an enzyme selected from carbon monoxide dehydrogenase, hydrogenase, NAD(P)H: ferredoxin oxidoreductase, ferredoxin, and
  • the microbial organism can utilize a carbon feedstock selected from CO, C0 2 , and H 2 , synthesis gas comprising CO and H 2 , and synthesis gas comprising CO, C0 2 , and H 2 .
  • the such a microbial organism can further comprise a pathway for a desired product.
  • the microbial organism can comprise an isopropanoi pathway, said isopropanoi pathway converting acetyl-CoA to isopropanoi, wherein said isopropanoi pathway comprises 1) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • phosphotransacetoacetylase/aeetoacetate kinase 3) an acetoacetate decarboxylase, and 4) an isopropanoi dehydrogenase; a 1 ,3-butanediol pathway; the 1,3-butanediol pathway converting acetyl-CoA to 1 ,3-butanediol, wherein said 1,3-butanediol pathway comprises at least three enzymes selected from 1) Acetoacetyl-CoA thiolase (AtoB), 2) Acetoacetyl-CoA reductase
  • CoA transferase an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • the at least one exogenous nucleic acid can be a heterologous nucleic acid.
  • a non-naturally occurring microbial organism can be in a substantially anaerobic culture medium.
  • the invention additionally provides a method for enhancing carbon flux through acetyl-CoA, comprising cuituring a non- natural ly occurring microbial organism of the invention under condi tions and for a suffi cient period of time to produce a product having acetyl-CoA as a building block.
  • Such a method can be performed, for example, with the non-naturally occurring microbial organism is in a substantially anaerobic culture medium.
  • the method can be performed where the microbial organism utilizes a carbon feedstock selected from CO, C0 2 ,and H 2 , synthesis gas comprising CO and H 2 , and synthesis gas comprising CO, C0 2 , and H 2 .
  • the invention additionally provides a non-naturally occurring microbial organism comprising a microbial organism having a Wood-Ljungdahl pathway comprising at least one exogenous nucleic acid encoding a Wood-Ljungdahl pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA, wherein the at least one exogenous nucleic acid is selected from a) Formate dehydrogenase, b) Formyitetrahydrofolate synthetase, c) Methenyltetrahydrofolate cyclohydrolase, d) Methylenetetrahydrofolate dehydrogenase, e) Methyl eneietrahydro folate reductase, f) Methyltetrahydrofolatexorrinoid protein
  • microbial organism optionally: produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway; produces a desired product at a concentration of at least 0.01 grams per liter of culture; produces a desired product with a yield of at least 0.005 grams per wet cell weight; produces a desired product at a rate of at least 0.01 grams per liter per hour; is present in a culture volume of at least one liter; and/or is resistant to toxicity of the desired product.
  • the microbial organism produces a desired product with at least 1 % higher yield than a parent microbial organism lacking said reductive TCA pathway. In another embodiment, the microbial organism produces a desired product at a concentration of at least 0.01 grams per liter of culture. In other embodiments, the microbial organism produces a desired product with a yield of at least 0.005 grams per wet cell weight. In some embodiments, the microbial organism produces a desired product at a rate of at least 0.01 grams per liter per hour, in another embodiment, the microbial organism is present in a culture volume of at least one liter. In some embodiments, the microbial organism is resi stant to toxicity of t he desired product.
  • the microbial organism can comprise at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, or at least twelve exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme.
  • such a microbial organism can further comprise a pathway for a desired product.
  • Such a desired product pathway can be, for example, an isopropanol pathway, the isopropanol pathway converting acetyl-CoA to isopropanol, wherein said isopropanol pathway comprises 1) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyi-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • phosphotransacetoacetylase/acetoacetate kinase 3) an acetoacetate decarboxylase, and 4) an isopropanol dehydrogenase; a 1,3-butanediol pathway; said 1,3-butanediol pathway converting acetyl-CoA to 1,3-butanediol, wherein the 1,3-butanediol pathway comprises at least three enzymes selected from 1) Acetoacetyl-CoA thiolase, 2) Acetoacetyl-CoA.
  • CoA transferase an acetoaeetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • the invention further provides a non-naturally occurring microbial organism comprising a microbial organism having a methanol Wood-Ljungdahl pathway comprising at least one exogenous nucleic acid encoding a methanol Vood-Ljungdahl pathway enzyme expressed in a sufficient amount to enhance carbon flux through acetyl-CoA, wherein the at least one exogenous nucleic acid is selected from a) Methanol methyltransferase, b) Corrinoid protein, c) Methyltetrahydro folate: corrinoid protein methyltransferase, d)
  • Methyltetrahydrofolatexorrinoid protein methyltransferase e) Corrinoid iron-sulfur protein, f) Nickel-protein assembly protein, g) Ferredoxin, h) Acetyl-CoA synthase, i) Carbon monoxide dehydrogenase, j) Pyruvate ferredoxin oxidoreductase or pyruvate dehydrogenase, k) pyruvate formate lyase, and 1) NAD(P)H: ferredoxin oxidoreductase; and further where the microbial organism optionally produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway; produces a desired product at a concentration of at least 0.01 grams per liter of culture; produces a desired product with a yield of at least 0.005 grams per wet cell weight; produces a desired product at a rate of at least 0.01
  • the microbial organism produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway. In another embodiment, the microbial organism produces a desired product at a concentration of at least 0.01 grams per liter of culture. In other embodiments, the microbial organism produces a desired product with a yield of at least 0.005 grams per wet cell weight.
  • the microbial organism produces a desired product at a rate of at least 0.01 grams per liter per hour, in another embodiment, the microbial organism is present in a culture volume of at least one liter. In some embodiments, the microbial organism is resistant to toxicity of the desired product.
  • such a microbial organism can comprise at least two, at least three, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or at least eleven exogenous nucleic acids each encoding a methanol
  • the microbial organism can further a pathway for a desired product.
  • a desired product can be, for example, an isopropanol pathway, the isopropanol pathway converting acetyl-CoA to isopropanol, wherein said isopropanol pathway comprises 1) an acetoacetyl-CoA thiolase, 2) an acetoacetyi-CoA transferase, an acetoacetyi-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • CoA transferase an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • the invention provides a non-naturally occurring microbial organism comprising at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock, wherein said at least one exogenous nucleic acid is selected from a carbon monoxide dehydrogenase, a hydrogenase, an
  • NAD(P)H ferredoxin oxidoreductase, and a ferredoxin
  • a microbial organism optionally produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway; produces a desired product at a concentration of at least 0.01 grams per liter of culture; produces a desired product with a yield of at least 0.005 grams per wet cell weight; produces a desired product at a rate of at least 0.01 grams per liter per hour; is present in a culture volume of at least one liter; and/or is resistant to toxicity of the desired product.
  • the microbial organism produces a desired product with at least 1% higher yield than a parent microbial organism lacking said reductive TCA pathway. In another embodiment, the microbial organism produces a desired product at a concentration of at least 0.01 grams per liter of culture. In other embodiments, the microbial organism produces a desired product with a yield of at least 0.005 grams per wet cell weight. In some embodiments, the microbial organism produces a desired product at a rate of at least 0.01 grams per liter per hour. In another embodiment, the microbial organism is present in a culture voiume of at least one liter. In some embodiments, the microbial organism is resistant to toxicity of the desired product.
  • such a microbial organism can comprise at least two, at least three or at least four exogenous nucleic acids encoding said enzymes.
  • the four exogenous nucleic acids can encode a carbon monoxide dehydrogenase, a hydrogenase, an NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin.
  • such a microbial organism can further comprise one or more nucleic acids encoding an enzyme selected from a phosphoenolpyruvate carboxylase, a phosphoenoipyruvate carboxykinase, a pyruvate carboxylase, and a malic enzyme; or one or more nucleic acids encoding an enzyme selected from a malate dehydrogenase, a fumarase, a fumarate reductase, a succinyl-CoA synthetase, and a succinyi-CoA transferase.
  • such a microbial organism can comprise a pathway for a desired product.
  • a desired product can be, for example, a 1,4-butanediol pathway comprising at least one exogenous nucleic acid encoding an enzyme selected from 1) Succinyl- CoA transferase, or Succinyl-CoA synthetase (or succinyl-CoA ligase), 2) Succinyl-CoA reductase (aldehyde forming), 3) 4-Hydroxybutyrate dehydrogenase, 4) 4-Hydroxybutyrate kinase, 5) Phosphotrans-4-hydroxybutyrylase, 6) 4-HydroxybutyryI-CoA reductase (aldehyde forming), 7) 1 ,4-butanediol dehydrogenase, 8) Succinate reductase, 9) Succinyl-CoA transferase, or
  • such a microbial organism can comprise a pathway selected from a 6-aminocaproic acid pathway, a hexamethylenedi amine pathway, an adipic acid pathway, a 1,3-propanediol pathway, and a glycerol pathway.
  • the invention provides a method for enhancing the availability of reducing equivalents in the presence of carbon monoxide or hydrogen thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock, the method comprising culturing such a non-naturally occurring microbial organism under conditions and for a sufficient period of time to produce a product.
  • the invention further provides a non-naturally occurring microbial organism comprising a microbial organism having a reductive TCA pathway comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme; said at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ketoglutaraterferredoxin oxidoreductase; and at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H:ferredoxm
  • oxidoreductase and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) C0 2 and I3 ⁇ 4, 3) CO and C0 2 , 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, C0 2 , and H 2 ; and where such a microbial organism optionally produces a desired product with at least 1 % higher yield than a parent microbial organism lacking said reductive TCA pathway; produces a desired product at a concentration of at least 0.01 grams per liter of culture; produces a desired product with a yield of at least 0.005 grams per wet cell weight; produces a desired product at a rate of at least 0.01 grams per liter per hour; is present in a culture volume of at least one liter; and/ or is resistant to toxicity of the desired product.
  • the microbial organism produces a desired product with at least 1 % higher yield than a parent microbial organism lacking said reductive TCA pathway. In another embodiment, the microbial organism produces a desired product at a concentration of at least 0.01 grams per liter of culture. In other embodiments, the microbial organism produces a desired product with a yield of at least 0.005 grams per wet cell weight. In some embodiments, the microbial organism produces a desired product at a rate of at least 0.01 grams per liter per hour. In another embodiment, the microbial organism is present in a culture volume of at least one liter. In some embodiments, the microbial organism is resi stant to toxicity of the desired product.
  • such a microbial organism can further comprise at least one exogenous nucleic acid encoding a citrate lyase, an aconitase, an isocitrate dehydrogenase, a succinyl-CoA synthetase, a succinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a phosphotransacetylase, and an acetyl-CoA synthetase.
  • Such a microbial organism can also comprise a pathway for a desired product.
  • Such a desired product can be, for example, an isopropanol pathway, the isopropanol pathway converting acetyi-CoA to isopropanol, wherein said isopropanol pathway comprises 1 ) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a phosphotraiisacetoacetylase/ ' acetoacetate kinase, 3) an acetoacetate
  • the invention additionally provides a method comprising culturmg such a non- naturally occurring microbial organism having a reductive TCA pathway comprising at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme; said at least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ket.oglutarate:ferredoxin oxidoreductase; and at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a
  • NAD(P)H ferredoxin oxidoreductase, and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) C0 2 and I3 ⁇ 4, 3) CO and C0 2 , 4) synthesis gas comprising CO and 3 ⁇ 4, and 5) synthesis gas comprising CO, CQ->, and H 2 to produce a product.
  • the present invention provides a non-naturally occurring microbial organism that includes a microbial organism having a reductive TCA pathway in which at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme is expressed in a sufficient amount to enhance carbon flux through acetyl-CoA.
  • At least one exogenous nucleic acid is selected from an ATP-citrate lyase, citrate lyase, a fumarate reductase, and an alpha-ketoglutarate: ferredoxin oxidoreductase.
  • the non-naturally occurring microbial organism includes two exogenous nucleic acids each encoding a reductive TCA pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes three exogenous nucleic acids each encoding a reductive TCA pathway enzyme, in some embodiments, the non-naturally occurring microbial organism includes three exogenous nucleic acids encoding an ATP-citrate lyase, a fumarate reductase, and an alpha-ketoglutarate:ferredoxin oxidoreductase.
  • the non-naturally occurring microbial organism includes three exogenous nucleic acids encoding a citrate lyase, a fumarate reductase, and an alpha- ketoglutarate:ferredoxin oxidoreductase.
  • the non-naturally occurring microbial organism mcludes at least one exogenous nucleic acid that is a heterologous nucleic acid.
  • the non-naturally occurring microbial organism is in a
  • the non-naturally occurring microbial organism further includes an exogenous nucleic acid encoding an enzyme selected from a pyruvate :ferredoxin oxidoreductase, an aconitase, an isocitrate dehydrogenase, a succmyl-CoA synthetase, a succinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a
  • phosphotransacetylase an acetyi-CoA synthetase, an NAD(P)H:ferredoxin oxidoreductase, and combinations thereof.
  • the non-naturally occurring microbial organism further includes an isopropanol pathway, the isopropanol pathway converting acetyl-CoA to
  • isopropanol wherein the isopropanol pathway includes 1 ) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyi-CoA synthetase, or a phosphotransacetoacetylase/acetoacetate kinase, 3) an acetoacetate decarboxylase, and 4) an isopropanol dehydrogenase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the isopropanol pathway which is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes four enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1 ,3 -butanedioi pathway; said 1 ,3-butanediol pathway converting acetyl -Co A to 1,3- butanediol, wherein said 1,3-butanediol pathway comprises at least three enzymes selected from 1) Acetoacetyl-CoA thiolase (AtoB), 2) Acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), 3) 3-oxobutyraldehyde reductase (aldehyde reducing), 4) 4-hydroxy,2-butanone reductase, 5) Acetoacetyl-CoA reductase (CoA-dependent, aldehyde forming), 6) 3- oxobutyraldehyde reductase (ketone reducing), 7) 3-hydroxybutyraidehyde reductase
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1,3-butanediol pathway which is encoded by an exogenous nucleic acid.
  • the non-naturally occurring microbial organism include sat least two enzymes of the 1,3-butanediol pathway are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism includes at least three enzymes of the 1 ,3-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microb al organ sm further includes a 1 ,4-butanediol pathway, the 1 ,4-butanediol pathway converting acetyl-CoA to 1,4- butanediol, wherein the 1 ,4-butanediol pathway includes at least five enzymes selected from 1) Acetoacetyl-CoA thiolase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3)
  • Crotonase Crotonase (Crt), 4) Crotonyl-CoA. hydrolase (4-Budh), 5) 4-hydroxybutyryl-CoA. reductase (alcohol forming), 6) 4-hydroxybutyryl-CoA reductase (aldehyde forming), 7) 1 ,4-butanediol dehydrogenase, 8) 4-Hydroxybutyryl-CoA transferase, 4-Hydroxybutyryl-CoA synthetase, 4- Hydroxybutyryl-CoA hydrolase, or Phosphotrans-4-hydroxybutyrylase/4-Hydroxybutyrate kinase, and 9) 4-Hydroxybutyrate reductase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1 ,4-butanediol path way which is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturaliy occurring microbial organism includes at least four enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of said 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturaliy occurring microbial organism further includes a 4-hydroxybutyrate pathway, the 4-hydroxybutyrate pathway converting acetyl-CoA to 4-hydroxybutyrate, wherein the 4-hydroxybutyrate pathway includes at least five enzymes selected from 1 ) Acetoacetyl-CoA.
  • thiol ase (AtoB), 2) 3-HydroxybutyryI-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-HydroxybutyryI-CoA transferase, hydrolase or synthetase, 6) Phosphotrans-4-hydroxybutyrylase, and 7) 4- Hydroxybutyrate kinase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the 4-hydroxybutyrate pathway which is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least four enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids.
  • the non-naturaliy occurring microbial organism includes at least five enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. [00120] In some embodiments, the non-naturally occurring microbial organism further includes an exogenous nucleic acid encoding an enzyme selected from carbon monoxide dehydrogenase, acetyl-CoA. synthase, ferredoxin, AD(P)H :ferredoxin oxidoreductase and combinations thereof.
  • the non-naturally occurring microbial organism utilizes a carbon feedstock selected from CO, C0 2 , C0 2 and I3 ⁇ 4, synthesis gas comprising CO and H 2 , and synthesis gas comprising CO, C0 2 , and PL.
  • a non-naturally occurring microbial organism includes a microbial organism having a Wood-Ljungdahl pathway that includes at least one exogenous nucleic acid encoding a Wood-Ljungdahl pathway enzyme expressed in a sufficient amount to enhance carbon flux through acety -CoA.
  • the at least one exogenous nucleic acid is selected from a) Formate dehydrogenase, b) Formyltetrahydrofolate synthetase, c)
  • Methyltetrahydrofolate cyclohydrolase d) Methyienetetrahydrofolate dehydrogenase, e) Methylenetetrahydrofolate reductase, f) Methyltetrahydrofoiatexorrinoid protein
  • the non-naturally occurring microbial organism includes two exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes three exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non- naturally occurring microbial organism includes four exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes five exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme.
  • the non-naturally occurring microbial organism includes six exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes seven exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme, in some embodiments, the non-naturally occurring microbial organism includes eight exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes nine exogenous nucleic acids each encoding a Wood- Ljungdahl pathway enzyme.
  • the non-naturaliy occurring microbial organism includes ten exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes eleven exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-narurally occurring microbial organism includes twelve exogenous nucleic acids each encoding a Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturaily occurring microbial organism includes at least one exogenous nucleic acid that is a heterologous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes is in a substantially anaerobic culture medium.
  • the non-naturally occurring microbial organism further includes an isopropanol pathway, the isopropanol pathway converting acetyl-CoA to
  • the isopropanol pathway includes 1) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a phosphotransacetoacetylase/acetoacetate kinase, 3) an acetoacetate decarboxylase, and 4) an isopropanol dehydrogenase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the isopropanol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids. In some
  • the non-naturally occurring microbial organism includes the four enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1,3-butanediol pathway; the 1 ,3-butanediol pathway converting acetyl-CoA to 1,3- butanediol.
  • the 1,3-butanediol pathway includes at least three enzymes selected from 1) Acetoacetyl-CoA thiolase (AtoB), 2) Acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), 3) 3-oxobutyraldehyde reductase (aldehyde reducing), 4) 4-hydroxy,2-butanone reductase, 5) Acetoaeetyl-CoA reductase (Co A -dependent, aldehyde forming), 6) 3- oxobutyraldehyde reductase (ketone reducing), 7) 3-hydroxybutyraldehyde reductase, 8) Acetoacetyl-CoA reductase (ketone reducing), 9) 3-hydroxybutyryl-CoA reductase (aldehyde forming), 10) 3-hydroxybutyryl-CoA reductase (alcohol forming), 11) an
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1,3-butanediol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1,3-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1,3-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1,4-butanediol pathway, the 1,4-butanediol pathway converting acetyi-CoA to 1,4- butanediol.
  • the 1,4-butanediol pathway includes at least five enzymes selected from 1) Acetoacetyl-CoA thiolase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-hydroxybutyryl-CoA reductase (alcohol forming), 6) 4-hydroxybutyryl-CoA reductase (aldehyde forming), 7) 1,4-butanediol dehydrogenase, 8) 4-Hydroxybutyryl-CoA transferase, 4-Hydroxybutyryl-CoA synthetase, 4- Hydroxybutyryl-CoA hydrolase, or Phosphotrans-4-hydroxybutyi lase/4-Hydroxybutyrate kinase, and 9) 4-Hydroxybuty
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1 ,4-butanediol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1,4-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1,4-butanediol path way which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism includes at least four enzymes of the 1,4-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of the 1,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 4-hydroxybutyrate pathway, the 4-hydroxybutyrate pathway converting acetyl-CoA to 4-hydroxybutyrate.
  • the 4-hydroxybutyrate pathway includes at least five enzymes selected from 1) Acetoacetyi-CoA thiolase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-Hydroxybutyryl-CoA transferase, hydrolase or synthetase, 6) Phosphotrans-4-hydroxybutyrylase, and 7) 4-Hydroxybutyrate kinase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the 4-hydroxybutyrate pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least four enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of the 4-hydroxy butyrate pathway which are encoded by exogenous nuclei c acids.
  • a non-naturally occurring microbial organism includes a microbial organism having a methanol Wood-Ljungdahl pathway that includes at least one exogenous nucleic acid encoding a Wood-Ljungdahl pathway enzyme expressed in a sufficient amount to enhance carbon flux through aeetyl-CoA.
  • the at least one exogenous nucleic acid is selected from a) Methanol methyltransferase (MtaB), b) Corrinoid. protein (MtaC), c)
  • Methyltetrahydrofolatexorrinoid protein methyltransferase (MtaA), d)
  • Methyltetrahydrofolate I corrinoid protein methyltransferase (AcsE), e) Corrinoid iron-sulfur protein (AcsD), f) Nickel-protein assembly protein (AcsF & CooC), g) Ferredoxin (Orf7), h) Acetyl-CoA synthase (AcsB & AcsC), i) Carbon monoxide dehydrogenase (AcsA), j) Pyruvate ferredoxin oxidoreductase, k) NAD(P)H:ferredoxin oxidoreductase, 1) Pyruvate dehydrogenase, m) Pyruvate formate lyase, n) Formate dehydrogenase.
  • AcsE Corrinoid protein methyltransferase
  • AcsD Corrinoid iron-sulfur protein
  • the non-naturally occurring microbial organism includes two exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme. In some embodiments, the non-natural iy occurring microbial organism includes three exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism mcludes four exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme.
  • the non- naturally occurring microbial organism mcludes five exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme, in some embodiments, the non-naturally occurring microbial organism includes six exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes seven exogenous nucleic acids each encoding a methanol Wood- Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism mcludes eight exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme.
  • the non-naturally occurring microbial organism mcludes nine exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes ten exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes eleven exogenous nucleic acids each encoding a methanol Wood-Ljungdahl pathway enzyme. In some embodiments, the non-naturally occurring microbial organism includes at least one exogenous nucleic acid that is a heterologous nucleic acid. In some embodiments, the non-naturally occurring microbial organism is in a substantially anaerobic culture medium.
  • the non-naturally occurring microbial organism further mcludes an isopropanol pathway, the isopropanol pathway converting acetyl-CoA to isopropanol.
  • the isopropanol pathway includes 1) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a phosphotransacetoacetylase/acetoacetate kinase, 3) an acetoaeetate decarboxylase, and 4) an isopropanol dehydrogenase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the isopropanol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturaily occurring microbial organism includes at least two enzymes of the isopropanol pathway which are encoded by exogenous nuclei c acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids. In some
  • the non-naturally occurring microbial organism includes four enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1,3-butanediol pathway, the 1 ,3-butanediol pathway converting acetyl-CoA to 1,3- butanediol.
  • the 1,3-butanediol pathway includes at least three enzymes selected from I) Acetoacetyl-CoA thiolase (AtoB), 2) Acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), 3) 3-oxobutyraldehyde reductase (aldehyde reducing), 4) 4-hydroxy,2-butanone reductase, 5) Acetoacetyl-CoA reductase (CoA-dependent, aldehyde forming), 6) 3- oxobutyraldehyde reductase (ketone reducing), 7) 3-hydroxybutyraldehyde reductase, 8) Acetoacetyl-CoA reductase (ketone reducing), 9) 3-hydrox.ybutyryl-CoA.
  • reductase (aldehyde forming), 10) 3-hydroxybutyryl-CoA reductase (alcohol forming), 11) an aeetoaeetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1,3-butanediol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1,3-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1,3-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1 ,4-butanediol pathway, the 1,4-butanediol pathway converting acetyl-CoA to 1 ,4- butanediol.
  • the 1,4-butanediol pathway includes at least five enzymes selected from I) Aeetoacetyl-CoA thioiase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-hydroxybutyryl-CoA reductase (alcohol forming), 6) 4-hydroxybutyryi-CoA reductase (aldehyde forming), 7) 1,4-butanediol dehydrogenase, 8) 4-Hydroxybutyryl-CoA transferase, 4-Hydroxybutyryl-CoA synthetase, 4- Hydroxybutyryl-CoA hydrolase, or Phosphotrans-4-hydroxybutyr ⁇ ase/4-Hydroxybutyrate kinase, and 9) 4-H
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1,4-butanedioi pathway that is encoded by an exogenous nuclei c acid . In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1,4-butanediol path way which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism includes at least four enzymes of the 1,4-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 4-hydroxybutyrate pathway, the 4-hydroxybtityrate pathway converting acetyl-CoA to 4-hydroxybutyrate.
  • the 4-hydroxybutyrate pathway includes at least five enzymes selected from 1) Acetoacetyi-CoA thioiase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-Hydroxybutyryl-CoA transferase, hydrolase or synthetase, 6) Phosphotrans-4-hydroxybutyrylase, and 7) 4-Hydroxybutyrate kinase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the 4-hydroxybutyrate pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least four enzymes of the 4-hydroxy butyrate pathway which are encoded by exogenous nuclei c acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids.
  • the present invention provides a non-naturally occurring microbial organism that includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock.
  • the at least one exogenous nucleic acid is selected from a carbon monoxide dehydrogenase, a hydrogenase, an NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin.
  • the non-naturally occurring microbial organism includes two exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes three exogenous nucleic acids. In some embodiments, the non-naturally occumng microbial organism includes four exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes four exogenous nucleic acids encoding a carbon monoxide dehydrogenase, a hydrogenase, an NAD(P)H: ferredoxin oxidoreductase, and a ferredoxin.
  • the non-naturally occurring microbial organism includes at least one exogenous nucleic acid that is a heterologous nucleic acid. In some embodiments, the non-naturally occurring microbial organism is in a substantially anaerobic culture medium.
  • the non-naturally occurring microbial organism further includes one or more nucleic acids encoding an enzyme selected from a phosphoenoipyruvate carboxylase, a phosphoenoipyruvate carboxykinase, a pyruvate carboxylase, and a malic enzyme.
  • the non-naturally occumng microbial organism further includes one or more nucleic acids encoding an enzyme selected from a maiate dehydrogenase, a fumarase, a fumarate reductase, a succinyl-CoA synthetase, and a succinyl-CoA transferase,
  • the noii-naturaliy occurring microbial organism includes a 1,4-butanediol pathway that includes at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase, 3) Succinyl-CoA transferase, Succinyl-CoA hydrolase, or Succinyf-CoA synthetase (or succinyl-CoA ligase), 4) Succinyl-CoA reductase (aldehyde forming), 5) 4-Hydroxybutyrate dehydrogenase, 6) 4- Hydroxybutyrate kinase, 7) Phosphotrans-4-hydroxybutyrylase, 8) 4-Hydroxybutyryl-CoA reductase (aldehyde forming), 9) 1,4-butanediol dehydrogenase, 10) Succinate reductase
  • an enzyme selected from 1) Hydro
  • the non -naturally occurring microbial organism further includes a 1 ,3-butanediol pathway comprising at least one exogenous nucleic acid encoding an enzyme selected from : 1) Hydrogenase, 2) Carbon monoxide dehydrogenase, 3) Succinyl-CoA.
  • the non-naturally occurring microbial organism includes a butanoi pathway that includes at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase, 3) Succinyl-CoA transferase, or Succinyl-CoA synthetase (or succinyl-CoA ligase), 4) Succinyl-CoA reductase (aldehyde forming), 5) 4-Hydroxybutyrate dehydrogenase, 6) 4-Hydroxybutyrate kinase, 7) Phosphotrans- 4-hydroxybutyrylase, 8) 4-Hydroxybutyryl-CoA dehydratase, 9) butyryl-CoA dehydrogenase, 10) Butyryl-CoA reductase (aldehyde forming), 11) Butyraldehyde reductase, 12)
  • an enzyme selected from 1) Hydro
  • the non-naturally occurring microbial organism further includes a 6-aminocaproic acid pathway that includes at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase , 3) 3- Oxoadipyl-CoA thiolase, 4 ) 3-Oxoadipyl-CoA reductase, 5) 3-Hydroxyadipyl-CoA
  • dehydratase 6) 5-Carboxy-2-pentenoyl-CoA reductase, 7) Adipyf-CoA reductase (aldehyde forming), and 8) 6-Aminocaproate transaminase, or 6-Aminocaproate dehydrogenase,
  • the non-naturally occurring microbial organism further includes a hexamethylenedi amine pathway comprising at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase , 3) 3- Oxoadipyl-CoA thiolase, 4 ) 3-Oxoadipyl-CoA reductase, 5) 3-Hydroxyadipyl-CoA
  • dehydratase 6) 5-Carboxy-2-pentenoyl-CoA reductase, 7) Adipyl-CoA reductase (aldehyde forming), 8) 6-Aminocaproate transaminase, or 6-Aminocaproate dehydrogenase, 9) 6- Aminocaproyl-CoA/acyl-CoA transferase, or 6-Aminocaproyl-CoA synthase, 10) 6- Aminocaproyl-CoA reductase (aldehyde forming), and 11) HMD A transaminase, or HMD A dehydrogenase.
  • the non-naturally occurring microbial organism includes an adipic acid pathway.
  • the non-naturally occurring microbial organism further includes a capro lactam pathway that includes at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase , 3) 3-Oxoadipyl- CoA thiolase, 4 ) 3-Oxoadipyl-CoA reductase, 5) 3-Hydroxyadipyl-CoA dehydratase, 6) 5- Carboxy-2-pentenoyl-CoA reductase, 7) Adipyl-CoA reductase (aldehyde forming), 8) 6- Aminocaproate tramaminase, or 6-Aminocaproate dehydrogenase, 9) 6-Aminocaproyl- CoA/acyl-CoA transferase, or 6-Aminocaproyl-CoA synthase, 10) amidohydrolase, and 1 1) Sp
  • the non-naturally occurring microbial organism further includes a glycerol pathway that includes at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase , 3)
  • the non-naturally occurring microbial organism includes a 1,3 -propanediol pathway that at least one exogenous nucleic acid encoding an enzyme selected from 1) Hydrogenase, 2) Carbon monoxide dehydrogenase , 3) Dihydroxyacetone kinase, 4) Glycerol dehydrogenase, 5) Glycerol dehydratase, and 6) 1,3 -Propanediol dehydrogenase.
  • the non-naturally occurring microbial organism includes a microbial organism having: a reductive TCA pathway that includes at least one exogenous nucleic acid encoding a reductive TCA pathway enzyme; the at least one exogenous nucleic acid is selected from an ATP-citrate lyase, a citrate lyase, a fumarate reductase, and an alpha- ketoglutarate: ferredoxin oxidoreductase; and at least one exogenous enzyme selected from a carbon monoxide dehydrogenase, a hydrogenase, a NAD(P)H:ferredoxin oxidoreductase, and a ferredoxin, expressed in a sufficient amount to allow the utilization of 1) CO, 2) C0 2 and H 2 , 3) CO and C0 2 , 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, CO?, and H 2 .
  • the non-naturally occurring microbial organism further includes at least one exogenous nucleic acid encoding a citrate lyase, an aconitase, an isocitrate dehydrogenase, a suecinyl-CoA synthetase, a suecinyl-CoA transferase, a fumarase, a malate dehydrogenase, an acetate kinase, a phosphotransacetylase, an aeetyl-CoA synthetase, and a ferredoxin.
  • the non-naturally occurring microbial organism further includes an isopropanol pathway, the isopropanol pathway converting acetyl-CoA to isopropanol
  • the isopropanol pathway includes 1) an acetoacetyl-CoA thiolase, 2) an acetoacetyl-CoA transferase, an acetoacetyl-CoA hydrolase, an acetoacetyl-CoA synthetase, or a phosphotransacetoacetylase/ ' aeetoacetate kinase, 3) an acetoaeetate decarboxylase, and 4) an isopropanol dehydrogenase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the isopropanol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturaily occurring microbial organism includes at least two enzymes of the isopropanol pathway which are encoded by exogenous nuclei c acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids. In some
  • the non-naturally occurring microbial organism includes four enzymes of the isopropanol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1,3-butanediol pathway, thel,3-butanediol pathway converting acetyi-CoA to 1 ,3- butanediol.
  • the 1,3-butanediol pathway includes at least three enzymes selected from I) Acetoacetyl-CoA thiolase (AtoB), 2) Acetoacetyl-CoA reductase (CoA-dependent, alcohol forming), 3) 3-oxobutyraldehyde reductase (aldehyde reducing), 4) 4-hydroxy,2-butanone reductase, 5) Acetoacetyl-CoA reductase (CoA-dependent, aldehyde forming), 6) 3- oxobutyraldehyde reductase (ketone reducing), 7) 3-hydroxybutyraldehyde reductase, 8) Acetoacetyl-CoA reductase (ketone reducing), 9) 3-hydrox.ybutyryl-CoA.
  • reductase (aldehyde forming), 10) 3-hydroxybutyryl-CoA reductase (alcohol forming), 11) an aeetoaeetyl-CoA transferase, an acetoacetyi-CoA hydrolase, an acetoacetyl-CoA synthetase, or a
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1,3-butanediol pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1,3-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1,3-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 1 ,4-butanediol pathway, the 1,4-butanediol pathway converting acetyl-CoA to 1 ,4- butanediol.
  • the 1,4-butanediol pathway includes at least five enzymes selected from I) Aeetoacetyl-CoA thioiase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-hydroxybutyryl-CoA reductase (alcohol forming), 6) 4-hydroxybutyryi-CoA reductase (aldehyde forming), 7) 1,4-butanediol dehydrogenase, 8) 4-Hydroxybutyryl-CoA transferase, 4-Hydroxybutyryl-CoA synthetase, 4- Hydroxybutyryl-CoA hydrolase, or Phosphotrans-4-hydroxybutyr ⁇ ase/4-Hydroxybutyrate kinase, and 9) 4-H
  • the non-naturally occurring microbial organism includes at least one enzyme of the 1,4-butanedioi pathway that is encoded by an exogenous nuclei c acid . In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 1,4-butanediol path way which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism includes at least four enzymes of the 1,4-butanediol pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of the 1 ,4-butanediol pathway which are encoded by exogenous nucleic acids.
  • the non-naturally occurring microbial organism further includes a 4-hydroxybutyrate pathway, the 4-hydroxybtityrate pathway converting acetyl-CoA to 4-hydroxybutyrate.
  • the 4-hydroxybutyrate pathway includes at least five enzymes selected from 1) Acetoacetyi-CoA thioiase (AtoB), 2) 3-Hydroxybutyryl-CoA dehydrogenase (Hbd), 3) Crotonase (Crt), 4) Crotonyl-CoA hydratase (4-Budh), 5) 4-Hydroxybutyryl-CoA transferase, hydrolase or synthetase, 6) Phosphotrans-4-hydroxybutyrylase, and 7) 4-Hydroxybutyrate kinase.
  • the non-naturally occurring microbial organism includes at least one enzyme of the 4-hydroxybutyrate pathway that is encoded by an exogenous nucleic acid. In some embodiments, the non-naturally occurring microbial organism includes at least two enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least three enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids. In some embodiments, the non-naturally occurring microbial organism includes at least four enzymes of the 4-hydroxy butyrate pathway which are encoded by exogenous nuclei c acids. In some embodiments, the non-naturally occurring microbial organism includes at least five enzymes of the 4-hydroxybutyrate pathway which are encoded by exogenous nucleic acids.
  • Enzymes of the reductive TCA cycle useful in th e non-naturally occurring microbial organisms of the present invention include one or more of ATP-citrate lyase and three €02- fixing enzymes: isocitrate dehydrogenase, alpha-ketoglutarate:ferredoxin oxidoreductase, pyruvaterferredoxin oxidoreductase.
  • isocitrate dehydrogenase alpha-ketoglutarate:ferredoxin oxidoreductase
  • pyruvaterferredoxin oxidoreductase pyruvaterferredoxin oxidoreductase.
  • the presence of ATP-citrate lyase or citrate lyase and alpha-ketogiutarate:ferredoxin oxidoreductase indicates the presence of an active reductive TCA cy cle in an organism. Enzymes for each of these steps are
  • ATP citrate lyase (ACL, EC 2.3,3.8), also called ATP citrate synthase, catalyzes the ATP-dependent cleavage of citrate to oxaioacetate and acetyl-CoA.
  • ACL is an enzyme of the rTC A cycle that has been studied in green sulfur bacteria Chlorobium limicola and Chlorobium tepidum.
  • the alpha(4)beta(4) heteromeric enzyme from Chlorobium limicola was cloned and characterized in E. coli (Kanao et al., Eur. J, Biochem. 269:3409-3416 (2002). The C.
  • Chlorobium tepidum a recombinant ACL from Chlorobium tepidum was also expressed in E. coli and the holoenzyme was reconstituted in vitro, in a study elucidating the role of the alpha and beta subumts in the catalytic mechanism (Kim and Tabita, J. Bacteriol, 1 88:6544-6552 (2006).
  • ACL enzymes have also been identified in Balnearium lithotrophicum, Sulfurihydrogenibium subterraneum and other members of the bacterial phylum Aquificae (Hugler et al, Environ. Microbiol. 9:81-92 (2007)). This activity has been reported in some fungi as well. Exemplary organisms include Sordaria macrospora (Nowrousian et al, Curr. Genet. 37:189-93 (2000) , Aspergillus nidulans and Yarrowia lipolytica (Hynes and Murray, Eukaryotic Cell, July: 1039-1048, (2010) , and Aspergillus niger (Meijer et al, J. Ind.
  • adA ABI50076.1 114054981 Balnearium Hthotrophicum adB .45/50075.1 114054980 Balnearium Hthotrophicum adA ABI50085.1 //40J5O4O Sulfurihydrogenibium subterraneum adB ABI50084.1 1 14055039 Sulfurihydrogenibium subterranewn adA AAX76834.1 62199504 Sulfurimonas denitrificans adB AAX76835.1 62199506 Sulfurimonas denitrificans adl XP 504787.1 50554757 Yarrowia lipolytica
  • citryl-CoA synthetase EC 6.2.1.18
  • citryl-CoA lyase EC 4.1.3.34
  • Citryl-CoA synthetase catalyzes the activation of citrate to citryl-CoA.
  • the Hydrogenobacter thermophilus enzyme is composed of large and small subimits encoded by ccsA and ccsB, respectively (Aoshima et al., Mol. Micrbioi. 52:751-761 (2004)).
  • the citryl-CoA synthetase of Aquifex aeolicus is composed of alpha and beta subimits encoded by sued and sucDl (Hugler et al., Environ. Microbiol. 9:81-92 (2007)).
  • Citryl-CoA lyase splits citryl-CoA into oxa!oacetate and acetyl-CoA.
  • This enzyme is a homotrimer encoded by eel in Hydrogenobacter thermophilus (Aoshima et al., Mol. Microbiol. 52:763-770 (2004)) and aq 150 in Aquifex. aeolicus (Hugler et al., supra (2007)).
  • the genes for this mechanism of converting citrate to oxaloacetate and citryi-CoA have also been reported recently in Chlorobium tepidum (Eisen et al, PNAS 99(14): 9509-14 (2002).
  • Oxaloacetate is converted into malate by malate dehydrogenase (EC 1.1.1.37), an enzyme which functions in both the tonvard and reverse direction.
  • malate dehydrogenase EC 1.1.1.37
  • S. cerevisiae possesses three copies of malate dehydrogenase, MDHl (McAlister-Henn and Thompson, J. Bacteriol.
  • MDH2 Minard and McAlister-Henn, MoL Cell. Biol. 1 1 :370-380 (1991); Gibson and McAlister-Henn, J. Biol. Chem. 278:25628-25636 (2003)), and MDH3 (Steffan and McAlister-Henn, J. Biol. Chem. 267:24708-24715 (1992)), which localize to the mitochondrion, cytosol, and peroxisome, respectively.
  • E. coli is known to have an active malate dehydrogenase encoded by mdh.
  • Fumarate hydratase (EC 4.2.1.2) catalyzes the reversible hydration of fumarate to malate.
  • FumB is oxygen sensitive and is active under anaerobic conditions.
  • FumA is active under microanaerobic conditions, and FumC is active under aerobic growth conditions (Tseng et al, J, Bacteriol. 183 :461-467 (2001);Woods et al., Biochim. Biophys. Acta 954: 14-26 (1988); Guest et al., J. Gen.
  • S. cerevisiae contains one copy of a fumarase-encoding gene, FUMI, whose product localizes to both the cytosol and mitochondrion (Sass et af., J. Biol. Chem. 278:45109-451 16 (2003)). Additional fumarase enzymes are found in Campylobacter jejuni (Smith et al, Int. J. Biochem. Cell Biol. 31 :961-975 (1999)), Therm s thermophilus (Mizobata et al, Arch.
  • Fumarate reductase catalyzes the reduction of fumarate to succinate.
  • the fumarate reductase ofE. coli composed of four subunits encoded by frdABCD, is membrane-bound and active under anaerobic conditions.
  • the electron donor for this reaction is menaquinone and the two protons produced in this reaction do not contribute to the proton gradient (I erson et al, Science 284: 1961 -1966 (1999)).
  • the yeast genome encodes two soluble fumarate reductase isozymes encoded by FRDS 1 (Enomoto et al., DNA Res. 3 :263-267 (1996)) and FRDS2 (Muratsubaki et al., Arch. Biochem.
  • Alpha-ketogiutaratetferredoxin oxidoreductase (EC 1.2.7.3), also known as 2- oxogiutarate synthase or 2-oxoglutarate:ferredoxin oxidoreductase (OFOR), forms alpha- ketoglutarate from C02 and succinyl-CoA with concurrent consumption of two reduced ferredoxin equivalents.
  • OFOR and pyruvate :ferredoxin oxidoreductase are members of a diverse family of 2-oxoacid:ferredoxin (flavodoxin) oxidoreductases which utilize thiamine pyrophosphate, CoA and iron-sulfur clusters as cofactors and ferredoxin, flavodoxin and FAD as electron carriers (Adams et al, Archaea. Adv. Protein Chem. 48: 101-180 (1996)).
  • Enzymes in this class are reversible and function in the carboxylation direction in organisms that fix carbon by the RTCA cycle such as Hydrogenobacter thermophilus, Desulfobacter
  • OFOR enzymes that function in the decarboxylation direction under physiological conditions can also catalyze the reverse reaction.
  • the OFOR. from the thermoacidophilic archaeon Sulfolobus sp. strain 7, encoded by ST2300 has been extensively studied (Zhang et al. 1996.
  • a plasmid-based expression system has been developed for efficiently expressing this protein in E. coli (Fukuda et al., Eur, J. Biochem. 268:5639-5646 (2001 )) and residues involved in substrate specificity were determined (Fukuda and Wakagi, Biocbim. Biophys. Acta 1597:74- 80 (2002)).
  • Rhodospirillum rubrum A similar enzyme can be found in Rhodospirillum rubrum by sequence homology. A two subunit enzyme has also been identified in Chlorobium tepidum (Eisen et al., PNAS 99(14): 9509-14 (2002)).
  • Isocitrate dehydrogenase catalyzes the reversible decarboxylation of isocitrate to 2- oxoglutarate coupled to the reduction of NAD(P) 1 .
  • 1DH enzymes in Saccharomyces cerevisiae and Escherichia coli are encoded by IDPI and icd, respectively (Haburgck and McAlister- Henn, J. Biol. Chem. 266:2339-2345 (1991); Nimmo, H.G., Biochem. J.
  • oxalosuccinate (Aoshima and Igarashi, Mol. Microbiol. 62:748-759 (2006)). This enzyme is a large complex composed of two subunits. Biotinyiation of the large (A) subunit is required for enzyme function (Aoshima et al., Mol. Microbiol. 51 :791-798 (2004)).
  • Oxalosuccinate reductase (EC 1 .1.1.-) catalyzes the NAD-dependent conversion of oxalosuccinate to ⁇ -threo- isocitrate.
  • the enzyme is a homodimer encoded by icd in H. thermophilus.
  • Aconitase (EC 4.2.1.3) is an iron-sulfur-containing protein catalyzing the reversible isomerization of citrate and iso-citrate via the intermediate czs-aconitate.
  • Two aconitase enzymes are encoded in the E, coli genome by acnA and acnB.
  • AcnB is the main catabolic enzyme, while AcnA is more stable and appears to be active under conditions of oxidative or acid stress (Cunningham et al., Microbiology 143 (Pt 12):3795-38()5 (1997)).
  • the PFOR from Desulfovibrio africanus has been cloned and expressed in E. coli resulting in an active recombinant enzyme that was stable for several days in the presence of oxygen (Pieulle et al., J Bacteriol. 179:5684-5692 (1997)). Oxygen stability is relatively uncommon in PFORs and is believed to be conferred by a 60 residue extension in the polypeptide chain of the D. africanus enzyme.
  • ydbK uncharacterized open reading frame, ydbK, that encodes a protein that is 51% identical to the M. thermoacetica PFOR.
  • Evidence for pyruvate oxidoreductase activity in E. coli has been described (Blaschkowski et al, Eur. J. Biochem. 123:563-569 (1982)).
  • PFORs have also been described in other organisms, including, Rhodobacter capsulatas (Yakunin and Hallenbeck, Biochimica et Biophysica Acta 1409 (1998) 39-49 (1998)) and Choloboum tepidum (Eisen et al, PNAS 99(14): 9509-14 (2002)).
  • pyruvate dehydrogenase can transform pyruvate into acetyl-CoA with the concomitant reduction of a molecule of NAD into NADH. It is a multi-enzyme complex that catalyzes a series of partial reactions which results in acy latin g oxidative decarboxylation of pyruvate.
  • the enzyme comprises of three subunits: the pyruvate decarboxylase (El), dihydrolipoamide acyltransferase (E2) and dihydrolipoamide
  • E3 dehydrogenase
  • This enzyme is naturally present in several organisms, including E. coli and S. cerevisiae.
  • specific residues in the El component are responsible for substrate specificity (Bisswanger, B., J. Biol. Chem. 256:815-82 (1981); Bremer, J., Eur. J. Biochem. 8:535-540 (1969); Gong et al., J. Biol. Chem. 275: 13645- 13653 (2000)).
  • Enzyme engineering efforts have improved the E. coli PDH enzyme activity under anaerobic conditions (Kim et al, J. Bacterid. 190:3851-3858 (2008); Kim et al, Appl.
  • pyruvate formate lyase Yet another enzyme that can catalyze this conversion is pyruvate formate lyase.
  • This enzyme catalyzes the conversion of pyruvate and CoA into acetyl-CoA and formate.
  • Pyruvate formate lyase is a common enzyme in prokaryotic organisms that is used to help modulate anaerobic redox balance.
  • Exemplary enzymes can be found in Escherichia coli encoded by pflB (Knappe and Sawers, FEMS. Microbiol Rev.
  • E. coli possesses an additional pyruvate formate lyase, encoded by tdcE, that catalyzes the conversion of pyruvate or 2-oxobutanoate to acetyl-CoA or propionyl-CoA, respectively (Hesslinger et al., Mol.
  • pflB and tdcE from E. coli require the presence of pyruvate formate lyase activating enzyme, encoded bypflA.
  • a short protein encoded by yfliD in E. coli can associate with and restore activity to oxygen-cleaved pyruvate formate lyase (Vey et al., ProcNatl. Acad. Sci. U.S.A. 105: 16137-16141 (2008). Note that pflA and pflB from E. coli were expressed in S.
  • acetyl-CoA is obtained in the cytosol by first decarboxylatmg pyruvate to form acetaldehyde; the latter is oxidized to acetate by acetaldehyde dehydrogenase and subsequently activated to form acetyl-CoA by acetyl-CoA synthetase.
  • Acetyl-CoA synthetase is a native enzyme in several other organisms including E. coli (Rumari et al., J. Bacteriol. 177:2878-2886 (1995)), Salmonella enterica (Starai et ah, Microbiology 151 :3793-3801 (2005); Starai et al., J. Biol. Chem. 280:26200-26205 (2005)), mA Moorella thermoacetica (described already).
  • acetate can be activated to form acetyi-CoA by acetate kinase and phosphotransacetylase.
  • Acetate kinase first converts acetate into acetyl- phosphate with the accompanying use of an ATP molecule. Acetyl-phosphate and Co A are next converted into acetyl-CoA with the release of one phosphate by phosphotransacetylase. Both acetate kinase and phosphotransacetlyase are well-studied enzymes in several Clostridia and Methanosarcina thennophila.
  • Pyravate oxidase converts pyruvate into acetate, using ubiquione as the electron acceptor. In E. coli, this activity is encoded by poxB. PoxB has similarity to pyruvate decarboxylase of S.
  • the enzyme has a thiamin pyrophosphate cofaetor ( oland and Gennis, Biochemistry 21 :4438-4442 (1982)); O'Brien et al., Biochemistry 16:3105-3109 (1977); O'Brien and Gennis, J. Biol. Chem. 255:3302-3307 (1980)) and a flavin adenine dinucleotide (FAD) cofaetor.
  • Acetate can then be converted into acetyi-CoA by either acetyi- CoA synthetase or by acetate kinase and phosphotransacetylase, as described earlier.
  • Some of these enzymes can also catalyze the reverse reaction from aeetyl-CoA to pyruvate.
  • Ferredoxin ADP + oxidoreductase (FNR, EC 1.18.1.2) has a noncovalently bound FAD cofactor that facilitates the reversible transfer of electrons from NADPH to low- potential acceptors such as ferredoxins or flavodoxins (Biaschkowski et ah, Eur, J. Biochem. 123:563-569 (1982); Fujii et a!., 1977).
  • the Helicobacter pylori FNR encoded by HP!
  • ferredoxi oxidoreductase of E. coli, encoded by hcaD, is a component of the 3- phenylproppionate dioxygenase system involved in involved in aromatic acid utilization (Diaz et al. 1998).
  • NADH ferredoxin reductase activity was detected in cell extracts of
  • Ferredoxins are small acidic proteins containing one or more iron-sulfur clusters that function as intracellular electron carriers with a low reduction potential. Reduced ferredoxins donate electrons to Fe-dependent enzymes such as ferredoxin-NADP + oxidoreductase, pyruvate :ferredox in oxidoreductase (PFOR) and 2-oxoglutarate:ferredoxin oxidoreductase (OFOR). The H.
  • thermophilus gene fdxl encodes a [4Fe-4S]-type ferredoxin that is required for the reversible carbox iation of 2-oxoglutarate and pyruvate by OFOR and PFOR, respectively (Yaniamoto et aL Extremophiies 14:79-85 (2010)), The ferredoxin associated with the
  • Suljblobus solfataricus 2-oxoacid:ferredoxin reductase is a monomelic dicluster [3Fe-4S][4Fe- 4S] type ferredoxin (Park et a!. 2006). While the gene associated with this protein has not been fully sequenced, the N-terminal domain shares 93% homology with the zfx ferredoxin from S. acidocaidarius . The E. coli genome encodes a soluble ferredoxin of unknown physiological function, 3 ⁇ 4 .
  • Succinyl-CoA transferase catalyzes the conversion of succinyl-Co A to succinate while transferring the CoA moiety to a CoA acceptor molecule.
  • Many transferases have broad specificity and can utilize CoA acceptors as diverse as acetate, succinate, propionate, butyrate, 2-methylacetoacetate, 3-ketohexanoate, 3-ketopentanoate, valerate, crotonate, 3- mercaptopropionate, propionate, vinylacetate, and butyrate, among others,
  • the conversion of succinate to succinyl-CoA can be carried by a transferase which does not require the direct consumption of an ATP or GTP, This type of reaction is common in a number of organisms.
  • the conversion of succinate to succinyl-CoA can also be catalyzed by succinyl-CoA:Acetyl-CoA transferase.
  • the gene product of cat! of Clostridium kluyveri has been shown to exhibit succinyi-CoA: acetyl-CoA transferase activity (Sohling and Gottschalk, J. Bacterid. 178:871-880 (1996)).
  • the activity is present in Trichomonas vaginalis (van Grinsven et al, 2008) and Trypanosoma brucei (Riviere et al. 2004).
  • Similar succinyl-CoA transferase activities are also present in Trichomonas vaginalis (van Grinsven et al. 2008), Trypanosoma brucei (Riviere et al.
  • An additional exemplary transferase that converts succinate to succinyl-CoA while converting a 3-ketoacyl-CoA to a 3-ketoacid is succinyf-CoA:3 :ketoacid-CoA transferase (EC 2.8.3.5).
  • Exemplary succinyl-CoA:3 :ketoacid-Co A transferases are present in Helicobacter pylori (Corthesy-Theulaz et al . 1997), Bacillus subiilis, and Homo sapiens (Fukao et al. 2000; Tanaka et al. 2002), The aforementioned proteins are identified below. Protein GenBank ID Gl Number Organism
  • Converting succinate to succinyl-CoA by suceinyl ⁇ CoA:3 :ketoacid-CoA transferase requires the simultaneous conversion of a 3-ketoacyl-CoA such as acetoacetyl-CoA to a 3- ketoacid such as acetoacetate. Conversion of a 3-ketoacid back to a 3-ketoacyl-CoA. can be catalyzed by an acetoacetyl-CoA:acetate:CoA transferase. Acetoacetyl-CoA: acetate: Co A transferase converts acetoacetyl-CoA and acetate to acetoacetate and acetyl-CoA, or vice versa.
  • Exemplary enzymes include the gene products of atoAD from E. coli (Hanai et a!., Appl Environ Microbiol 73 :7814-7818 (2007), ctfAB from C. acetobutylicum (Jojima et al, Appl Microbiol Biotechnol 77: 1219-1224 (2008), and ctfAB from Clostridium
  • CoA acceptor is benzylsucei ate, Succinyl-CoA:(R)- Benzylsuecmate CoA-Transferase functions as part of an anaerobic degradation pathway for toluene in organisms such as Thauera aromatica (Leutwein and Heider, J. Bad. 183(14) 4288- 4295 (2001)).
  • Bomologs can be found in Azoarcus sp. T, Aromatoleum aromaticum EbNl , and Geobacter metallireducens GS-15. The aforementioned proteins are identified below. Protein GenBank ID Gl Number Organism
  • yg/H encodes a propionyl CoA:succinate CoA transferase in E. coll (Hailer et al., Biochemistry, 39(16) 4622-4629). Close homologs can be found in, for example, Citrobacter youngae ATCC 29220, Salmonella enterica subsp. arizonae serovar, and Yersinia intermedia ATCC 29909. The aforementioned proteins are identified below.
  • Citrate lyase (EC 4.1.3.6) catalyzes a series of reactions resulting in the cleavage of citrate to acetate and oxaloacetate.
  • the enzyme is active under anaerobic conditions and is composed of three subunits: an acyl-carrier protein (ACP, gamm a), an ACP transferase (alpha), and a acyl iyase (beta).
  • ACP acyl-carrier protein
  • alpha alpha
  • acyl iyase beta
  • Enzyme activation uses covending binding and acetylation of an unusual prosthetic group, 2 ' -(5"-phosphoribosyl)-3- ' -dephospho-CoA, which is similar in structure to acetyl-CoA.
  • coii enzyme is encoded by citEFD and the citrate lyase synthetase is encoded by citC (Nilekani and SivaRaman, Biochemistry 22:4657-4663 (1983)).
  • citC citrate lyase synthetase
  • the Leuconostoc mesenteroides citrate iyase has been cloned, characterized and expressed in E. coii (Bekal et al,, J. Bacterid. 180:647-654 ( 1998)).
  • Citrate lyase enzymes have also been identified in enterobacteria that utilize citrate as a carbon and energy source, including Salmonella lyphimurium. and Klebsiella pneumoniae (Bott, Arch. Microbiol.
  • Acetate kinase (EC 2.7.2.1) catalyzes the reversible ATP-dependent phosphorylation of acetate to acetylphosphate.
  • Exemplar ⁇ ' acetate kinase enzymes have been characterized in many organisms including E. coli, Clostridium acetobutylicum and Methanosarcina thermophila (Ingram-Smith et a!., J. Bacterial. 187:2386-2394 (2005); Fox and Roseman, J. Biol. Chern. 261 : 13487-13497 (1986); Winzer et al, Microbioloy 143 (Pt 10):3279-3286 (1997)).
  • Acetate kinase activity has also been demonstrated in the gene product of f. coli pur T (Marolewski et al., Biochemistry 33:2531-2537 ( 1994).
  • Some butyrate kinase enzymes (EC 2.7.2.7), for example bukl and bukl from Clostridium acetobutylicum, also accept acetate as a substrate (Hartmanis, M.G., J. Biol. Chem. 262:617-621 (1987)).
  • phosphotransacetylase (EC 2.3.1.8).
  • the pta gene from E. coli encodes an enzyme that reversibly converts aeetyl-CoA into acetyl-phosphate (Suzuki, T., Biochim. Biophys. Acta 191 :559-569 (969)).
  • Additional aceiyltransferase enzymes have been characterized in Bacillus subtilis (Rado and Hoch, Biochim. Biophys. Acta 321 : 114-125 ( 1973), Clostridium kluyveri (Stadtman, E., Methods Enzymol. 1 :5896-599 (1955), and Thennotoga maritima (Bock et ai., J. Bacterioi. 181 : 1 861-1867 (1999)). This reaction is also catalyzed by some
  • phosphotranbutyrylase enzymes (EC 2.3.1.19) including the ptb gene products from
  • acylation of acetate to aeetyl-CoA is catalyzed by enzymes with acetyl-CoA synthetase activity.
  • Two enzymes that catalyze this reaction are AM -forming acetyl-CoA synthetase (EC 6.2.1.1) and ADP-forming acetyl-CoA synthetase (EC 6.2.1.13).
  • AMP-forming acetyl-CoA synthetase (A CS) is the predominant enzyme for activation of acetate to acetyl- CoA.
  • Exemplar ACS enzymes are found in E. coli (Brown et al., J. Gen. Microbiol.
  • ADP-forming acetyl-CoA synthetases are reversible enzymes with a generally broad substrate range (Musfeldt and Schonheit, J. Bacteriol. 184:636-644 (2002)).
  • Two isozymes of ADP-forming acetyi-CoA synthetases are encoded in the Archaeoglobus fulgidus genome by are encoded by AF1211 and AF1983 (Musfeldt and Schonheit, supra (2002)).
  • Haloarcula marismortui annotated as a succinyl-CoA synthetase
  • the enzyme from Haloarcula marismortui also accepts acetate as a substrate and reversibility of the enzyme was demonstrated (Brasen and Schonheit, Arch. Microbiol. 182:277-287 (2004)).
  • aerophilum showed the broadest substrate range of all characterized ACDs, reacting with acetate, isobutyryl-CoA (preferred substrate) and phenyiacetyl-CoA (Brasen and Schonheit, supra (2004)). Directed evolution or engineering can be used to modify this enzyme to operate at the physiological temperature of the host organism.
  • marismortui and P. aerophilum have ail been cloned, functionally expressed, and characterized in E. coli (Brasen and Schonheit, supra (2004); Musfeldt and Schonheit, supra (2002)).
  • Additional candidates include the succinyl-CoA synthetase encoded by sucCD in E. coli (Buck et al., Biochemistry 24:6245-6252 (1985)) and the acyl-CoA ligase from Pseudomonas putida (Fernandez- Valverde et al., Appl. Environ. Microbiol. 59: 1 149-1154 ( 1993)).
  • PAE3250 NP___560604.1 18313937 Pyrobaculum aerophilum sir.
  • Formate dehydrogenase is a two subunit selenocysteine-containing protein that catalyzes the incorporation of C0 2 into formate in Mooreila thermoacetica (Andreesen and Ljungdahl, J. Bacteriol. 116:867-873 (1973); Li et al., J. Bacteriol 92:4-50412 (1966);
  • dehydrogenase while the beta subunit is encoded by Moth_2314 (Pierce et al., Environ, Microbiol. 10:2550-2573 (2008)).
  • Another set of genes encoding formate dehydrogenase activity with a propensity for C0 2 reduction is encoded by Sfum_2703 through Sfum_2706 in Syntrophobacter fumaroxidans (Reda et al., Proc. Natl. Acad. Sci. U.S.A. 105: 10654-10658 (2008); de Bok et al, Eur. J. Biochem. 270:2476-2485 (2003). Similar to their M.
  • thermoacetica counterparts Sfum_2705 and Sfum__2706 are actually one gene.
  • a similar set of genes that have been indicated to cany out the same function are encoded by CHY 0731, CHY_0732, and CHY_0733 in C. hydro genoformans (Wu et al., PLoS Genet. I :e65 (2005)).
  • Homologs are also found in C. carboxidivorans P7. Protein GenBank ID GI Number Organism
  • thermoacetica E. coli, and C. hydrogenoformans, methenyltetrahydro folate cyclohydrolase and metbyienetetrahydrofolate dehydrogenase are carried out by the bi- functional gene products of Moth 1516, folD, and CHY 1878, respectively (Pierce et al, Environ, Microbiol. 10:2550-2573 (2008); Wu et al., PLoS Genet, I :e65 (2005); D'Ari and Rabinowitz, J. Biol. Chem. 266:23953-23958 (1991)).
  • a homolog exists in C. carboxidivorans P7.
  • Several other organisms also encode for this Afunctional protein as tabulated below.
  • thermoacetica genes and its C. hydrogenoformans counterpart, are located near the
  • CODH/ACS gene cluster separated by putative hydrogenase and heterodisul.fi de reductase genes. Some additional gene candidates found bioinformatically are listed below.
  • ACS/CODH is the central enzyme of the carbonyi branch of the Wood-Ljungdahl pathway. It catalyzes the reversible reduction of carbon dioxide to carbon monoxide and also the synthesis of acetyl-CoA from carbon monoxide. Coenzyme A, and the methyl group from a methylated corrinoid-iron-sulfur protein. The corrinoid-iron-sulfur-protein is methylated by methyitetrahydrofolate via a methyltransferase.
  • ACS/CODH Expression of ACS/CODH in a foreign host entails introducing one or more of the following proteins and their corresponding activities: Methyltetrahydrofoiate orrinoid protein methyltransferase (AcsE), Corrinoid iron-sulfur protein (AcsD), Nickel-protein assembly protein (AcsF), Ferredoxin (Or/7), Acetyl-CoA synthase (AcsB and AcsC), Carbon monoxide dehydrogenase (AcsA), and Nickel-protein assembly protein (CooC).
  • the genes used for carbon-monoxide dehydrogenase/aceryl-CoA synthase activity typically reside in a limited region of the native genome that can be an extended operon (Ragsdale, S.W., Crit. Rev. Biochem. Mol. Biol. 39: 165-195 (2004); Morton et al., J. Biol. Chem, 266:23824-23828 (1991); Roberts et al, Proc. Natl. Acad. Set U.S.A. 86:32-36 (1989).
  • Each of the genes in this operon from the acetogen, M. thermoacetica has already been cloned and expressed actively in E. coli (Morton et al. supra; Roberts et al. supra; Lu et al., J. Biol. Chem. 268:5605-5614 ( 1993).
  • GenBank accession numbers The protein sequences of these genes can be identified by the following GenBank accession numbers.
  • the hydrogenic bacterium Carhoxydothermus hydro genqfbrnians, can utilize carbon monoxide as a growth substrate by means of aeetyl-CoA synthase (Wu et al., PLoS Genet. 1 :e65 (2005)).
  • aeetyl-CoA synthase enzyme complex lacks carbon monoxide dehydrogenase due to a frameshift mutation (Wu et al. supra (2005)) , whereas in strain DSM 6008, a functional unframeshifted full-length version of this protein has been purified
  • Homologous ACS/CODH genes can also be found in the draft genome assembly of Clostridium carboxidivorans P7.
  • This organism contains two sets of genes that encode ACS/CODH activity (Rother and Metcalf, Proc. Natl. Acad. Sci. U.S.A. 101 : 16929-16934 (2004)).
  • the protein sequences of both sets of M. aceiivorans genes are identified by the following GenBank accession numbers. Protein GenBank ID GI number Organism
  • the AcsC, AcsD, AcsB, AcsEps, and AcsA proteins are commonly referred to as the gamma, delta, beta, epsilon, and alpha subunits of the methanogenic CODH/ACS. Homoiogs to the epsilon encoding genes are not present in acetogens such as M. thermoacetica or hydrogenogenic bacteria such as C. hydrogenofonnans. Hypotheses for the existence of two active CODH/ACS operons m " M.
  • acetivorans include catalytic properties (i.e., m , V max , k cat ) that favor carboxidotrophic or aceticiastic growth or differential gene regulation enabling various stimuli to induce CODH/ACS expression (Rother et al., Arch, Microbiol. 188:463-472 (2007)).
  • MtaB is a zinc protein that catalyzes the transfer of a methyl group from methanol to MtaC, a corrinoid protein.
  • Exemplar ⁇ ' genes encoding MtaB and MtaC can be found in methanogenic archaea such as Methanosarcina barken (Maeder et al., J. Bacteriol. 188:7922- 7931 (2006) and Methanosarcina acetivorans (Galagan et al.. Genome Res. 12:532-542 (2002), as well as the acetogen, Moorella ihermoacetica (Das et al.. Proteins 67:167-176 (2007).
  • MtaB and MtaC genes are adjacent to one another on the chromosome as their activities are tightly interdependent.
  • the protein sequences of various MtaB and MtaC encoding genes in M. barken, M. acetivorans, and M. thermoaceticum can be identified by their following GenBank accession numbers.
  • MtaC YP_430065 83590056 Moorella thermoacetica [00204] The MtaBl and MtaCl genes, YP_304299 and YP_304298, from M. barkeri were cloned into E. coli and sequenced ( Sauer et al., Eur, J, Biochem. 243:670-677 (1997)). The crystal structure of this methanoi-cobalamin metbyltransferase complex is also available (Hagemeier et al, Proc. Natl. Acad. Set U.S.A. 103: 18917-18922 (2006)). The MtaB genes, YP_307082 and YP_304612, in M. barkeri were identified by sequence homology to
  • MtaC genes YP 307081 and YP 30461 1 , were identified based on their proximity to the MtaB genes and also their homology to YP_304298.
  • the three sets of MtaB and MtaC genes from acetivorans have been genetically, physiologically, and biochemically characterized (Pritchett and Metcalf. Mol. Microbiol.
  • M. ihermoacetica MtaB gene was identified based on homology to the methanogenic MtaB genes and also by its adjacent chromosomal proximity to the methanol-indueed corrinoid protein, MtaC, which has been crystallized (Zhou et al., Acta Crystallogr. Sect. F. Struct. Biol. Cyrst. Comrnun. 61 :537-540 (2005) and further characterized by Northern hybridization and Western Blotting ((Das et al, Proteins 67: 167-176 (2007)).
  • MtaA is zinc protein that catalyzes the transfer of the methyl group from MtaC to either Coenzyme M in methanogens or methyltetrahydrofolate in acetogens.
  • MtaA can also utilize methylcobalamin as the methyl donor.
  • Exemplary genes encoding MtaA can be found in methanogenic archaea such as Methanosarcina barkeri (Maeder et al., J. Bacterial. 188:7922- 7931 (2006) and Methanosarcina acetivorans (Galagan et al., Genome Res.
  • MtaA proteins that catalyze the transfer of the methyl group from ⁇ ! h-VkaC are difficult to identify bioinformatically as they share similarity to other corrinoid protein methyltransferases and are not oriented adjacent to the MtaB and MtaC genes on the chromosomes. Nevertheless, a number of MtaA encoding genes have been characterized. The protein sequences of these genes m M. barken mdM, acetivorans can be identified by the following GenBank accession numbers.
  • MtaA gene YP_304602, from M. harkeri was cloned, sequenced, and functionally overexpressed in E. coli (Harms and Thauer, Eur. J. Biochem. 235:653-659 (1996)).
  • MtaAl is required for growth on methanol, whereas MtaA2 is dispensable even though methane production from methanol is reduced in MtaA2 mutants (Bose et al., J, Bacteriol. 190:4017-4026 (2008)).
  • MtaA homologs in M. harkeri and M. acetivorans that are as yet ncharacterized, but may also catalyze corrinoid protein methyltransferase activity.
  • Putative MtaA encoding genes in M. thermoacetica were identified by their sequenc similarity to the characterized methanogenic MtaA genes. Specifically, three M. thermoacetica genes show high homology (>30% sequence identity) to YP_304602 from harkeri. Unlike methanogenic MtaA proteins that naturally catalyze the transfer of the methyl group from C3 ⁇ 4 MtaC to Coenzyme M, an M. thermoacetica MtaA is likely to transfer the methyl group to methyltetrahydrofoiate given the similar roles of methyUetrahydrofolate and Coenzyme M in metbanogens and acetogens, respectively.
  • the protein sequences of putative MtaA encoding genes from M. thermoacetica can be identified by the following GenBank accession numbers.
  • the product yields per C-mof of substrate of microbial cells synthesizing reduced fermentation products such as ethanoi, butanol, isobutanoi, 2-butanol, isopropanol, 1 ,4- butanediol, succinic acid, fumaric acid, malic acid, 4-bydroxybutyric acid, adipic acid, 6- aminocaproic acid, hexamethylenediamme, caproiactam, 3-hydroxyisobutyric acid, 2- hydroxyisobutyric acid, methacrylic acid, acrylic acid, 1 ,3 -propanediol, glycerol, etc., are limited by insufficient reducing equivalents in the carbohydrate feedstock.
  • Reducing equivalents, or electrons can be extracted from synthesis gas components such as CO and H? using carbon monoxide dehydrogenase (CODH) and hydrogenase enzymes, respectively.
  • CODH carbon monoxide dehydrogenase
  • the reducing equivalents are then passed to acceptors such as oxidized ferredoxins, oxidized quinones, oxidized cytochromes, ADP+, water, or hydrogen peroxide to form reduced ferredoxin, reduced quinones, reduced cytochromes, NAD(P)H, 3 ⁇ 4, or water, respectively.
  • Reduced ferredoxin and NAD(P)H are particularly useful as they can serve as redox carriers for various Wood-Ljungdahl pathway and reductive TCA cycle enzymes.
  • syngas components CO and 3 ⁇ 4 can be utilized to generate reducing equivalents by employing the hydrogenase and CO dehydrogenase.
  • the reducing equivalents generated from syngas components will be utilized to power the glucose to BDO production pathways. Theoretically, all carbons in glucose will be conserved, thus resulting in a maximal theoretical yield to produce 1 ,4-BDO from glucose at 2 mol 1 ,4-BDO per mol of glucose under either aerobic or anaerobic conditions as shown in Figure 7 A:
  • Butanol is yet another example of a reduced product.
  • the production of butanol through fermentation has a theoretical yield of 1 mol butanol per mol of glucose. It is currently manufactured from propylene and usually used close to the point of manufacture.
  • Butanol is largely used as an industrial intermediate, particularly for the manufacture of butyl acrylate, butyl acetate, dibutyl phthaiate, dibutyl sebacate and other butyl esters.
  • Other industrial uses include the manufacture of pharmaceuticals, polymers, plastics, and herbicide.
  • Butanol has also been proposed as the next generation biofuel to substitute for diesel fuel and gasoline. It is also used in a wide range of consumer products.
  • Hexamethylenediamine can be used to produce nylon 6,6, a linear polyamide made by condensing hexamethylenediamine with adipic acid. This is employed for manufacturing different kinds of fibers.
  • HMDA Hexamethylenediamine
  • nylon-6,6 a linear polyamide made by condensing hexamethylenediamine with adipic acid.
  • HMDA is also utilized to make hexaniethylene diisocyanate, a monomer feedstock used in the production of polyurethane.
  • the diamine also serves as a cross-linking agent in epoxy resins.
  • HMDA is presently produced by the hydrogenation of adiponitrile.
  • Caprolactam is an organic compound which is a lactam of 6-aminohexanoic acid ( ⁇ - aminohexanoic acid, 6-ammocaproic acid). It can alternatively be considered a cyclic amide of caproic acid.
  • One use of caprolactam is as a monomer in the production of nylon-6.
  • Caprolactam can be synthesized from cyclohexanone via an oximation process using hydroxylammonium sulfate followed by catalytic rearrangement using the Beckmann rearrangement process step.
  • the production of caprolactam through fermentation has a theoretical yield of 0.8 mol caprolactam per mol of glucose.
  • 1 ,3-propanedioi (1 ,3-PDO) and glycerol.
  • 1 ,3- PDO is mainly used as a building block in the production of polymers. It can be formulated into a variety of industrial products including composites, adhesives, laminates, coatings, moldings, aliphatic polyesters, copolyesters. It is also a solvent and used as an antifreeze and wood paint.
  • 1 ,3-PDO can be chemically synthesized via the hydration of acrolein or by the hydro ibrmylation of ethylene oxide to afford 3-hydroxypropkmaldebyde.
  • the resultant aldehyde is hydrogenated to give 1 ,3-PDO.
  • 1 ,3-PDO can be produced biologically.
  • the production of 1 ,3-PDO through fermentation has a theoretical yield of 1.5 moi 1 ,3-PDO per mol of glucose.
  • the production of glycerol through fermentation can be improved by the combined feedstock strategy.
  • the production of glycerol through fermentation has a theoretical yield of 1 .71 mol glycerol per mol of glucose.
  • a combined feedstock strategy where syngas is combined with a sugar-based feedstock or other carbon substrate can greatly improve the theoretical yields.
  • syngas components H 2 and CO can be utilized by the hydrogenase and CO dehydrogenase to generate reducing equivalents, that can be used to power chemical production pathways in which the carbons from sugar or other carbon substrates will be maximally conserved and the theoretical yields improved.
  • the theoretical yields improve from 1 mol or 1 .09 mol products per mol of glucose to 2 mol products per mol of glucose.
  • CODH is a reversible enzyme that interconverts CO and C0 2 at the expense or gain of electrons.
  • the natural physiological role of the CODH in ACS/CODH complexes is to convert C0 2 to CO for incorporation into acetyi-CoA by acetyl- CoA synthase. Nevertheless, such CODH enzymes are suitable for the extraction of reducing equivalents from CO due to the reversible nature of such enzymes. Expressing such CODH enzymes in the absence of ACS allows them to operate in the direction opposite to their natural physiological role (i.e., CO oxidation),
  • thermoacetica In thermoacetica, C. hydrogenoformans, C. carboxidivorans P7, and several other organisms, additional CODH encoding genes are located outside of the ACS/CODH operons. These enzymes provide a means for extracting electrons (or reducing equivalents) from the conversion of carbon monoxide to carbon dioxide.
  • the M. thermoacetica gene (Genbank Accession Number: YP_430813) is expressed by itself in an operon and is believed to transfer electrons from CO to an external mediator like ferredoxin in a "Ping-pong" reaction.
  • the reduced mediator then couples to other reduced nicolinaniide adenine dmucleotide phosphate (NAD(P)H) carriers or ferredoxin-dependent cellular processes (Ragsdaie, Annals of the New York Academy of Science J 125: 129-136 (2008)).
  • NAD(P)H reduced nicolinaniide adenine dmucleotide phosphate
  • Similar ACS-free CODH enzymes can be found in a diverse array of organisms including Geobacter metallireducens GS-15, Chlorobium phaeobacteroides DSM 266, Clostridium cellulolyticum H10, Desulfovibrio desulfuricans subsp. desulfuricans str, ATCC 27774, Pelobacter carbinolicus DSM 2380, and Campylobacter curvus 525,92,
  • CODH CooS (CODH) YPJDOI 407343.1 154175407 Campylobacter ciirvus 525.92
  • hydrogenase encoding genes are located adjacent to a CODH.
  • Rhodospirillum rubrum the encoded CODH/hydrogenase proteins form a membrane-bound enzyme complex that has been indicated to be a site where energy, in the form of a proton gradient, is generated from the conversion of CO and H?0 to C0 2 and H? (Fox et al., J
  • CODH COS AAC45123 1498748 Rhodospirilhim ruhrum
  • E. coli Bacterial. 164: 1324-1331 (1985); Sawers and Boxer, Eur.J Biochem. 156:265-275 (1986); Sawers et al., J Bacterial. 168:398-404 (1986)).
  • E. coli or another host organism can provide sufficient hydrogenase activity to split incoming molecular hydrogen and reduce the corresponding acceptor.
  • E. coli possesses two uptake hydrogenases, Hyd-1 and Hyd-2, encoded by the hyaABCDEF and hybOABCDEFG gene clusters, respectively (Lukey et al., Flow E. coli is equipped to oxidize hydrogen under different redox conditions, J Biol Chem published online Nov 16, 2009).
  • Hyd-1 is oxygen-tolerant, irreversible, and is coupled to quinone reduction via the hyaC cytochrome.
  • Hyd-2 is sensitive to 0 2 , reversible, and transfers electrons to the periplastic ferredoxin hyhA which, in turn, reduces a quinone via the hybB integral membrane protein.
  • Reduced quinones can serve as the source of electrons for fumarate reductase in the reductive branch of the TCA cycle.
  • Reduced ferredoxins can be used by enzymes such as NAD(P)H: ferredoxin oxidoreductases to generate NADPH or NADH.
  • the hydrogen- lyase systems of E. coli include hydrogenase 3, a membrane -bound enzyme complex using ferredoxin as an acceptor, and hydrogenase 4 that also uses a ferredoxin acceptor.
  • Hydrogenase 3 and 4 are encoded by the hyc and hyf gene clusters, respectively.
  • Hydrogenase 3 has been shown to be a reversible enzyme (Maeda et al., Appl Microbiol Bioteehnoi 76(5): 1035-42 (2007)). Hydrogenase activity in E.
  • M. thermoacetica hydrogenases are suitable for a host that lacks sufficient endogenous hydrogenase activity, M. thermoacetica can grow with CO? as the exclusive carbon source indicating that reducing equivalents are extracted from H 2 to enable acetyl-CoA synthesis via the Wood-Ljungdahi pathway (Drake, H. L., J. Bacterial, 150:702-709 (1982); Drake and Daniel, Res. Microbiol. 155:869-883 (2004); Kelium and Drake, J, Bacterial. 160:466-469 (1984)) (see Figure 2A).
  • M. thermoacetica has homologs to several hyp, hyc, and hyf genes from E. coli. The protein sequences encoded for by these genes are identified by the following GeiiBank accession numbers.
  • Ralstonia eutropha HI 6 uses hydrogen as an energy source with oxygen as a terminal electron acceptor. Its membrane- bound uptake [NiFe] -hydrogenase is an "02-tolerant" hydrogenase (Cracknell, et al. Proc Nat Acad Sci, 106(49) 20681-20686 (2009)) that is peri lasmically-oriented and connected to the respiratory chain via a b-type cytochrome (Schink and Schiegel, Biochim. Biophys. Acta, 567, 315-324 ( 1979); Bernhard et al., Eur. J. Biochem. 248, 179-186 (1997)). R.
  • eutropha also contains an 0 2 -tolerant soluble hydrogenase encoded by the Hox operon which is cytoplasmic and directly reduces NAD+ at the expense of hydrogen (Schneider and Schiegel, Biochim. Biophys. Acta 452, 66-80 (1976); Burgdorf, J. Bact. 187(9) 3122-3132(2005)). Soluble hydrogenase enzymes are additionally present in several other organisms including Geobacter sulfurreducens (Coppi, Microbiology 151, 1239-1254 (2005)), Synechocystis str. PCC 6803 (Germer, J.
  • the Synechocystis enzyme is capable of generating N ADPH from hydrogen.
  • Qverexpression of both the Hox operon from Synechocystis str. PCC 6803 and the accessor ⁇ ' genes encoded by the Hyp operon from Nostoc sp. PCC 7120 led to increased hydrogenase activity compared to expression of the Box genes alone (Germer, J. Biol. Chem. 284(52), 36462-36472 (2009)).
  • PEP carboxylase enzymes are encoded by ppc in E. coii (Km et al, Arch. Biochem. Biophys. 414:170-179 (2003), ppcA in Methylobacterium extorquens AMI (Arps et al, J. Bacterial. 175:3776-3783 (1993), and ppc in Corynebacterium glutamicum (Eikmaniis et al., Mo I. Gen. Genet. 218:330-339 (1989).
  • PEP carboxykinase An alternative enzyme for converting phosphoenolpyruvate to oxaloacetate is PEP carboxykinase, which simultaneously forms an ATP while carboxylating PEP.
  • PEP carboxykinase serves a gluconeogenic function and converts oxaloacetate to PEP at the expense of one ATP.
  • S. cerevisiae is one such organism whose native PEP carboxykinase, PCK1, screes a gluconeogenic role (Valdes-Hevia et al., FEBS Lett. 258:313- 316 (1989).
  • coii is another such organism, as the role of PEP carboxykinase in producing oxaloacetate is believed to be minor when compared to PEP carboxylase, which does not form ATP, possibly due to the higher K m for bicarbonate of PEP carboxykmase (Kim et ai, Appl. Environ. Microbiol 70: 1238-1241 (2004)). Nevertheless, activity of the native E. coli PEP carboxykmase from PEP towards oxaloacetate has been recently demonstrated in ppc mutants ofE. coli K-12 (Kwon et al, J. Microbiol. Biotechnol. 16: 1448-1452 (2006)).
  • Pyruvate carboxylase (EC 6.4.1.1) directly converts pyruvate to oxaloacetate at the cost of one ATP. Pyruvate carboxylase enzymes are encoded by PYCl (Walker et al., Biochem. Biophys. Res. Commun. 176:1210-1217 (1991) and PYC2 (Walker et al., supra) in
  • Malic enzyme can be applied to convert C0 2 and pyruvate to malate at the expense of one reducing equivalent.
  • Malic enzymes for this purpose can include, without limitation, malic enzyme (NAD-dependent) and malic enzyme (NADP-dependent).
  • malic enzyme NAD-dependent
  • NADP-dependent malic enzyme
  • one of the E. coli malic enzymes Takeo, J. Biochem. 66:379-387 (1969)
  • a similar enzyme with higher activity can be expressed to enable the conversion of pyruvate and C0 2 to malate.
  • malic enzyme By fixing carbon to pyruvate as opposed to PEP, malic enzyme allows the high-energy phosphate bond from PEP to be conserved by pyruvate kinase whereby ATP is generated in the formation of pyruvate or by the phosphotransferase system for glucose transport.
  • malic enzyme is typically assumed to operate in the direction of pyruvate formation from malate, overexpression of the N AD-dependent enzyme, encoded by maeA, has been demonstrated to increase succi nate production in E. coli while restoring the lethal Apfl-AldhA phenotype under anaerobic conditions by operating in the carbon-fixing direction (Stols and Donnelly, Appl. Environ. Microbiol.
  • the enzymes used for converting oxaloacetate formed from, for example, PEP carboxylase, PEP earboxykmase, or pyruvate carboxylase) or malate (formed from, for example, malic enzyme or malate dehydrogenase) to succinyl-CoA via the reductive branch of the TCA cycle are malate dehydrogenase, fumarate dehydratase (fumarase), fumarate reductase, and succinyl-CoA transferase.
  • the genes for each of the enzymes are described herein above.
  • Enzymes, genes and methods for engineering pathways from succinyl-CoA to various products into a microorganism are now known in the art.
  • the additional reducing equivalents obtained from CO and H 2 as disclosed herein, improve the yields of all these products when utilizing carbohydrate-based feedstock.
  • 1,4-butanediol can be produced from succinyi-CoA via previously disclosed pathways (see for example, Burk et a!., WO
  • Exemplary enzymes for the conversion succinyl-CoA to 1,4-butanediol include succinyl-CoA reductase (aldehyde forming), 4-hydroxybutyrate dehydrogenase, 4- hydroxybiityrate kinase, phosphotrans-4-hydroxybutyrylase, 4-hydroxybutvryl-CoA reductase (aldehyde forming), 1,4-butanediol dehydrogenase, succinyi-CoA reductase (alcohol forming), 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryi-CoA synthetase, 4-hydroxybutyryl- phosphate reductase, 4-hydroxybutyrate reductase, and 4-hydroxybutyryl-CoA reductase (alcohol forming).
  • succinate reductase can be additionally useful in converting succinate directly to the 1,4-butanediol pathway intermediate, succinate semialdehyde.
  • succinyi- CoA can be converted by alpha-ketoglutarate :ferredoxin oxidoreductase to alpha-ketoglutarate whose decarboxylation by alpha-ketoglutarate decarboxylase leads to the formation of succinate semialdehyde.
  • 1 ,3-butanediol can be produced from succinyl-CoA via the pathways have been described.
  • Exemplary enzymes for the conversion succinyl-CoA to 1 ,3-butanediol include succinyl-CoA reductase (aldehyde forming), 4-hydroxybutyrate dehydrogenase, 4- hydroxybutyrate kinase, phosph.otrans-4-hydroxybutyrylase, 4-hydroxybutyryl-CoA
  • Succinate reductase can be
  • succinate semialdehyde is a compound that has a 1,3-butanediol pathway intermediate, succinate semialdehyde.
  • succmyl-CoA can be converted by alpha- ketoglutarate:ferredoxin oxidoreductase to aipha-ketoglutarate whose decarboxylation by alpha- ketoglutarate decarboxylase leads to the formation of succinate semialdehyde.
  • n-butanol can be produced from succinyi-CoA via known pathways.
  • Exemplary enzymes for the conversion succinyl-CoA to butanol include succinyl-CoA reductase (aldehyde forming), 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyrate kinase, phosphotrans-4- hydroxybutyrylase, 4-hydroxybutyryI-CoA dehydratase, butyryl-CoA dehydrogenase, butyryl- CoA hydrolase, butyryl-coA synthetase, butyryl-coA transferase, butyrate reductase, butyryl- CoA reductase (aldehyde forming), butyraklehyde reductase, butyryl-CoA reductase (alcohol forming), succinyl-CoA reductase (alcohol forming), 4-hydroxybutyryl-CoA transferase
  • succinate reductase can be additionally useful by converting succinate directly to the butanol pathway intermediate, succinate semialdehyde.
  • succinyi-CoA can be converted by aipha-ketoglutarate :ferredoxin oxidoreductase to aipha- ketoglutarate whose decarboxylation by aipha-ketoglutarate decarboxylase leads to the formation of succinate semialdehyde.
  • Isobutanol can be produced from succinyi-CoA via known pathways.
  • Exemplary enzymes for the conversion succinyl-CoA to isobutanol include succmyl-CoA reductase (aldehyde forming), 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyrate kinase,
  • phosphotrans-4-hydroxybutyrylase 4-hydroxybutyryi-CoA dehydratase, butyryl-CoA dehydrogenase, isobutyryl-CoA mutase, isobutyryl-CoA hydrolase, isobutyryi-coA synthetase, isobutyryi-coA transferase, isobutyrate reductase, isobutyryl-CoA reductase (aldehyde forming), iso butyraklehyde reductase, isobutyryl-CoA reductase (alcohol forming), succinyl- CoA reductase (alcohol forming), 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryl-CoA synthetase.
  • succinate reductase can be additionally useful by converting succinate directly to the isobutanol pathway intermediate, succinate semialdehyde.
  • succinyl-CoA can be converted by alpha-ketogiutarate:ferredoxin oxidoreductase to aipha-ketoglutarate whose decarboxylation by aipha-ketoglutarate decarboxylase leads to the formation of succinate semialdehyde.
  • Isopropanol can be produced from succinyl-CoA via known pathways.
  • Exemplary enzymes for the conversion succinyi-CoA to isopropanol include succinyl-CoA reductase (aldehyde forming), 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyrate kinase,
  • phosphotrans-4-hydroxybutyrylase 4-hydroxybutyryl-CoA dehydratase, crotonase, 3- hydroxybutyryl-CoA dehydrogenase, acetoacetyi-CoA synthetase, acetoacetate-CoA transferase, acetoacetyi-CoA hydrolase, acetoacetate decarboxylase, acetone reductase, succinyl-CoA reductase (alcohol forming), 4-hydroxybutyryl-CoA transferase, and 4 ⁇ hydroxybutyryl-CoA synthetase.
  • succinate reductase can be additionally useful by converting succinate directly to the isopropanol pathway intermediate, succinate semialdehyde.
  • succinyl-CoA can be converted by alpha-ketoglutarate:ferredoxin oxidoreductase to alpha- ketoglutarate whose decarboxylation by alpha-ketoglutarate decarboxylase leads to the formation of succinate semialdehyde.
  • n-propanol can be produced from succinyl-CoA via known pathways.
  • exemplary enzymes for the conversion succinyl-CoA to n-propanol include propionaldehyde
  • dehydrogenase propanol dehydrogenase, propionyl-CoArphosphate propatioyltransferase, propionyl-CoA hydrolase, propionyl-CoA transferase, propionyl-CoA synthetase, propionate kinase, propionate reductase, propionyi phosphate reductase, methylmalonyl-CoA. mutase, methylmalonyl-CoA epimerase, methylmalonyl-CoA decarboxylase, and methylmalonyl-CoA carboxy tran sferase .
  • Adipate can be produced from succinyl-CoA via known pathways (see for example, Burgard et al., (WO/2009/15 ⁇ 728 A2).
  • Exemplar ⁇ ' enzymes for the conversion of succinyl-CoA to adipate include succinyl-CoA:acetyl-CoA acyl transferase, 3-hydroxyacyl-CoA
  • dehydrogenase 3-hydroxyadipyl-CoA dehydratase, 5-carboxy-2-pentenoyl-CoA reductase, adipyl-CoA synthetase, phosphotransadipylase, adipate kinase, adipyl-CoA:acetyI-CoA transferase, adipyi-CoA hydrolase, 3-oxoadipyl-CoA transferase, 3-oxoadi ate reductase, 3- hydroxyadipate dehydratase, and 2-enoate reductase.
  • 6-aminocaproate can be produced from succinyl-CoA via known pathways.
  • Exemplary enzymes for the conversion of succinyl-CoA to 6-aminocaproate include succinyi- CoA:acetyi-CoA acyl transferase, 3-hydroxyacyl-CoA dehydrogenase, 3-hydroxyadipyl-CoA dehydratase, 5-earboxy-2-pentenoyl-CoA reductase, adipyl-CoA synthetase,
  • phosphotransadipylase adipate kinase, adipy l-Co A :acetyl-CoA transferase, adipyl-CoA hydrolase, adipate reductase, adipyl-CoA reductase, Co A -dependent aldehyde dehydrogenase (e.g., adipyl-CoA reductase (aldehyde forming), transaminase (e.g., 6-aminocaproate transaminase), 6-aminocaproate dehydrogenase, 3-oxoadipyl-CoA transferase, 3-oxoadipate reductase, 3-hydrox adipate dehydratase, and 2-enoate reductase.
  • aldehyde dehydrogenase e.g., adipyl-CoA reductase (aldehyde forming)
  • Hexamethylenediamine can be produced from succinyl-CoA via known pathways.
  • Exemplary enzymes for the conversion of succinyl-CoA to adipate include succinyl- CoA:acetyl-CoA acyl transferase, 3-hydroxyacyl-CoA dehydrogenase, 3-hydroxyadipyl-CoA dehydratase, 5-carboxy-2-pentenoyl-CoA reductase, adipyl-CoA synthetase,
  • phosphotransadipylase adipate kinase, adipyl-CoA:acetyl-CoA transferase, adipyl-CoA hydrolase, adipate reductase, adipyl-CoA reductase, CoA-dependent aldehyde dehydrogenase (e.g., adipyl-CoA reductase (aldehyde forming), transaminase (e.g., 6-aminocaproate transaminase), 6-arninocaproate dehydrogenase, 3-oxoadipyl-CoA transferase, 3-oxoadipate reductase, 3-hydroxyadipate dehydratase, 2-enoate reductase, 6-aminocaproyl-CoA/acyl-CoA transferase, 6-aminocaproyl-CoA synthase, 6-aminocaproyl-CoA reductas
  • Enzymes, genes and methods for engineering pathways from glycolysis intermediates to various products into a microorganism are known in the art.
  • the additional reducing equivalents obtained from CO and H?, as described herein, improve the yields of ail these products on carbohydrates.
  • glycerol and 1,3-propanediol can be produced from the glycolysis intermediate, dihydroxyacetone phosphate, via the pathways described in
  • Exemplary enzymes for the conversion of dihydroxyacetone phosphate to glycerol include glycerol-3 -phosphate dehydrogenase and glycerol-3 -phosphate phosphatase.
  • Exemplary enzymes for the conversion of dihydroxyacetone phosphate to 1,3-propanediol include glycerol-3 -phosphate
  • the reductive TCA cycle coupled with carbon monoxide and hydrogenase enzymes, can be employed to allow syngas utilization by microorganisms.
  • Synthesis gas is a mixture of primarily H 2 and CO that can be obtained via gasification of any organic feedstock, such as coal, coal oil, natural gas, biomass, or waste organic matter.
  • Any organic feedstock such as coal, coal oil, natural gas, biomass, or waste organic matter.
  • Numerous gasification processes have been developed, and most designs are based on partial oxidation, where limiting oxygen avoids full combustion, of organic materials at high temperatures (500 ⁇ 150G°C) to provide syngas as a 0.5: 1-3: 1 H 2 /CO mixture, in addition to coal, biomass of many types has been used for syngas production and represents an inexpensive and flexible feedstock for the biological production of renewable chemicals and fuels.
  • the C0 2 -fixing reductive tricarboxylic acid (RTCA) cycle is an endergenic anabolic pathway of C0 2 assimilation, requiring reducing equivalents and ATP.
  • the reductive TCA cycle was first reported in the green sulfur photosyiithetic bacterium Chlorobium limicola (Evans et al., Proc. Natl. Acad. Sci. U.S.A. 55:928-934 (1966)). Similar pathways have been characterized in some prokaiyotes (proteobacteria, green sulfur bacteria and thermophillic Knallgas bacteria) and sulfur-dependent archaea (Hugler et al., J. Bacteriol.
  • the components of synthesis gas can provide sufficient CO?., reducing equivalents, and ATP for the reductive TCA cycle to operate.
  • One turn of the RTCA cycle assimilates two moles of C0 2 into one mole of acetyl-CoA and requires 2 ATP and 4 reducing equivalents.
  • CO and H 2 can provide reducing equivalents by means of carbon monoxide dehydrogenase and hydrogenase enzymes, respectively.
  • Reducing equivalents can come in the form of NADH, NADPH, FADH, reduced quinones, reduced ferredoxins, reduced fiavodoxins and reduced thioredoxins.
  • the reducing equivalents can serve as cefaclors for the RTCA cycle enzymes (e.g., malate dehydrogenase, fumarate reductase, alpha-ketoglutarate:ferredoxin oxidoreductase (alternatively known as 2- oxoglutarate:ferredoxin oxidoreductase, alpha-ketoglutarate synthase, or 2-oxogkitarate synthase), and isocitrate dehydrogenase).
  • malate dehydrogenase e.g., malate dehydrogenase, fumarate reductase, alpha-ketoglutarate:ferredoxin oxidoreductase (alternatively known as 2- oxoglutarate:ferredoxin oxidoreductase, alpha-ketoglutarate synthase, or 2-oxogkitarate synthase)
  • the electrons from these reducing equivalents can alternatively pass through an ion-gradient producing electron transport chain where the)' are passed to an acceptor such as oxygen, nitrate, oxidized metal ions, protons, or an electrode.
  • the ion-gradient can then be used for ATP generation via an ATP synthase or similar enzyme.
  • TCA cycle Many of the enzymes in the TCA cycle are reversible and can catalyze reactions in the reductive and oxidative directions. However, some TCA cycle reactions are irreversible in vivo and thus different enzymes are used to catalyze these reactions in the directions required for the reverse TCA cycle. These reactions are: 1. conversion of citrate to oxaloacetate and acetyi-CoA, 2. conversion of fu arate to succinate, 3. conversion of succinyl-CoA to alpha- ketoglutarate. In the TCA cycle, citrate is formed from the condensation of oxaloacetate and acetyl-CoA.
  • citrate lyase can be coupled to acetyl-CoA synthetase, an acetyl-CoA transferase, or phosphotransacetylase and acetate kinase to form acetyl-CoA and oxaloacetate from citrate.
  • succinate dehydrogenase The conversion of succinate to fumarate is catalyzed by succinate dehydrogenase while the reverse reaction is catalyzed by fumarate reductase.
  • succinyl-CoA is formed from the NAD(P) T dependent decarboxylation of oxaloacetate by the alpha-ketoglutarate dehydrogenase complex.
  • the reverse reaction is catalyzed by alpha-ketoglutarate:ferredoxin ox doreductase,
  • An organism capable of utilizing the reverse tricarboxylic acid cycle to enable production of acetyi-CoA-derived products on 1) CO, 2) C0 2 and H 2 , 3) CO and CO?, 4) synthesis gas comprising CO and H 2 , and 5) synthesis gas comprising CO, C0 2 , and H 2 can include any of the following enzyme activities: ATP-citrate lyase, citrate lyase, aconitase, isocitrate dehydrogenase, alpba ⁇ ketoglutarate:ferredoxin oxidoreductase, succinyl-CoA synthetase, succinyl-CoA transferase, fumarate reductase, fumarase, malate dehydrogenase, acetate kinase, phosphotransacetylase, acetyl-CoA synthetase, NAD(P)H:ferredoxin
  • Carbon from syngas can be fixed via the reverse TCA cycle and components thereof.
  • the organisms and conversion routes described herein provide an efficient means of converting synthesis gas and its components to products such as isopropanol, butanoi, 4- hydroxybutyrate, 1 ,3-butanediol or 1 , -butanediol, or other desired products.
  • Additional product molecules that can be produced by the teachings of this invention include but are not limited to ethanol, n-propanol, isobutanol, succinic acid, fumaric acid, malic acid, 3- hydroxypropionic acid, lactic acid, adipic acid, 6-aminocaproic acid, hexamethylenediamine, 3- hydoxyisobutyric acid, 2-hydroxyisobutyric acid, methacrylic acid, acrylic acid, and long chain hydrocarbons, alcohols, acids, and esters,
  • the invention additionally provides a non-naturaily occurring microbial organism comprising at least one exogenous nucleic acid encoding a 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol, or other desired product pathway enzyme expressed in a sufficient amount to produce an intermediate of a 1 ,4-butanediol, 4- hydroxyb tyrate, 1,3-butanediol, or isopropanol pathway, or other product intermediate.
  • a 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway are exemplified in Figures 1 -4. Therefore, in addition to a microbial organism containing a 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway that produces 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol, the invention additionally provides a non-naturaily occurring microbial organism comprising at least one exogenous nucleic acid encoding a 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol pathway enzyme, where the microbial organism produces a 1,4-butanediol, 4- hydroxybutyrate, 1,
  • such a microbial organism that produces an intermediate can be used in combination with another microbial organism expressing downstream pathway enzymes to produce a desired product.
  • a non-naturaily occurring microbial organism that produces a 1,4-butanediol, 4- hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product pathway intermediate can be utilized to produce the intermediate as a desired product.
  • the invention is described herein with general reference to the metabolic reaction, reactant or product thereof, or with specific reference to one or more nucleic acids or genes encoding an enzyme associated with or catalyzing, or a protein associated with, the referenced metabolic reaction, reactant or product. Unless otherwise expressly stated herein, those skilled in the art will understand that reference to a reaction also constitutes reference to the reactants and products of the reaction. Similarly, unless otherwise expressly stated herein, reference to a reactant or product also references the reaction, and reference to any of these metabolic constituents also references the gene or genes encoding the enzymes that catalyze or proteins involved in the referenced reaction, reactant or product.
  • reference herein to a gene or encoding nucleic acid also constitutes a reference to the corresponding encoded enzyme and the reaction it catalyzes or a protein associated with the reaction as well as the reactatits and products of the reaction.
  • the non-natural [y occurri ng microbial organisms of the invention can be produced by introducing expressible nucleic acids encoding one or more of the enzymes or proteins participating in one or more 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-b tanediol, or isopropanol, or other desired product biosynthetic pathways.
  • nucleic acids for some or all of a particular 1 ,4-butanediol, 4- hydroxybutyrate, 1 ,3-butanediol, or isopropanol, or other desired product biosynthetic pathway can be expressed.
  • a chosen host is deficient in one or more enzymes or proteins for a desired biosynthetic pathway, then expressible nucleic acids for the deficient enzyme(s) or protein(s) are introduced into the host for subsequent exogenous expression.
  • the chosen host exhibits endogenous expression of some pathway genes, but is deficient in others, then an encoding nucleic acid is needed for the deficient enzyme(s) or protein(s) to achieve 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol, or other desired product biosynthesis.
  • a non-naturally occurring microbial organism of the invention can be produced by introducing exogenous enzyme or protein activities to obtain a desired biosynthetic pathway or a desired biosynthetic pathway can be obtained by introducing one or more exogenous enzyme or protein activities that, together with one or more endogenous enzymes or proteins, produces a desired product such as 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3- butanediol, or isopropanol or other desired product.
  • Host microbial organisms can be selected from, and the non-naturally occurring microbial organisms generated in, for example, bacteria, yeast, fungus or any of a variety of other microorganisms applicable to fermentation processes.
  • Exemplary bacteria include species selected from Escherichia coli, Klebsiella oxytoca, Anaerobiospirillum succiniciproducens, Actinobacilliis succinogenes, Mannheimia siicciniciproducens, Rhizobhim etli.
  • yeasts or fungi include species selected from Saccharomyces cerevisiae, Schizosaccharomyc.es pombe, Kluyveromyces lactis, Kluyveromyces marxianus, Aspergillus terreus, Aspergillus niger, Pichia pastoris, Rhizopus arrhizus, Rhizobus oryzae, and the like
  • E. coli is a particularly useful host organism since it is a well characterized microbial organism suitable for genetic engineering.
  • Other particularly useful host organisms include yeast such as Saccharomyces cerevisiae. It is understood that any suitable microbial host organism can be used to introduce metabolic and/or genetic
  • the non-natural ly occurring microbial organisms of the invention will include at least one exogenously expressed 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product pathway-encoding nucleic acid and up to all encoding nucleic acids for one or more 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol biosynthetic pathways.
  • 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product biosynthesis can be established in a host deficient in a pathway enzyme or protein through exogenous expression of the corresponding encoding nucleic acid.
  • exogenous expression of all enzyme or proteins in the pathway can be included, although it is understood that ail enzymes or proteins of a pathway can be expressed even if the host contains at least one of the pathway enzymes or proteins.
  • exogenous expression of all enzymes or proteins in a pathway for production of 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product can be included.
  • a non-naturally occurring microbial organism of the invention can have one, two, three, four, five, six, seven, eight, or up to all nucleic acids encoding the enzymes or proteins constituting a 1 ,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product biosynthetic pathway disclosed herein.
  • the non-naturally occurring microbial organism of the invention can have one, two, three, four, five, six, seven, eight, or up to all nucleic acids encoding the enzymes or proteins constituting a 1 ,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product biosynthetic pathway disclosed herein.
  • the non-naturally occurring can have one, two, three, four, five, six, seven, eight, or up to all nucleic acids encoding the enzymes or proteins constituting a 1
  • a host microbial organism is selected such that it produces the precursor of a 1,4-butanediol, 4-hydroxybutyrate, 1,3 -butanediol, or isopropanol or other desired product pathway, either as a naturally produced molecule or as an engineered product that either provides de novo production of a desired precursor or increased production of a precursor naturally produced by the host microbial organism.
  • a host organism can be engineered to increase production of a precursor, as disclosed herein.
  • a microbial organism that has been engineered to produce a desired precursor can be used as a host organism and further engineered to express enzymes or proteins of a 1,4-butanediol, 4-hydroxybutyrate, 1,3- butanediol, or isopropanol or other desired product pathway.
  • a non-naturally occurring microbial organism of the invention is generated from a host that contains the enzymatic capability to synthesize 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • Increased synthesis or accumulation can be accomplished by, for example, overexpression of nucleic acids encoding one or more of the above-described 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway enzymes or proteins.
  • Over expression the enzyme or enzymes and/or protein or proteins of the 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway can occur, for example, through exogenous expression of the endogenous gene or genes, or through exogenous expression of the heterologous gene or genes.
  • Naturally occurring organisms can be readily generated to be non-naturally occurring microbial organisms of the invention, for example, producing 1,4-butanediol , 4-hydroxybutyrate, 1,3-butanediol , or isopropanoi, through overexpression of one, two, three, four, five, six , seven, eight, up to all nucleic acids encoding 1,4-butanediol, 4-hydroxyb ' tttyrate, 1,3-butanediol, or isopropanoi biosynthetic pathway enzymes or proteins, in addition, a non-natural [y occurring organism can be generated by mutagenesis of an endogenous gene that results in an increase in activity of an enzyme in the 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanoi biosynthetic pathway.
  • exogenous expression of the encoding nucleic acids is employed.
  • Exogenous expression confers the ability to custom tailor the expression and/or regulatory elements to the host and application to achieve a desired expression level that is controlled by the user.
  • endogenous expression also can be utilized in other embodiments such as by removing a negative regulatory effector or induction of the gene's promoter when linked to an inducible promoter or other regulator ⁇ ' element.
  • an endogenous gene having a naturally occurring inducible promoter can be up-regulated by providing the appropriate inducing agent, or the regulatory region of an endogenous gene can be engineered to incorporate an inducible regulatory element, thereby allowing the regulation of increased expression of an endogenous gene at a desired time.
  • an inducible promoter can be included as a regulatory element for an exogenous gene introduced into a non-naturally occurring microbial organism.
  • any of the one or more exogenous nucieic acids can be introduced into a microbial organism to produce a non-naturally occurring microbial organism of the invention.
  • the nucleic acids can be introduced so as to confer, for example, a 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanoi or other desired product biosynthetic pathway onto the microbial organism.
  • encoding nucleic acids can be introduced to produce an intermediate microbial organism having the biosynthetic capability to catalyze some of the required reactions to confer 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanoi or other desired product biosynthetic capability.
  • a non-naturally occurring microbial organism having a 1,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanoi or other desired product biosynthetic pathway can comprise at least two exogenous nucleic acids encoding desired enzymes or proteins.
  • the non-naturally occurring microbial organisms and methods of the invention also can be utilized in various combinations with each other and with other microbial organisms and methods well known in the art to achieve product biosynthesis by other routes.
  • one alternative to produce 1,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol other than use of the 1,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol producers is through addition of another microbial organism capable of converting a 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3- butanediol, or isopropanol pathway intermediate to 1,4-butanediol, 4-hydroxybutyrate, 1,3- butanediol, or isopropanol.
  • One such procedure includes, for example, the fennentation of a microbial organism that produces a 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway intermediate.
  • the 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway intermediate can then be used as a substrate for a second microbial organism that converts the 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway intermediate to 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol.
  • the 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol pathway intermediate can be added directly to another cul ture of the second organism or the original culture of the 1,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product pathway intermediate producers can be depleted of these microbial organisms by, for example, cell separation, and then subsequent addition of the second organism to the fennentation broth can be utilized to produce the final product without intermediate purification steps.
  • the non-naturally occurring microbial organisms and methods of the invention can be assembled in a wide variety of subpathways to achieve biosynthesis of, for example, 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • biosynthetic pathways for a desired product of the invention can be segregated into different microbial organisms, and the different microbial organisms can be co-cultured to produce the final product.
  • the product of one microbial organism is the substrate for a second microbial organism until the final product is synthesized.
  • the biosynthesis of 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3- butanediol, or isopropanol or other desired product can be accomplished by constructing a microbial organism that contains biosynthetic pathways for conversion of one pathway intermediate to another pathway intermediate or the product.
  • 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product also can be biosynthetically produced from microbial organisms through co-culture or co-fermentation using two organ sms in the same vessel, where the first m crobial organism produces a 1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product intermediate and the second microbial organism converts the intermediate to 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • Sources of encoding nucleic acids for a 1,4-butanediol, 4-hydroxybutyrate, 1 ,3- butanediol, or isopropanol or other desired product pathway enzyme or protein can include, for example, any species where the encoded gene product is capable of catalyzing the referenced reaction.
  • species include both prokaryotic and eukaryotic organisms including, but not limited to, bacteria, including archaea and eubacteria, and eukaryotes, including yeast, plant, insect, animal, and mammal, including human.
  • Exemplary species for such sources include, for example, Escherichia coli.S. cerevisiae, B.
  • subtilis subtilis, Candida hoidinii, as well as other exemplary species disclosed herein or available as source organisms for corresponding genes.
  • the complete genome sequence available for now more than 550 species including 395 microorganism genomes and a variety of yeast, fungi, plant, and mammalian genomes
  • the identification of genes encoding the requisite 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol or other desired product biosynthetic activity for one or more genes in related or distant species including for example, homologues, orthologs, paralogs and nonorthoiogous gene displacements of known genes, and the interchange of genetic alterations between organisms is routine and well known in the art.
  • the metabolic alterations allowing biosynthesis of 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product described herein with reference to a particular organism such as E. coli can be readily applied to other microorganisms, including prokaryotic and eukaryotic organisms alike. Given the teachings and guidance provided herein, those skilled in the art will know that a metabolic alteration exemplified in one organism can be applied equally to other organisms.
  • 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product biosynthetic pathway exists in an unrelated species
  • 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product biosynthesis can be conferred onto the host species by, for example, exogenous expression of a paralog or paralogs from the unrelated species that catalyzes a similar, yet non- identical metabolic reaction to replace the referenced reaction.
  • Methods for constructing and testing the expression levels of a non-naturally occurring 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol-producing, or other desired product, host can be performed, for example, by recombinant and detection methods well known in the art. Such methods can be found described in, for example, Sambrook et al, Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New- York (2001); and Ausubei et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999).
  • Exogenous nucleic acid sequences involved in a pathway for production of 1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product can be introduced stably or transiently into a host cell using techniques well known in the art including, but not limited to, conjugation, electroporation, chemical transformation, transduction, transfection, and ultrasound transformation.
  • conjugation, electroporation, chemical transformation, transduction, transfection, and ultrasound transformation for exogenous expression in E.
  • nucleic acid sequences in the genes or cDNAs of eukaryotic nucleic acids can encode targeting signals such as an N-terminai mitochondrial or other targeting signal, which can be removed before transformation into prokaryotic host cells, if desired.
  • targeting signals such as an N-terminai mitochondrial or other targeting signal, which can be removed before transformation into prokaryotic host cells, if desired.
  • removal of a mitochondrial leader sequence led to increased expression in E. coli (Hoffmeister et al, J. Biol. Chem. 280:4329-4338 (2005)).
  • genes can be expressed in the cytosol without the addition of leader sequence, or can be targeted to mitochondrion or other organelles, or targeted for secretion, by the addition of a suitable targeting sequence such as a mitochondrial targeting or secretion signal suitable for the host cells.
  • a suitable targeting sequence such as a mitochondrial targeting or secretion signal suitable for the host cells.
  • An expression vector or vectors can be constructed to include one or more 1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product biosynthetic pathway encoding nucleic acids as exemplified herein operably linked to expression control sequences functional in the host organism.
  • Expression vectors applicable for use in the microbial host organisms of the invention include, for example, plasmids, phage vectors, viral vectors, episomes and artificial chromosomes, including vectors and selection sequences or markers operable for stable integration into a host chromosome. Additionally, the expression vectors can include one or more selectable marker genes and appropriate expression control sequences.
  • Selection control sequences can include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like which are well known in the art.
  • both nucleic acids can be inserted, for example, into a single expression vector or in separate expression vectors.
  • the encoding nucleic acids can be operationally linked to one common expression control sequence or linked to different expression control sequences, such as one inducible promoter and one constitutive promoter.
  • exogenous nucleic acid sequences involved in a metabolic or synthetic pathway can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis such as Northern blots or polymerase chain reaction (PCR) amplification of mRNA, or immunoblotting for expression of gene products, or other suitable analytical methods to test the expression of an introduced nucleic acid sequence or its corresponding gene product. It is understood by those skilled in the art that the exogenous nucleic acid is expressed in a sufficient amount to produce the desired product, and it is further understood that expression levels can be optimized to obtain sufficient expression using methods well known in the art and as disclosed herein.
  • the present invention provides a method for enhancing carbon flux through acetyl-CoA that includes culturing the aforementioned non-naturaily occurring microbial organisms under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block.
  • Such culturing can be in a substantially anaerobic culture medium and can include organisms having any number of exogenous nucleic acids as described herein above.
  • these cultured organisms can have an isopropanol pathway, a 1,3-butanediol pathway; a 1 ,4-butanediol pathway, a 4-hydroxybutrate pathway, or any other functional pathway that utilizes acetyl-CoA.
  • the culturing of these microbial organism can be performed with a carbon feedstock selected from CO, C0 2 , and H 2 , synthesis gas comprising CO and H 2 , and synthesis gas comprising CO, CO?, and H 2 .
  • Suitable purification and/or assays to test for the production of 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product can be performed using well known methods. Suitable replicates such as triplicate cultures can be grown for each engineered strain to be tested. For example, product and byproduct formation in the engineered production host can be monitored. The final product and i termediates, and other organic compounds, can be analyzed by methods such as HPLC (High Performance Liquid
  • the 1. ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product can be separated from other components in the culture using a variety of methods well known in the art.
  • separation methods include, for example, extraction procedures as well as methods that include continuous liquid-liquid extraction, pervaporation, membrane filtration, membrane separation, reverse osmosis, electrodialysis, distillation, crystallization, centrifugation, extractive filtration, ion exchange chromatography, size exclusion chromatography, adsorption chromatography, and ultrafiltration.
  • Ail of the above methods are w r ell known in the art.
  • any of the non-natural ly occurring microbial organisms described herein can be cultured to produce and/or secrete the biosynthetic products of the invention.
  • the 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product producers can be cultured for the biosynthetic production of 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • the recombinant strains are cultured in a medium with carbon source and other essential nutrients. It is sometimes desirable and can be highly desirable to maintain anaerobic conditions in the fermenter to reduce the cost of the overall process. Such conditions can be obtained, for example, by first sparging the medium with nitrogen and then sealing the flasks with a septum and crimp-cap.
  • microaerobic or substantially anaerobic conditions can be applied by perforating the septum with a small hole for limited aeration.
  • Exemplar ⁇ ' anaerobic conditions have been described previously and are well-known in the art.
  • Exemplary aerobic and anaerobic conditions are described, for example, in United State publication 2009/0047719, filed August 10, 2007. Fermentations can be performed in a batch, fed-batch or continuous manner, as disclosed herein.
  • the pH of the medium can be maintained at a desired pH, in particular neutral pH, such as a pH of around 7 by addition of a base, such as NaOH or other bases, or acid, as needed to maintain the culture medium at a desirable pH.
  • the growth rate can be determined by measuring optical density using a spectrophotometer (600 nm), and the glucose uptake rate by monitoring carbon source depletion over time.
  • the growth medium can include, for example, any carbohydrate source which can supply a source of carbon to the non-naturaily occurring microorganism.
  • Such sources include, for example, sugars such as glucose, xylose, arabinose, galactose, mannose, fructose, sucrose and starch.
  • Other sources of carbohydrate include, for example, renewable feedstocks and biomass.
  • Exemplary types of biomasses that can be used as feedstocks in the methods of the invention include cellulosic biomass, hemicellulosic biomass and lignin feedstocks or portions of feedstocks.
  • Such biomass feedstocks contain, for example, carbohydrate substrates useful as carbon sources such as glucose, xylose, arabinose, galactose, mannose, fructose and starch.
  • carbohydrate substrates useful as carbon sources such as glucose, xylose, arabinose, galactose, mannose, fructose and starch.
  • renewable feedstocks and biomass other than those exemplified above also can be used for culturing the microbial organisms of the invention for the production of 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • the 1 ,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol microbial organisms of the invention also can be modified for growth on syngas as its source of carbon.
  • one or more proteins or enzymes are expressed in the 1,4-butanediol, 4- hydroxyb tyrate, 1,3-butanediol, isopropanol, or other desired product, producing organisms to provide a metabolic pathway for utilization of syngas or other gaseous carbon source.
  • the carbon feedstock and other cellular uptake sources such as phosphate, ammonia, sulfate, chloride and other halogens can be chosen to alter the isotopic distribution of the atoms present in 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product, or any 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product pathway intermediate.
  • Uptake sources can provide isotopic enrichment for any atom present in the product 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product, or 1,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product pathway intermediate including any 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product impurities generated in diverging away from the pathway at any point.
  • Isotopic enrichment can be achieved for any target atom including, for example, carbon, hydrogen, oxygen, nitrogen, sulfur, phosphorus, chloride or other halogens.
  • the uptake sources can be selected to alter the carbon- 1.2, carbon- 13, and carbon- 14 ratios. In some embodiments, the uptake sources can be selected to alter the oxygen- 16, oxygen- 17, and oxygen- 18 ratios. In some embodiments, the uptake sources can be selected to alter the hydrogen, deuterium, and tritium ratios. In some
  • the uptake sources can selected to alter the nitrogen- 14 and nitrogen- 15 ratios. In some embodiments, the uptake sources can be selected to alter the sulfur-32, sulfur-33, sulfur- 34, and suifur-35 ratios. In some embodiments, the uptake sources can be selected to alter the phosphorus-31 , phosphortts-32, and phosphorus-33 ratios. In some embodiments, the uptake sources can be selected to alter the chlorine-35, chlorine-36, and chlorine-37 ratios.
  • the isotopic ratio of a target atom can be varied to a desired ratio by selecting one or more uptake sources.
  • An uptake source can be derived from a natural source, as found in nature, or from a man-made source, and one skilled in the art. can select, a natural source, a man-made source, or a combination thereof, to achieve a desired isotopic ratio of a target atom .
  • An example of a man-made uptake source includes, for example, an uptake source that is at least partially derived from a chemical synthetic reaction.
  • Such isotopically enriched uptake sources can be purchased commercially or prepared in the laboratory and/or optionally mixed with a natural source of the uptake source to achieve a desired isotopic ratio.
  • a target atom isotopic ratio of an uptake source can be achieved by selecting a desired origin of the uptake source as found in nature.
  • a natural source can be a biobased derived from or synthesized by a biological organism or a source such as petroleum-based products or the atmosphere.
  • a source of carbon for example, can be selected from a fossil fuel-derived carbon source, which can be relatively depleted of carbon- 14, or an environmental or atmospheric carbon source, such as C0 2 , which can possess a larger amount of carbon- 14 than its petroleum-derived counterpart.
  • the unstable carbon isotope carbon-14 or radiocarbon makes up for roughly 1 in 10 f 2 carbon atoms in the earth's atmosphere and has a half- life of about 5700 years.
  • the stock of carbon is replenished in the upper atmosphere by a nuclear reaction involving cosmic rays and ordinary nitrogen ( i4 N).
  • Fossil fuels contain no carbon-14, as it decayed long ago. Burning of fossil fuels lowers the atmospheric carbon-14 fraction, the so-called "Suess effect”.
  • Isotopic enrichment is readily assessed by mass spectrometry using techniques known in the art such as accelerated mass spectrometry (AMS), Stable Isotope Ratio Mass Spectrometr (SIRMS) and Site-Specific Natural Isotopic Fractionation by Nuclear Magnetic Resonance (SNIF-NMR).
  • AMS accelerated mass spectrometry
  • SIRMS Stable Isotope Ratio Mass Spectrometr
  • SNIF-NMR Site-Specific Natural Isotopic Fractionation by Nuclear Magnetic Resonance
  • mass spectral techniques can be integrated with separation techniques such as liquid chromatography (LC), high performance liquid
  • HPLC high performance liquid chromatography
  • gas chromatography and/or gas chromatography, and the like.
  • ASTM D6866 was developed in the United States as a standardized analytical method for determining the biobased content of solid, liquid, and gaseous samples using radiocarbon dating by the American Society for Testing and Materials (ASTM) International. The standard is based on the use of radiocarbon dating for the determination of a product's biobased content. ASTM D6866 was first published in 2004, and the current active version of the standard is ASTM D6866-1 1 (effective April 1, 2011).
  • Radiocarbon dating techniques are well known to those skilled in the art, including those described herein.
  • the biobased content of a compound is estimated by the ratio of carbon- 14 ( l4 C) to carbon- 12 ( C).
  • Modem is defined as 95% of the radiocarbon concentration (in AD 1950) of National Bureau of Standards (NBS) Oxalic Acid I (i.e., standard reference materials (SRM) 4990b) normalized to 6 1j C VPDB ::: ⁇ per mil (Olsson, The use of Oxalic acid as a Standard, in, Radiocarbon Variations and Absolute Chronology, Nobel Symposium, 12th Proc, John Wiley & Sons, New York (1970)).
  • the standard calculations take into account the differential uptake of one istope with respect to another, for example, the preferential uptake in biological systems of C over C li over C' 4 , and these corrections are reflected as a Fm corrected for 6 lj .
  • An oxalic acid standard (SRM 4990b or HOx 1) was made from a crop of 1955 sugar beet. Although there were 1000 lbs made, this oxalic acid standard is no longer commercially available.
  • the Oxalic Acid II standard (HOx 2; N.I.S.T designation SRM 4990 C) was made from a crop of 1977 French beet molasses. In the early 1980's, a group of 12 laboratories measured the ratios of the two standards. The ratio of the activity of Oxalic acid II to 1 is 1.2933 ⁇ 0,001 (the weighted mean). The isotopic ratio of HOx II is -17.8 per mille.
  • ASTM D6866-1 1 suggests use of the available Oxalic Acid II standard SRM 4990 C (Hox2) for the modem standard (see discussion of original vs. currently available oxalic acid standards in Mann, Radiocarbon, 25(2):519-527 (1983)).
  • a Fm : : 0% represents the entire lack of carbon - 14 atoms in a material, thus indicating a fossil (for example, petroleum based) carbon source.
  • a Fm ;: 100%, after correction for the post-1950 injection of carbon- 14 into the atmosphere from nuclear bomb testing, indicates an entirely modern carbon source. As described herein, such a "modern" source includes biobased sources.
  • the percent modern carbon can be greater than 100% because of the continuing but diminishing effects of the 1950s nuclear testing programs, which resulted in a considerable enrichment of carbon- 14 in the atmosphere as described in ASTM D6866-1 1. Because all sample carbon- 14 activities are referenced to a "pre-bomb" standard, and because nearly all new biobased products are produced in a post-bomb environment, all pMC values (after correction for isotopic fraction) must be multiplied by 0.95 (as of 2010) to better reflect the true biobased content of the sample. A biobased content that is greater than 103% suggests that either an analytical error has occurred, or that the source of biobased carbon is more than several years old,
  • polypropylene terephthalate (PPT) polymers derived from renewable 1,3-propanediol and petroleum-derived terephthalic acid resulted in Fm values near 30% (i.e., since 3/1 1 of the polymeric carbon derives from renewable 1,3-propanediol and 8/11 from the fossil end member terephthalie acid) (Currie et al., supra, 2000).
  • polybutylene terephthalate polymer derived from both renewable 1 ,4-butanediol and renewable terephthalie acid resulted in bio-based content exceeding 90% (Colonna et al., supra, 2011).
  • the present invention provides 1 ,4-butanediol, 4- hydroxybutyrate, 1 ,3-butanedioi, isopropanol, or other desired products or a 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products pathway intermediate that has a carbon- 12, carbon- .13, and carbon- .14 ratio that reflects an atmospheric carbon, also referred to as environmental carbon, uptake source.
  • the 1 ,4- butanediol, 4-bydroxybutyrate, 1 ,3-butanediol, isopropanol, or other desired products or a .1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, isopropanol, or other desired products pathway intermediate can have an Fm value of at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or as much as 100%.
  • the uptake source is C0 2 .
  • the present invention provides 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products or a .1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, isopropanol, or other desired products pathway intermediate that has a carbon- 12, carbon- 13, and carbon- 14 ratio that reflects petroleum-based carbon uptake source.
  • the 1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, isopropanol, or other desired products or a 1 ,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products pathway intermediate can have an Fm value of less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%), less than 10%), less than 5%, less than 2% or less than 1%.
  • the present invention provides 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products or a 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products pathway intermediate that has a carbon- 12, carbon- 13, and carbon- 14 ratio that is obtained by a combination of an atmospheric carbon uptake source with a petroleum-based uptake source.
  • Using such a combination of uptake sources is one way by which the carbon- 12, carbon- 13, and carbon- 14 ratio can be varied, and the respective ratios woul d reflect the proportions of the uptake sources,
  • the present invention relates to the biologically produced 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products or 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products pathway intermediate as disclosed herein, and to the products derived therefrom, wherein the 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products or a 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products pathway intermediate has a carbon- 12, carbon- 13, and carbon- 14 isotope ratio of about the same value as the C0 2 that occurs in the environment.
  • the invention provides bioderived 1,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, isopropanol, or other desired products or a bioderived 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products intermediate having a carbon- 12 versus carbon-13 versus carbon- 14 isotope ratio of about the same value as the C0 2 that occurs in the environment, or any of the other ratios disclosed herein.
  • a product can have a carbon- 12 versus carbon-13 versus carbon- 14 isotope ratio of about the same value as the C0 2 that occurs in the environmen t, or any of the ratios disclosed herein, wherein the product is generated from bioderived 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products or a bioderived 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products pathway intermediate as disclosed herein, wherein the bioderived product is chemically modified to generate a final product.
  • the invention further provides products derived from 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products, having a carbon- 12 versus carbon-13 versus carbon- 14 isotope ratio of about the same value as the C0 2 that occurs in the environment, wherein the derived products are generated directly from or in combination with bioderived 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired products or a bioderived 1,4-butanediol, 4-hydroxybutyrate, 1,3- butanediol, isopropanol, or other desired products pathway intermediate as disclosed herein.
  • the present invention provides 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product, or a 1 ,4-butanediol, 4- hydroxy butyrate, 1,3-butanediol, isopropanol, or other desired product intermediate that has a carbon-12, carbon-13, and carbon- 14 ratio that reflects an atmospheric carbon uptake source.
  • the uptake source is C0 2 .
  • the present invention provides 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product, or a 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product intermediate that has a carbon-12, carbon-13, and carbon- 14 ratio that reflects petroleum-based carbon uptake source.
  • the present invention provides 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product, or a 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, isopropanol, or other desired product intermediate that has a carbon-12, carbon-13, and carbon- 14 ratio that is obtained by a combination of an atmospheric carbon uptake source with a petroleum-based uptake source.
  • Such combination of uptake sources is one way by which the carbon-12, carbon-13, and carbon - 14 ratio can be varied.
  • the desired product produced by a microbial organism of the invention is distinguishable from that of the corresponding petrochemical based product by a different isotopic ratio, as described above.
  • a non-naturally occurring microbial organism can be produced that secretes the biosynthesized compounds of the invention when grown on a carbon source such as a carbohydrate.
  • a carbon source such as a carbohydrate.
  • Such compounds include, for example, 1 ,4-butanediol, 4-hydroxybutyrate, 1,3- butanediol, or isopropanol or other desired product and any of t he intermediate metabolites in the 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product pathway.
  • All that is required is to engineer in one or more of the required enzyme or protein activities to achieve biosynthesis of the desired compound or intermediate including, for example, inclusion of some or all of the 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product biosynthetic pathways.
  • the invention provides a non-naturally occurring microbial organism that produces and/or secretes 1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product when grown on a carbohydrate or other carbon source and produces and/or secretes any of the intermediate metabolites shown in the 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product pathway when grown on a carbohydrate or other carbon source.
  • the l,4 ⁇ butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product producing microbial organisms of the invention can initiate synthesis from an intermediate.
  • the non-naturally occurring microbial organisms of the invention are constructed using methods well known in the art as exemplified herein to exogenously express at least one nucleic acid encoding a 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product pathway enzyme or protein in sufficient amounts to produce 1 ,4- butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • the microbial organisms of the invention are cultured under conditions sufficient to produce 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product.
  • the non-naturally occurring microbial organisms of the invention can achieve biosynthesis of 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product resulting in intracellular concentrations between about 0.1 -200 mM or more.
  • the intracellular concentration of 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product is between about 3-150 mM, particularly between about 5-125 mM and more particularly between about 8-100 mM, including about 10 mM, 20 mM, 50 mM, 80 mM, or more.
  • Intracellular concentrations between and above each of these exemplary ranges also can be achieved from the non-naturally occurring microbial organisms of the invention.
  • the present invention relates to increasing production of a desired product by (i) enhancing carbon fixation via the reductive TCA cycle, and/or (ii) accessing additional reducing equivalents from gaseous carbon sources and/or syngas components such as CO, CO?,, and/or 3 ⁇ 4.
  • gaseous carbon sources and/or syngas components such as CO, CO?,, and/or 3 ⁇ 4.
  • the microbial organims and methods of using such organisms provide an increase in yield of a desired product, including 1 ,4- butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol as described herein. It is therefore understood that a particularly useful microbial organism of the invention is one in.
  • gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, C0 2 , and/or 3 ⁇ 4.
  • Such an increase in yield can be readily determined by one skilled in the art by measuring the product yield of a microbial organism engineered to express a desired product and comparing that product yield to the product yield of a microbial organism engineered to express both the desired product and to express one or more enzymes providing enhanced carbon fixation via the reductive TCA cycle, and/or access to additional reducing equivalents from gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, C0 2 , and/or 3 ⁇ 4, as disclosed herein.
  • Such a measurable increase in product yield is referred to herein as an increase in product yield relative to a parent microbial organism, that is, the same host microbial organism lacking a genetic modification to enhance carbon fixation via the reductive TCA cycle, and/or access to additional reducing equivalents from gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, C0 2 , and/or H 2 , as disclosed herein,
  • the increase in product yield can be, for example, at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,
  • the increase in product yield can result in production of at least 0.01 , 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
  • the increase in product yield can result in production of at least 0.005, 0.01, 0.02, 0.05, 0.1, 0.2, 03, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45,
  • wet cell weight is generally determined by pelleting the ceils, generally using centrifugation, and removing the liquid supernatant, leaving a cel l pel let which can be weighed.
  • the productivity of the microbial organisms of the invention as described herein and above includes those microbial organisms which provide the above-described product yields, where the product is measured to provide the above yields either i tracellularly, extracelluarly, or a combination thereof.
  • the microbial organisms of the invention can have an increase in product yield by exhibiting an increased rate of production of a desired product, where the increased rate of production occurs in a microbi al organism engineered to have a genetic modification to enhance carbon fixation via the reductive TCA cycle, and/or access to additional reducing equivalents from gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, CO 3 ⁇ 4 and/or H 2 , as disclosed herein.
  • the rate of product formation is at least 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 , 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 grams per liter per hour or even a higher rate of production of a desired product,
  • culture conditions include anaerobic or substantial!)' anaerobic growth or maintenance conditions.
  • Exemplary anaerobic conditions have been described previously and are well known in the art.
  • Exemplar ⁇ ' anaerobic conditions for fennentation processes are described herein and are described, for example, in U.S. publication
  • any of these conditions can be employed with the non- naturally occurring microbial organisms as well as other anaerobic conditions well known in the art.
  • the 1,4-butanediol, 4- hydroxyb tyrate, 1,3-butanediol, or isopropanol or other desired product producers can synthesize 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product at intracellular concentrations of 5-10 mM or more as well as all other concentrations exemplified herein.
  • 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol producing microbial organisms can produce 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropano or other desired productl intracellularly and/or secrete the product into the culture medium,
  • growth condition for achieving biosynthesis of 1,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product can include the addition of an osmoprotectant to the culturing conditions.
  • the non-naturally occurring microbial organisms of the invention can be sustained, cultured or fermented as described herein in the presence of an osmoprotectant.
  • an osmoprotectant refers to a compound that acts as an osmoiyte and helps a microbial organism as described herein survive osmotic stress.
  • Osmoprotectants include, but are not limited to, betaines, amino acids, and the sugar trehalose. Non-limiting examples of such are glycine betaine, praline betaine, dimethylthetin,
  • the osmoprotectant is glycine betaine. It is understood to one of ordinary skill in the art that the amount and type of osmoprotectant suitable for protecting a microbial organism described herein from osmotic stress will depend on the microbial organism used.
  • the amount of osmoprotectant in the culturing conditions can be, for example, no more than about 0.1 mM, no more than about 0.5 rnM, no more than about 1.0 rnM, no more than about 1.5 mM, no more than about 2.0 mM, no more than about 2.5 mM, no more than about 3.0 mM, no more tha about 5.0 mM, no more than about 7.0 mM, no more than about lOniM, no more than about 50mM, no more than about lOOmM or no more than about 500mM.
  • the culture conditions can include, for example, liquid culture procedures as well as fermentation and other large scale culture procedures. As described herein, particularly useful yields of the biosynthetic products of the invention can be obtained under anaerobic or substantially anaerobic culture conditions.
  • one exemplary growth condition for achieving biosynthesis of 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product includes anaerobic culture or fermentation conditions.
  • the non- naturally occurring microbial organisms of the invention can be sustained, cultured or fermented under anaerobic or substantially anaerobic conditions.
  • anaerobic conditions refer to an environment devoid of oxygen.
  • Substantially anaerobic conditions include, for example, a culture, batch fermentation or continuous fermentation such that the dissolved oxygen concentration in the medium remains between 0 and 10% of saturation.
  • Substantially anaerobic conditions also includes growing or resting cells in liquid medium or on solid agar inside a sealed chamber maintained with an atmosphere of less than 1% oxygen.
  • the percent of oxygen can be maintained by, for example, sparging the cuiture with an N 2 CO 2 mixture or other suitable non-oxygen gas or gases.
  • the cuiture conditions described herein can be scaled up and grown continuously for manufacturing of 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • Exemplary growth procedures include, for example, fed-batch fermentation and batch separation; fed-batch fermentation and continuous separation, or continuous fermentation and continuous separation. All of these processes are well, known in the art.
  • Fermentation procedures are particularly useful for the biosynthetic production of commercial quantities of 1. ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product.
  • the continuous and/or near- continuous production of 1 ,4-butanediol, 4-hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product will include culturing a non-naturally occurring 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product producing organism of the invention in sufficient nutrients and medium to sustain and/or nearly sustain growth in an exponential phase.
  • Continuous culture under such conditions can be included, for example, growth for 1 day, 2, 3, 4, 5, 6 or 7 days or more. Additionally, continuous culture can include longer time periods of 1 week, 2, 3, 4 or 5 or more weeks and
  • organisms of the invention can be cultured for hours, if suitable for a particular application. It is to be understood that the continuous and/or near-continuous culture conditions also can include all time intervals in between these exemplary periods. It is further understood that the time of culturing the microbial organism of the invention is for a sufficient period of time to produce a sufficient amount of product for a desired purpose.
  • Fermentation procedures are well known in the art. Briefly, fermentation for the biosyntheiic production of 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanoi or other desired product can be utilized in, for example, fed-batch fermentation and batch separation; fed-batch fermentation and continuous separation, or continuous fermentation and continuous separation. Examples of batch and continuous fermentation procedures are well known in the art.
  • the 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanoi or other desired product producers of the invention for continuous production of substantial quantities of 1 ,4-butanediol, 4- hydroxybutyrate, 1 ,3-butanediol, or isopropanoi, or other desired product
  • the 1 ,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanoi or other desired product producers also can be, for example, simultaneously subjected to chemical synthesis procedures to convert the product to other compounds or the product can be separated from the fermentation culture and sequentially subjected to chemical conversion to convert the product to other compounds, if desired.
  • microbial organisms of the invention having increased product yield, as described herein, can be used for convenient scale up to larger cultures since the yield of a desired product is increased.
  • the microbial organisms of the invention that produce a desired product and that are genetically engineered to enhance carbon fixation via the reductive TCA cycle, and/or access to additional reducing equivalents from gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, C0 2 , and/or 3 ⁇ 4 can be cultured, for example, in at least 1 liter of cell culture medium, for example, at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
  • the invention relates to microbial organisms having increased productivity of a desired product.
  • a product can be toxic to the microbial organism having increased product yield at higher concentrations.
  • a microbial organism of the invention can be resistant to the toxicity of the desired product, it is understood that resistance to toxicity of a desired product can be readily determined by methods well known to those ski lled in the art.
  • a microbial organism of the invention having increased product yield for example, comprising a genetic modification to enhance carbon fixation via the reductive TCA cycle, and/or access to additional reducing equivalents from gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, C0 2 , and/or 3 ⁇ 4, can be evolved to exhibit increased resistance to toxicity of the desired product by culturing the organism in the presence of increasing concentrations of the desired product.
  • Such methods can be utilized to select strains having improved properties of tolerance for increased concentrations of a desired product exhibiting toxicity. It is understood that toxicity can refer to microbicidal or microbistatic activity.
  • a desired compound that exhibits microbistatic activity can still be utilized for production of the desired product if the cells in a microbistatic state, that is, no longer capable of growth in the presence of the product, still produce the desired product at a suitable level for a desired memepose.
  • the microbial organisms of the invention include microbial organisms having increased resistance to toxicity of a desired product relative to a host strain that does not produce the product or a host strain that produces the product but is not geneiticaily engieneered to enhance carbon fixation via the reductive TCA cycle, and/or access to additional reducing equivalents from gaseous carbon sources and/or syngas or other gaseous carbon sources comprising components such as CO, C0 2 , and/or H 2 .
  • metabolic modeling can be utilized to optimize growth conditions. Modeling can also be used to design gene knockouts that additionally optimize utilization of the pathway (see, for example, U.S. patent publications US 2002/0012939, US 2003/0224363, US 2004/0029149, US 2004/0072723, US 2003/0059792, US 2002/0168654 and US 2004/0009466, and U.S. Patent K ! o. 7,127,379). Modeling analysis allows reliable predictions of the effects on cell growth of shifting the metabolism towards more efficient production of 1 ,4-butanediol, 4-hydroxybutyrate, 1 ,3-butanediol, or isopropanol or other desired product.
  • OptKnock is a metabolic modeling and simulation program that suggests gene deletion or disruption strategies that result in genetically stable microorganisms which overproduce the target product.
  • the framework examines the complete metabolic and/or biochemical network of a microorganism in order to suggest genetic manipulations that force the desired biochemical to become an obligator ⁇ ' byproduct of cell growth.
  • OptKnock is a term used herein to refer to a computational method and system for modeling cellular metabolism.
  • the OptKnock program relates to a framework of models and methods that incorporate particular constraints into flux balance analysis (FBA) models. These constraints include, for example, qualitative kinetic information, qualitative regulatory information, and/or DNA microarray experimental data.
  • FBA flux balance analysis
  • OptKnock also computes solutions to various metabolic problems by, for example, tightening the flux boundaries derived through flux balance models and subsequently probing the performance limits of metabolic
  • SirnPheny ⁇ Another computational method for identifying and designing metabolic alterations favoring biosynthetic production of a product is a metabolic modeling and simulation system termed SirnPheny ⁇ .
  • This computational method and system is described in, for example, U.S. publication 2003/0233218, filed June 14, 2002, and in International Patent Application No. PCT/US03/18838, filed June 13, 2003.
  • SirnPheny® is a computational system that can be used to produce a network model in silico and to simulate the flux of mass, energy or charge through the chemical reactions of a biological system to define a solution space that contains any and all possible functionalities of the chemical reactions in the system, thereby determining a range of allowed activities for the biological system.
  • constraints-based modeling because the solution space is defined by constraints such as the known stoichiornetry of the included reactions as well as reaction theiiiiodynamic and capacity constraints associated with maximum fluxes through reactions.
  • the space defined by these constraints can be interrogated to determine the phenotypic capabilitiesi ties and behavior of the biologi cal system or of its biochemical components.
  • the set of reactions that are to be disrupted in order to achieve production of a desired product are implemented in the target cell or organism by functional disruption of at least one gene encoding each metabolic reaction within the set.
  • One particularly useful means to achieve functional dismption of the reaction set is by del etion of each encoding gene.
  • Integer cut constraints effectively prevent the solution procedure from choosing the exact same set of reactions identified in any previous iteration that obligatorily couples product biosynthesis to growth. For example, if a previously identified growth-coupled metabolic modification specifies reactions 1 , 2, and 3 for disruption, then the following constraint prevents the same reactions from being simultaneously considered in subsequent solutions.
  • the integer cut method is well known in the art and can be found described in, for example, Burgard et al, Biotechnol. Prog. 17:791 -797 (2001).
  • the integer cut method of reducing redundancy in iterative computational analysis also can be applied with other computational frameworks well known in the art including, for example, SimPheny®.
  • the methods exemplified herein allow the construction of cells and organisms that biosyntheficaliy produce a desired product, including the obligatory coupling of production of a target biochemical product to growth of the cell or organism engineered to harbor the identified genetic alterations. Therefore, the computational methods described herein allow the identification and implementation of metabolic modifications that are identified by an in silico method selected from OptKnock or SimPheny®.
  • the set of metabolic modifications can include, for example, addition of one or more biosynthetic pathway enzymes and/or functional disruption of one or more metabolic reactions including, for example, disruption by gene deletion.
  • the OptKnock methodology was developed on the premise that mutant microbial networks can be evolved towards their computationally predicted maximum- growth phenotypes when subjected to long periods of growth selection. In other words, the approach leverages an organism's ability to self-optimize under selective pressures.
  • the OptKnock framework allows for the exhaustive enumeration of gene deletion combinations that force a coupling between biochemical production and cell growth based on network stoichiometry.
  • silica stoichiometric model of E. coil metabolism can be employed to identify essential genes for metabolic pathways as exemplified previously and described in, for example, U.S. patent publications US 2002/0012939, US 2003/0224363, US 2004/0029149, US
  • the OptKnock mathematical framework can be applied to pinpoint gene deletions leading to the growth-coupled production of a desired product. Further, the solution of the bilevel OptKnock problem provides only one set of deletions. To enumerate all meaningful solutions, that is, all sets of knockouts leading to growth-coupled production formation, an optimization technique, termed integer cuts, can be implemented. This entails ⁇ teratively solving the OptKnock problem with the incorporation of an additional constraint referred to as an integer cut at each iteration, as discussed above.
  • a nucleic acid encoding a desired activity of a 1,4-butanediol, 4- hydroxybutyrate, 1,3-butanediol, or isopropanol or other desired product pathway can be introduced into a host organism.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un organisme microbien non naturel qui comprend un organisme microbien ayant une voie réductrice TCA ou de Wood-Ljungdahl dans laquelle au moins un acide nucléique exogène codant des enzymes de ces voies est exprimé en une quantité suffisante pour augmenter le flux de carbone par l'acétyl-CoA. Un procédé d'augmentation du flux de carbone par l'acétyl-CoA comprend la culture de ces organismes microbiens non naturels dans certaines conditions et pendant une période suffisantes pour produire un produit ayant un acétyl-CoA comme précurseur. Un autre organisme microbien non naturel comprend au moins un acide nucléique exogène codant une enzyme exprimée en une quantité suffisante pour augmenter la biodisponibilité des équivalents réducteurs en présence de monoxyde de carbone ou d'hydrogène, ce qui augmente le rendement de produits à oxydo-rédution limitée par l'intermédiaire de matière première de carbone à base de glucides. Un procédé pour augmenter la biodisponibilité des équivalents réducteurs en présence de monoxyde de carbone ou d'hydrogène comprend la culture de cet organisme pendant une période suffisante pour produire un produit.
PCT/US2012/047278 2011-07-20 2012-07-19 Procédés pour augmenter des rendements en produits WO2013012975A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR112014001174A BR112014001174A2 (pt) 2011-07-20 2012-07-19 métodos para aumento de rendimentos de produto
EP12815606.4A EP2734627A4 (fr) 2011-07-20 2012-07-19 Procédés pour augmenter des rendements en produits

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161510066P 2011-07-20 2011-07-20
US61/510,066 2011-07-20
US201161512376P 2011-07-27 2011-07-27
US61/512,376 2011-07-27

Publications (1)

Publication Number Publication Date
WO2013012975A1 true WO2013012975A1 (fr) 2013-01-24

Family

ID=47558462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/047278 WO2013012975A1 (fr) 2011-07-20 2012-07-19 Procédés pour augmenter des rendements en produits

Country Status (3)

Country Link
EP (1) EP2734627A4 (fr)
BR (1) BR112014001174A2 (fr)
WO (1) WO2013012975A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150022530A (ko) * 2013-08-23 2015-03-04 삼성전자주식회사 4-히드록시부티레이트 생산 균주 및 이를 이용한 4-히드록시부티레이트의 혐기적 생산 방법
WO2016044713A1 (fr) 2014-09-18 2016-03-24 Genomatica, Inc. Organismes microbiens non naturels présentant une meilleure efficacité énergétique
WO2016196233A1 (fr) 2015-05-30 2016-12-08 Genomatica, Inc. Vinylisomérase déshydratases, alcénol déshydratases, linalool déshydratases et alcool crotylique déshydratases et procédés de fabrication et d'utilisation associés
WO2017016902A1 (fr) * 2015-07-29 2017-02-02 Evonik Degussa Gmbh Production de 3-hydroxybutyrate
WO2017075208A1 (fr) 2015-10-30 2017-05-04 Genomatica, Inc. Protéines hybrides de méthanol déshydrogénase
US9938542B2 (en) 2015-02-27 2018-04-10 White Dog Labs, Inc. Mixotrophic fermentation method for making acetone, isopropanol, butyric acid and other bioproducts, and mixtures thereof
WO2019152375A1 (fr) 2018-01-30 2019-08-08 Genomatica, Inc. Systèmes et procédés de fermentation assortie d'un taux d'absorption volumétrique sensiblement uniforme d'un constituant gazeux réactif
WO2020006058A2 (fr) 2018-06-26 2020-01-02 Genomatica, Inc. Micro-organismes modifiés avec une enzyme g3p---> 3pg et/ou la fructose -1,6-bisphosphatase comprenant ceux ayant une méthylotrophie synthétique ou améliorée
US10597684B2 (en) 2013-12-27 2020-03-24 Genomatica, Inc. Methods and organisms with increased carbon flux efficiencies
US10808262B2 (en) 2013-12-03 2020-10-20 Genomatica, Inc. Microorganisms and methods for improving product yields on methanol using acetyl-CoA synthesis
EP3583208A4 (fr) * 2017-02-17 2020-12-23 Industrial Microbes, Inc. Culture modifiée pour convertir du méthane ou du méthanol en 3-hydroxyproprionate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203070A1 (en) * 2007-11-10 2009-08-13 Joule Biotechnologies, Inc. Hyperphotosynthetic organisms
US20110008861A1 (en) * 2008-03-03 2011-01-13 Joule Unlimited, Inc. Engineered CO2 Fixing Microorganisms Producing Carbon-Based Products of Interest
US20110045575A1 (en) * 2009-06-04 2011-02-24 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003025A (es) * 2009-09-09 2012-06-27 Genomatica Inc Microorganismos y metodos para la co-produccion de isopropanol con alcoholes, dioles y acidos primarios.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203070A1 (en) * 2007-11-10 2009-08-13 Joule Biotechnologies, Inc. Hyperphotosynthetic organisms
US20110008861A1 (en) * 2008-03-03 2011-01-13 Joule Unlimited, Inc. Engineered CO2 Fixing Microorganisms Producing Carbon-Based Products of Interest
US20110045575A1 (en) * 2009-06-04 2011-02-24 Genomatica, Inc. Microorganisms for the production of 1,4-butanediol and related methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2734627A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102097065B1 (ko) * 2013-08-23 2020-04-03 삼성전자주식회사 4-히드록시부티레이트 생산 균주 및 이를 이용한 4-히드록시부티레이트의 혐기적 생산 방법
KR20150022530A (ko) * 2013-08-23 2015-03-04 삼성전자주식회사 4-히드록시부티레이트 생산 균주 및 이를 이용한 4-히드록시부티레이트의 혐기적 생산 방법
EP4296364A2 (fr) 2013-12-03 2023-12-27 Genomatica, Inc. Micro-organismes et procédés pour améliorer les rendements de produits sur le méthanol à l'aide de la synthèse d'acétyl-coa
EP3967747A1 (fr) 2013-12-03 2022-03-16 Genomatica, Inc. Microorganismes et procédés pour améliorer les rendements de produits sur le méthanol faisant appel à la synthèse de l'acétyl-coa
US10808262B2 (en) 2013-12-03 2020-10-20 Genomatica, Inc. Microorganisms and methods for improving product yields on methanol using acetyl-CoA synthesis
EP3744830A1 (fr) 2013-12-27 2020-12-02 Genomatica, Inc. Méthodes et organismes à rendements de flux de carbone accrus
US10597684B2 (en) 2013-12-27 2020-03-24 Genomatica, Inc. Methods and organisms with increased carbon flux efficiencies
EP4407037A2 (fr) 2013-12-27 2024-07-31 Genomatica, Inc. Procédés et organismes présentant des rendements de flux de carbone améliorés
EP3741865A1 (fr) 2014-09-18 2020-11-25 Genomatica, Inc. Organismes microbiens non naturels dotés d'une efficacité énergétique améliorée
WO2016044713A1 (fr) 2014-09-18 2016-03-24 Genomatica, Inc. Organismes microbiens non naturels présentant une meilleure efficacité énergétique
EP4421181A2 (fr) 2014-09-18 2024-08-28 Genomatica, Inc. Organismes microbiens non naturels à efficacité énergétique améliorée
US9938542B2 (en) 2015-02-27 2018-04-10 White Dog Labs, Inc. Mixotrophic fermentation method for making acetone, isopropanol, butyric acid and other bioproducts, and mixtures thereof
WO2016196233A1 (fr) 2015-05-30 2016-12-08 Genomatica, Inc. Vinylisomérase déshydratases, alcénol déshydratases, linalool déshydratases et alcool crotylique déshydratases et procédés de fabrication et d'utilisation associés
WO2017016902A1 (fr) * 2015-07-29 2017-02-02 Evonik Degussa Gmbh Production de 3-hydroxybutyrate
WO2017075208A1 (fr) 2015-10-30 2017-05-04 Genomatica, Inc. Protéines hybrides de méthanol déshydrogénase
EP3583208A4 (fr) * 2017-02-17 2020-12-23 Industrial Microbes, Inc. Culture modifiée pour convertir du méthane ou du méthanol en 3-hydroxyproprionate
WO2019152375A1 (fr) 2018-01-30 2019-08-08 Genomatica, Inc. Systèmes et procédés de fermentation assortie d'un taux d'absorption volumétrique sensiblement uniforme d'un constituant gazeux réactif
WO2020006058A2 (fr) 2018-06-26 2020-01-02 Genomatica, Inc. Micro-organismes modifiés avec une enzyme g3p---> 3pg et/ou la fructose -1,6-bisphosphatase comprenant ceux ayant une méthylotrophie synthétique ou améliorée

Also Published As

Publication number Publication date
BR112014001174A2 (pt) 2017-02-21
EP2734627A1 (fr) 2014-05-28
EP2734627A4 (fr) 2015-07-22

Similar Documents

Publication Publication Date Title
US10087470B2 (en) Methods for increasing product yields
US8048661B2 (en) Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
US11708592B2 (en) Microorganisms and methods for the production of caprolactone
US8268607B2 (en) Methods and organisms for converting synthesis gas or other gaseous carbon sources and methanol to 1,3-butanediol
US9109236B2 (en) Microorganisms and methods for conversion of syngas and other carbon sources to useful products
US9657316B2 (en) Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 1,4-butanediol related thereto
WO2012177599A2 (fr) Microorganismes destinés à la production de n-propanol, de 1,3-propanediol, de 1,2-propanediol ou de glycérol et leurs procédés associés
EP2734627A1 (fr) Procédés pour augmenter des rendements en produits
WO2012177619A2 (fr) Microorganismes pour la production de 1,3-butanediol et procédés associés à ceux-ci
WO2013003432A1 (fr) Micro-organismes pour produire du succinate et procédés associés
WO2012177983A2 (fr) Microorganismes capables de produire de l'éthylène glycol et procédés associés
WO2012177601A2 (fr) Microorganismes destinés à la production d'isobutanol et leurs procédés associés
US20120329111A1 (en) Microorganisms for Producing Cyclohexanone and Methods Related Thereto
AU2013203166A1 (en) Microorganisms for producing 1,3-butanediol and methods related thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815606

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2012815606

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012815606

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014001174

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014001174

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140117